UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Year Ended December 31, 20172022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Transition Period From To

Commission file number 001-13795

AMERICAN VANGUARD CORPORATION

Delaware

95-2588080

(State or other jurisdiction of

Incorporation or organization)

(I.R.S. Employer

Identification Number)

4695 MacArthur Court, Newport Beach, California

92660

(Address of principal executive offices)

(Zip Code)

(949) (949) 260-1200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:class

Trading

Symbol(s)

Name of each exchange on which registered:registered

Common Stock, $.10$0.10 par value

AVD

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act:

NONE

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

  (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

The aggregate market value of the voting stock of the registrant held by non-affiliates is $513.4$662.2 million. This figure is estimated as of June 30, 20172022 at which date the closing price of the registrant’s Common Stock on the New York Stock Exchange was $17.25$22.35 per share. For purposes of this calculation, shares owned by executive officers, directors, and 5% stockholders known to the registrant have been deemed to be owned by affiliates. The number of shares of $.10$0.10 par value Common Stock outstanding as of June 30, 2017,2022, was 29,761,490.30,749,184. The number of shares of $.10 par value Common Stock outstanding as of February 16, 2018March 6, 2023 was 29,848,921.29,476,112.


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

ANNUAL REPORT ON FORM 10-K

December 31, 20172022

Page No.

PART I

Item 1.

Business

12

Item 1A.

Risk Factors

710

Item 1B.

Unresolved Staff Comments

1017

Item 2.

Properties

1017

Item 3.

Legal Proceedings

1218

Item 4.

Mine Safety Disclosures

1418

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities

1519

Item 6.

Selected Financial DataReserved

1821

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

1922

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

3231

Item 8.

Financial Statements and Supplementary Data

32

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

32

Item 9A.

Controls and Procedures

32

Item 9B.

Other Information

3534

Item 9C.

PART IIIDisclosure Regarding Foreign Jurisdictions That Prevent Inspections

34

Item 10.

PART III

Item 10.

Directors, Executive Officers and Corporate Governance

35

Item 11.

Executive Compensation

35

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

35

Item 13.

Certain Relationships and Related Transactions, and Director Independence

35

Item 14.

Principal Accountant Fees and Services

35

PART IV

Item 15.

Exhibits and Financial Statement SchedulesSchedule

3641

Item 16.

Form 10-K Summary

3639

SIGNATURES AND CERTIFICATIONS

40

i

1


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

PART I

Unless otherwise indicated or the context otherwise requires, the terms “Company,” “we,” “us,” and “our” refer to American Vanguard Corporation and its consolidated subsidiaries (“AVD”).

Forward-looking statements in this report, including without limitation, statements relating to the Company’s plans, strategies, objectives, expectations, intentions, and adequacy of resources, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties. (Refer to Part I, Item 1A, Risk Factors and Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operation, included in this Annual Report.)

ITEM 1

BUSINESS

All dollar amounts reflected in the consolidated financial statements are expressed in thousands, except per share data.

ITEM 1 BUSINESS

American Vanguard Corporation (“AVD”) was incorporated under the laws of the State of Delaware in January 1969 and operates as a holding company. Unless the context otherwise requires, references to the “Company” or the “Registrant,” in this Annual Report refer to AVD. The Company conducts its business through its principle operating subsidiaries, including AMVAC Chemical Corporation (“AMVAC”), for its domestic business and AMVAC Netherlands BV (“AMVAC BV”) for its international business.

The operating subsidiaries in the U.S. include: AMVAC, GemChem, Inc. (“GemChem”), 2110 Davie CorporationEnvance Technologies, LLC (“DAVIE”Envance”), Quimica Amvac de Mexico S.A. de C.V.TyraTech Inc. (“TyraTech”) and OHP Inc. (“OHP”).

Internationally, the Company operates its business through the following subsidiaries: AMVAC BV, AMVAC Hong Kong Limited (“AMVAC M”Hong Kong”), AMVAC Mexico Sociedad de Responsabilidad Limitada (“AMVAC M Srl”M”), AMVAC de Costa Rica Sociedad de Responsabilidad Limitada (“AMVAC CR Srl”), AMVAC Switzerland GmbH (“AMVAC S”), AMVAC do Brasil Representácoes Ltda (“AMVAC B”), AMVAC C.V. (“AMVAC CV”), AMVAC Netherlands BV (“AMVAC BV”), Envance Technologies, LLC (“Envance”) and AMVAC Singapore Pte, Ltd (“AMVAC Sgpr”) and Huifeng AMVAC Innovation Co. Limited (“Hong Kong JV”), OHP Inc. (“OHP”) and Grupo AgriCenter (including the parent AgriCenter S.A. and its subsidiariessubsidiaries) (“AgriCenter”), AMVAC do Brasil Representácoes Ltda (“AMVAC do Brasil”), AMVAC do Brazil 3p LTDA (“AMVAC 3p”), American Vanguard Australia PTY Ltd (“AVD Australia”), AgNova Technologies PTY Ltd (“AgNova”), and the Agrinos group (“Agrinos”).

Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Refer to Part II, Item 7 for selective enterprise information.

AMVAC

AMVAC is a California corporation that traces its history from 1945 and is a specialtymanufacturer of chemical, manufacturerbiological and biorational products that develops and markets productssolutions for agricultural, commercial and consumer uses. It manufacturessynthesizes and formulates chemicals and ferments and extracts microbial products for crops, turf and ornamental plants, and human and animal health protection. These chemicals,products, which include insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, and soil fumigants, are marketed in liquid, powder, and granular forms. In prior years, AMVAC considered itself a distributor-formulator, but now AMVAC primarily synthesizes, formulates, and distributes its own proprietary products or custom manufactures, formulates or formulatesdistributes for others. In addition, the Company has carved out a leadership position in closed delivery systems, currently offers certain of its products in SmartBox, Lock ‘n Load and EZ Load systems, and is developing a precision applicationits most recent commercial high technology packaging system known as SIMPAS (see “Intellectual Property” below) which will permitpermits the delivery of multiple products (from AMVAC and/or other companies) at variable rates in a single pass. AMVAC has historically expanded its business through both the acquisition of established chemistries, (which it has revived in the marketplace) and the development and commercialization of new formulations or compounds through licensing arrangements. arrangements, the expansion of its global distribution network to gain broader market access, and self-funded research and development of precision application technology. Beginning in 2021, we have commenced basic molecular research and development of intellectual property related to our green solutions portfolio.

2


AMVAC BV is a Netherlands Corporation that was established in 2012 and is based in the Netherlands. AMVAC BV sells product both directly and through its network of subsidiaries in various international territories.

Below is a description of the Company’s acquisition/licensing activity over the past fivethree years.

On October 27, 2017,July 1, 2021, the Company’s Netherlands-based subsidiary, AMVAC BV,Company completed the purchase of AgriCenter S.A.certain assets from Syngenta Crop Protection related to the herbicide trifloxysulfuron ("Envoke"), a distributionincluding end-use registrations, data compensation claims, trademarks, formulation know-how, and books and records.

On October 8, 2020, the Company’s Australian subsidiary, AVD Australia, completed the purchase of all the outstanding shares of AgNova, an Australian company based in Costa Rica. AgriCenter marketsthat sources, develops, and distributes end-use chemicalspecialty crop protection and biological products throughout Central America, primarilyproduction solutions for crop applications.agricultural and horticultural producers and for selected non-crop users. AgNova has an established reputation for cost-effective product development from original concept through evaluation, registration, marketing, and sales, with new technologies flowing from its development pipeline. AgNova is committed to the provision of innovative, value-adding solutions for agriculture and related industries. The acquired assets included product registration, trade names and trademarks, customer lists, personnel,workforce, fixed assets, goodwill and existing working capital.

On October 2, 2017, AMVAC acquired substantially all of the assets of OHP, a US-based distribution company specializing in the greenhouse and nursery production markets. The acquired assets included existing product rights, trade names, customer relationships, personnel, goodwill, fixed assets and working capital.

On August 22, 2017, AMVAC BV, completed the acquisition of certain selective herbicides and contact fungicides including chlorothanonil, ametryn, and isopyrazam, sold in the Mexican agricultural market. The assets were purchased from Syngenta AG and used on various crops such as sugarcane, tomatoes, potatoes and hot peppers. The acquired assets included product registrations, trademarks and trade names, customer lists, and associated inventory.  

1


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

On June 6, 2017,2020, the Company’s principal operating subsidiary, AMVAC, completed an acquisitionthe purchase of certain herbicides, fungicides and insecticides assets relatingall the outstanding shares of Agrinos from Agrinos AS, a Norwegian holding company, from a liquidation proceeding of that entity before a Norwegian bankruptcy court in Oslo, Norway. In addition to the abamectin, chlorothalonilshares of Agrinos, AMVAC acquired a bank of microbial and paraquatmicronutrients, as well as about 150 pending or issued patents. Agrinos is a fully integrated biological input supplier with proprietary technology, manufacturing facilities, and global distribution capabilities. Its High Yield Technology® product lines from a groupplatform works in conjunction with other nutritional crop inputs to increase crop yield, improve soil health and reduce the environmental footprint of companies, including Adama Agricultural Solutions, Ltd. These products are used on a wide range of crops such as citrus, cotton, nuts, fruits and vegetables.traditional agricultural practices. The acquired assets included product registrations, trademarks andregistration, trade names customer lists, and associated inventory.

On January 13, 2017, the Company acquired from The Andersons, Inc. certain assets relating to proprietary formulations containing PCNB, chlorothalonil and propiconazole which are marketed under the name FFII and FFIII. The acquired assets included end use registrations.  

On June 27, 2017, both AMVAC BV and Huifeng made individual capital contributions of $950 to the Hong Kong JV. On July 7, 2017, the Hong Kong JV purchased 100% of the shares of Profeng Australia, Pty Ltd. (“Profeng”), for a total consideration of $1,900.

On February 29, 2016, AMVAC BV purchased shares constituting a 15% interest in BiPA NV/SA, a Belgian company specializing in the development and early commercialization of biological products for use in agriculture. Through this investment, AMVAC BV obtained possible future access to a pipeline of new biological products for potential commercialization either individually in certain territories or in combination with the Company’s existing product portfolio.

On October 26, 2015, AMVAC entered into a license and supply agreement with Badische Anilin-und Soda Fabrik (“BASF”) under which BASF sold and AMVAC acquired certain assets (principally inventory) relating to the imazaquin product line. Imazaquin is an herbicide that is used on soybeans and for certain non-crop applications.

On April 29, 2015, the registrant’s international subsidiary, AMVAC CV, completed the acquisition of certain assets related to the bromacil herbicide product line from DuPont Crop Protection. The assets acquired included the Hyvar® and Krovar® trademarks, product registrations, trade names, customer lists and associated inventory. The territory included all markets outside North America.  

On April 6, 2015, the registrant’s international subsidiary, AMVAC CV, completed the acquisition of certain assets related to the Nemacur® insecticide/nematicide product line from Adama Agricultural Solutions Ltd (“Adama”). The assets acquired include product registrations, trademarks, customer lists, manufacturing know-howworkforce, fixed assets, two factories and associated inventory. The territories include European countries.existing working capital.

On March 25, 2013, AVD made an equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils and other natural ingredients. As of December 31, 2017,April 1, 2020, the Company’s principal operating subsidiary, AMVAC, acquired 6,250,000 common shares of Clean Seed Capital Group Ltd. (Clean Seed), representing an ownership position in TyraTech wasof approximately 15.11%8%. At a special meeting conducted on December 27, 2017, TyraTech shareholders approved the sale of its Vamouse product lineIn addition, AMVAC licensed from Clean Seed certain intellectual property rights related to Alliance Pharmaceuticals, Ltd and the use of some of the proceeds from such sale for a tender offer for TyraTech shares.  That tender offer was concluded in January 2018.  AMVAC elected not to exercise its right to sell into such tender offer and, as a result, the Company’s ownership interest in TyraTech increased to approximately 35% at the conclusion of that transaction.  Clean Seed’s SMART planting technologies.

Seasonality

The agricultural chemical industry, in general, is cyclical in nature. The demand for AMVAC’sAVD’s products tends to be seasonal. Seasonal usage, however, does not necessarily follow calendar dates, but more closely follows varying growing seasonal patterns, weather conditions, geography, weather related pressure from pests and customer marketing programs. Further, growing seasons vary by geographical region; thus, there is no single seasonal cycle affecting our sales. Rather, multiple seasons transpire over the course of the calendar year.

Backlog

AMVAC does not believe that backlog is a significant factor in its business. AMVACAVD primarily sells its products based on the basis ofpurchase orders. The purchase orders althoughare typically fulfilled within a short time frame. As a result, backlog is not considered a significant factor of, or a valid metric for, AVD’s business. The 2022 year, however, did end with a significantly larger than normal backlog of orders, primarily resulting from time to time it has entered into requirements contracts with certain customers.supply chain challenges on one specific product line in the last three months of 2022.

Customers

The Company’s largest three customers accounted for 13%18%, 10%13% and 10%8% of the Company’s sales in 2017; 15%2022; 17%, 11%14% and 8% in 2016;2021; and 14%17%, 11%12% and 10% in 2015.2020.

2


AMERICAN VANGUARD CORPORATIONDistribution

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Distribution

In the U.S. AMVAC predominantly distributes its products domestically through national distribution companies and buying groups or co-operatives, which purchase AMVAC’s goods on a purchase order basis and, in turn, sell them to retailers/growers/end-users. The Company manages its international sales through

3


Internationally, AMVAC BV which has sales offices or wholly owned distributors in Central America, Mexico, Brazil, Australia, and Costa RicaIndia, and sales force executives or sales agents in several other territories. The Company’s domestic and international distributors, agents and customers typically have long-established relationships with retailers/end-users, far-reaching logistics and transportation capabilities, and/or customer service expertise. The markets for AMVACAVD’s products vary by region, target crop, use and type of distribution channel. AMVAC’sAVD’s customers are experts at addressing these various markets.

As more fully described above, during 2017, the Company acquired two distribution companies: the first, OHP, a domestic company operating in the turf and ornamental market, and the second, AgriCenter, which operates in several countries within Central America.  Both of these businesses primarily market and distribute the formulated end-use product of third parties under either the brand of the third party or as a private label product. Prior to being acquired by the Company, both OHP and AgriCenter distributed small quantities of the Company’s products.Competition

Competition

In its many marketplaces, AMVACAVD faces competition from both domestic and foreign manufacturers. Many of our competitors are larger and have substantially greater financial and technical resources than AMVAC. AMVAC’sAVD. AVD’s capacity to compete depends on its ability to develop additional applications (including delivery systems and precision application technologies) for its current products and/or expand its product lines and customer base. AMVACAVD competes principally based on the basis of the quality, andproduct efficacy, of its products, price, and the technical service and support given to its customers.

Generally, the treatment against pests of any kind is broad in scope, there being more than one way, or one product, for treatment, eradication, or suppression.customer support. In some cases, AMVACAVD has positioned itself in smaller niche markets, which are no longer addressed by larger companies. In other cases, for example in the MidwesternMidwest corn market,and soybean markets, the Company competes directly withagainst larger competitors.

Manufacturing

Through its four domesticsix manufacturing facilities (see Item 2, Properties), AMVACAVD synthesizes many of the technical grade active ingredients that are in its end-use products. Further, AMVACthe Company formulates and packages its end useend-use products at four of its own facilities or at the facilities of third-party formulators.formulators in the U.S. and at various international locations. Two of the Company’s manufacturing facilities are biological fermentation sites, one site in the U.S., and one in Mexico, and, in addition, has a product manufacturing arrangement at a third-party facility in India.

Raw Materials

AMVACAVD utilizes numerous companies to supply the various raw materials and components used in manufacturing its products. Many of these materials are readily available from domestic sources. In those instances where there is a single source of supply, or where the source is not domestic, AMVACAVD seeks to secure its supply by either long-term (multi-year) arrangements or purchasing on long lead times from its suppliers. Further, where the availability or cost of certain raw materials may be subject to the effect of tariffs and/or supply chain disruption, the Company may order goods at times or in volumes out of the ordinary course to optimize pricing and to ensure supply.

Intellectual Property

AMVAC’sAVD’s proprietary product formulations are protected, to the extent possible, as trade secrets and, to a lesser extent, by patents. Certain of the Company’s closed delivery systems are patented, and AMVACthe Company has made applications for related inventionsboth pending and issued patents relating to expand its equipment portfolio, particularly with respect to its Smart Integrated Multi-Product Precision Application System, (“SIMPAS”)SIMPAS and ULTIMUS technology. In addition, the Company owns multiple issued patents relating to both its low-impact Envance solutions as well as its Agrinos biological and microbial solutions. Further, AMVAC’sAVD’s trademarks bring value to its products in both domestic and foreign markets. AMVACAVD considers that, in the aggregate, its product registrations, trademarks, licenses, customer lists and patents constitute a valuable asset.assets. While it does not regard its current business as being materially dependent upon any single product registration, trademark, license, or patent, it believes that patents will play an increasingly important role in its developmental equipment technology may bring significant value in future years.precision application technologies and green solutions portfolio.

4


EPA Registrations

In the United States, AMVAC’sU.S., AVD’s products also receive protection afforded by the terms of the Federal Insecticide, Fungicide and Rodenticide Act (“FIFRA”) legislation. The legislation makes, pursuant to which it is unlawful to sell any pesticide in the United States,U.S., unless such

3


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

pesticide has first been registered by the United StatesU.S. Environmental Protection Agency (“USEPA”). Substantially allMost of AMVAC’sthe Company’s products that are sold in United States,the U.S. are subject to USEPA registration and periodic re-registration requirements and are registered in accordance with FIFRA. This registration by USEPA is based, among other things, on data demonstrating that the product will not cause unreasonable adverse effects on human health or the environment, when used according to approved label directions. In addition, each state requires a specific registration before any of AMVAC’sAVD’s products can be marketed or used in that state. State registrations are predominantly renewed annually with a smaller number of registrations that are renewed on a multiple year basis.

Foreign jurisdictions typically have similar registration requirements by statute.

In addition, certain of the Company’s biological products are labeled organic under the Organic Materials Review Institute (“OMRI”), Washington State Department of Agriculture (“WSDA”) and/or California Department of Food and Agriculture (“CDFA”) and, as such, are subject to the requirements of those certification standards, including with respect to raw materials and processes. As is the case with synthetic products, these biological products are also subject to specific labeling requirements that may vary from state to state.

The USEPA, state, and foreign agencies have required, and may require in the future, that certain scientific data requirements be performed on registered products sold by AMVAC. AMVAC,AVD. AVD, on its own behalf and in joint efforts with other registrants, has furnished, and is currently furnishing, required data relative to specific products.

Under FIFRA, the federal government requires registrants to submit a wide range of scientific data to support U.S. registrations.registrations, including in the case of adding labeled uses. This requirement results in operating expenses in such areas as regulatory compliance, with USEPA and other such bodies in the markets in which the Company sells its products. In addition, at times, the Company is required to generate new formulations of existing products and/or to produce new products in order to remain compliant. AMVACThe Company expensed $14,232, $11,544,$18,168, $16,568 and $9,831$15,613, during 2017, 20162022, 2021 and 20152020, respectively, on these activities.

 

2017

 

 

2016

 

 

2015

 

 

2022

 

 

2021

 

 

2020

 

Registration

 

$

9,450

 

 

$

7,750

 

 

$

6,375

 

 

$

12,118

 

 

$

10,612

 

 

$

10,914

 

Product development

 

 

4,782

 

 

 

3,794

 

 

 

3,456

 

 

 

6,050

 

 

 

5,956

 

 

 

4,699

 

 

$

14,232

 

 

$

11,544

 

 

$

9,831

 

Total

 

$

18,168

 

 

$

16,568

 

 

$

15,613

 

Environmental

Environmental

During 2017,2022, AMVAC continued activities to address environmental issues associated with its facility in Commerce, CA. (the “Facility”). An outline of the history of those activities follows.

In 1995, the California Department of Toxic Substances Control (“DTSC”) conducted a Resource Conservation and Recovery Act (“RCRA”) Facility Assessment (“RFA”) of those facilities having hazardous waste storage permits. In March 1997, the RFA culminated in DTSC accepting the Facility into its Expedited Remedial Action Program. Under this program, the Facility was required to conduct an environmental investigation and health risk assessment. This activity then took two paths: first, the RCRA permit closure and second, the larger site characterization.

With respect to the RCRA permit closure, in 1998, AMVAC began the formal process to close its hazardous waste permit at the Facility (which had allowed AMVAC to store hazardous waste longer than 90 days) as required by federal regulations. Formal regulatory closure actions began in 2005 and were completed in 2008, as evidenced by DTSC’s October 1, 2008, acknowledgement of AMVAC’s Closure Certification Report.

5


With respect to the larger site characterization, soil and groundwater characterization activities began in December 2002 in accordance with the Site Investigation Plan that was approved by DTSC. Additional activities were conducted from 2003 to 2014, with oversight provided by DTSC. In 2014, the Company submitted a remedial action plan (“RAP”) to DTSC, under the provisions of which, the Company proposed not to disturb sub-surface contaminants, but to continue monitoring, maintain the cover above affected soil, enter into restrictive covenants regarding the potential use of the property in the future, and provide financial assurances relating to the requirements of the RAP. In January 2017, the RAP was circulated for public comment. DTSC responded to those comments and, on September 29, 2017, approved the RAP as submitted by the Company. The Company intendscontinues to prepare an operationconduct groundwater monitoring and maintenance plan, to recordmaintain the cover above affected soil. In 2022, the Company recorded land use covenants on certain affected parcels and continues to work with DTSC to prepare a Remedial Action Completion Report and to obtain further clarification on financial assurance obligations relating to the RAP. At this stage, the Company does not believe that costs to be incurred in connection with the RAP will be material and has not recorded a loss contingency for these activities.

AMVAC is subject to numerous federal and state laws and governmental regulations concerning environmental matters and employee health and safety at its foursix manufacturing facilities. The Company continually adapts its manufacturing process to the latest environmental control standards of the various regulatory agencies. The USEPA and other federal and state agencies have the authority to promulgate regulations that could have an impact on the Company’s operations.

4


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

AMVAC expends substantial fundseffort to minimize the risk of discharge of materials in the environment and to comply with the governmental regulations relating to protection of the environment. Wherever feasible, AMVAC recovers and recycles raw materials and increases product yield in order to partially offset increasing pollution abatement costs.

The Company is committed to a long-term environmental protection program that reduces emissions of hazardous materials into the environment, as well as to the remediation of identified existing environmental concerns.

EmployeesHuman Capital Resources

We believe that, beyond being essential to our operations, our people have inestimable worth independent of our business. As outlined in our Human Rights Policy (see, www.american-vanguard.com under ESG tab), we believe that it is fundamental to our corporate responsibility and, indeed, to our humanity, that we recognize, respect and nurture the freedom and dignity of December 31, 2017,all persons. Accordingly, we have insinuated that belief throughout the fabric of our operations in our approach toward our employees. Indeed, the first two core values underlying our commitment to sustainability (see, Update to Corporate Sustainability Report, www.american-vanguard.com under ESG tab) are “Safety First” – which is a culture that begins with highly-regulated manufacturing plants, continues into the design of science-backed products and extends into market-leading delivery systems – and “Making a Difference” – under which, by rewarding achievement and giving our employees a voice, we attract diverse employees who want to make a difference in their careers, in the company and in the communities that we serve.

Our Human Capital program consists of the following elements:

Board Oversight – through our Nominating and Corporate Governance Committee (“N&CG”), our board of directors oversees human capital-related risks and opportunities. At least annually, the N&CG Committee requires that management update succession planning for key executives, including with respect to planning for the future with a commitment toward diversity, equity and inclusion.
Strategy and Development – the Company’s human capital strategy has two primary elements: giving our employees a voice and providing them with competitive benefits (including an outstanding health benefits plan and awards of common stock to the entire workforce). As we have covered in our Update to Corporate Sustainability Report, our Company is a destination for highly qualified employees who are drawn to a workplace where they can make a difference. Our managerial approach is that our functions work in a collaborative manner – cutting across departmental lines to arrive at better solutions with a high level of efficiency. This strategy has enabled the Company employed 605 employees. This includes 130to maximize retention, even in an increasingly competitive employment market.

6


Compensation – as mentioned in our Strategy above, compensation is an essential element of our human capital approach. During the pandemic in the midst of the so-called “Great Resignation” that affected many industries, we took measures to incentivize our workforce to remain with us, including across-the-board wage increases in certain of our manufacturing facilities. To the extent that our highly skilled personnel are being recruited by other companies, we endeavor to keep an open conversation on their needs and, where appropriate, have increased their total compensation (through a combination of wage, stock and/or vacation) to retain them.
Voice – our management style is to solicit good ideas from employees, involve them in implementation and give them recognition for ideas that joinedsucceed. For example, personnel from virtually any department (be it sales, technology, product development or otherwise) can submit ideas to our Innovation Review Committee (“IRC”) for consideration and potential funding. The IRC continues to be a source of new product ideas that has enabled us to launch several new formulations and other solutions on an annual basis. Similarly, our Beekeeper platform is a company-only social media channel on which employees anywhere in the world can report on their accomplishments, commendations of others and local developments.
Diversity, Equity and Inclusion (“DEI”) – the Company followingcontinues to expand its DEI program. And we believe that this commitment starts at the acquisitions completed duringtop. Three of nine members (33%) of our board of directors are female and two of nine (22%) are from underrepresented groups (LGBTQ and Latinx). Based upon the final quarterCompany’s most current EEO-1 (“Equal Employment Opportunity”) Report, representation of 2017.  African Americans in our domestic workforce exceeds the prevalence of that group in the national population, while representation of Hispanic personnel is slightly below the national average.
ESG at American Vanguard - at the center of our Environmental, Social Responsibility and Governance commitment is the principle of Sustainable Agriculture, which, we believe, is broad enough to encompass a comprehensive ESG program, but clear enough to give us direction in our outlook and purpose in our activities.

Sustainable Agriculture: We are committed to doing our best toward building a stable, affordable food supply both now and into the future. That commitment rests upon a foundation of social responsibility and equity. In that vein, we believe that sustainable agriculture must include these three principles:

Climate Equity – as outlined in our Climate Change Commitment, we are committed to making enterprise-wide, progressive and measurable efforts toward helping to arrest the trend of climate change. In making decisions, taking actions and conducting our operations we are mindful of climate equity, which holds that climate change has three primary effects – generational, regional and individual. To that end, we believe that reducing our carbon impact and, through our products and services, enabling others to do so will advance climate equity consistent with the 2-degree warmer world as per the Paris Agreement. We advance this commitment on multiple fronts. We offer over 100 eco-friendly products – such as natural oils from Envance (used in Proctor & Gamble’s Zevo product line), microbial High Yield solutions from Agrinos (that enhance soil health and promote carbon sequestration) and tailored bionutritional products from Greenplants. In addition, our patented SIMPAS® precision application system, which enables a grower to dispense multiple crop inputs at variable rates as per an agronomist’s prescription (“only what is needed, precisely where it is needed”) serves to maximize yield while minimizing the environmental footprint. Further, our Ultimus® technology enables us to measure, record and verify (“MRV”) crop input activity anywhere on the field. When linked to a permanent ledger, such as Blockchain, Ultimus can generate an immutable record of a grower’s activity and, particularly when used with our green solution products and SIMPAS, provides the ideal solution for the fast-growing carbon credit market. Through these means we are endeavoring to make the planet a better place than we found it.

7


Environmental Equity – we recognize that our planet has limited resources and that what we do with them has an effect on the habitat for both humans and other species, both for today and tomorrow. We also recognize that our activities can affect the environment generationally, regionally and individually. We are, therefore, committed to environmental equity in our operations. Specifically, and as more fully outlined in our sustainability reports (click on “ESG” on American-vanguard.com), we seek to conserve finite resources such as water, land and energy while protecting the environment and enhancing biodiversity, so that these resources are available in amounts and quality to support our neighbors and future generations. In addition, we have committed significant resources toward supporting growers with precision application technology – like SIMPAS and Ultimus – that enable growers to manage, optimize and trace the use of crop and soil inputs, and to use only what is needed, precisely where it is needed. And we are mindful of those who might be disproportionately affected by what we do, such as loaders and applicators of our products. To that end, we have been at the forefront of user-friendly, returnable, reusable closed delivery systems (from Lock ‘n Load to SMARTBox to SIMPAS/SmartCartridges) to minimize exposure and maximize safety for those on-the-ground.

Food Equity – Implicit in our commitment to sustainable agriculture is the principle of food equity, which has three aspects, once again, generational, regional and individual. First, food security – we believe it is essential to ensure the long-term sustainability and competitiveness of the Ag industry. We contribute toward food security by investing in both eco-friendly solutions that promote long-term soil and precision application and MRV technology, like SIMPAS and Ultimus, that give growers the best tools possible to ensure that their operations are viable, both today and tomorrow. Second, food availability – ensuring that food gets from field-to-table. As we saw in the pandemic, the supply chain for food can be broken, and those who suffer most are often those farthest from the fields. To that end, we support field-to-table efforts and programs to reduce food waste. Third, food affordability – ensuring that food prices can be maintained for all, including the impoverished. We do this by giving farmers effective tools, including precision application equipment, that optimize their costs, boost their yield, and enable them to produce and market food at reasonable costs.

Social Responsibility – our discussion of Sustainable Agriculture would not be complete without specific mention of our commitment to social responsibility. This concept is inherent in all forms of equity, be they climate, environmental or food related. However, social responsibility gives us pause to consider factors of a more fundamental nature, such as human rights. Our Human Rights Policy details our essential belief that we respect and support human rights, both within and article of our operations. We believe that it is fundamental to our corporate responsibility and, indeed, to our humanity, that we recognize, respect and nurture the freedom and dignity of all persons.

Under the umbrella of Sustainable Agriculture, we are committed to operating our business with a sense of mindfulness – toward the climate, toward the environment and toward the good of humans and other species. We consider ourselves to be part of a broader mission – one of ensuring that people can rely upon a stable, affordable food supply both now and in the future. It is a privilege to be part of that mission. With that privilege comes responsibility, and we take that responsibility seriously.

The Company employed 395822 employees as of December 31, 20162022, and 369804 employees as of December 31, 2015.2021. From time to time, due to the seasonality of its business, AMVACAVD uses temporary contract personnel to perform certain duties primarily related to packaging of its products. None of the Company’s employees are subject to a collective bargaining agreement. The Company believes it maintains positive relations with its employees.

Domestic operations

AMVAC is a California corporation that was incorporated under the name of Durham Chemical in August 1945. The name of the corporation was subsequently changed to AMVAC in January 1973.1971. As the Company’s main operating subsidiary, AMVAC owns and/or operates the Company’s domestic manufacturing facilities and is also the parent company (owns 99%) of AMVAC CV.facilities. AMVAC manufactures, formulates, packages and sells its products in the USAU.S. and is a wholly owned subsidiary of AVD.

GemChem is a California corporation that was incorporated in 1991 and was subsequently purchased by the Company in 1994. GemChem sells into the pharmaceutical, cosmetic and nutritional markets and, in addition, to purchasingpurchases key raw materials for the Company. GemChem is a wholly owned subsidiary of AVD.

DAVIE8


2110 Davie Corporation ("DAVIE") owns real estate for corporate use only. See also Part I, Item 2 of this Annual Report on Form 10-K.The site is the home to the Company’s research center and provides accommodation for the Company’s production control team. DAVIE is a wholly owned subsidiary of AVD.

Envance is a Delaware Limited Liability Company and is a majority owned subsidiary of the Company.  It was formed in 2012 with joint venture partner, TyraTech.  AMVAC’s initial shareholding was 60% and its shareholding increased to 87% in 2015.  Envance has the rights to develop and commercialize pesticide products and technologies made from natural oils in global consumer, commercial, professional, crop protection and seed treatment markets and has begun bringing products to market.

On October 2, 2017, AMVAC through a wholly-owned acquisition subsidiary, subsequently renamed OHP, purchased substantially all of the assets of OHP, a domestic distribution company specializing in products for the turf and ornamental market. OHP markets and sells end use products for third parties, either under the third party brandthird-party brands or else as its own label products.

International operations

In JulyEnvance is a Delaware Limited Liability Company that was formed in 2012 by AMVAC and joint venture partner TyraTech. Envance and TyraTech became wholly owned subsidiaries of the Company formed AMVAC CV, whichon November 9, 2018. Envance has the rights to develop and commercialize pesticide products and technologies based on TyraTech’s intellectual property. Products are made from natural oils in global consumer, commercial, professional, crop protection and seed treatment markets. Envance is incorporated in the Netherlands, for the purpose of managing foreign sales on behalf of the Company. AMVAC CV is owned jointlytaking products to market primarily by AMVAC as the general partner, and AVD licensing its intellectual property to third parties.

International LLC (also formed in July 2012 as a wholly owned subsidiary of AMVAC), as the limited partner, and is therefore a wholly owned subsidiary of AMVAC.operations

AMVAC BV is a registered Dutch private limited liability company that was formed in July 2012.2012 to manage foreign sales on behalf of the Company. AMVAC BV is located in the Netherlands and is a wholly owned bysubsidiary of AMVAC CV.Hong Kong. AMVAC Hong Kong is a wholly owned subsidiary of AMVAC. During 2017,2022, the international business sold the Company’s products in 6345 countries, as compared to 5954 countries in 2016.2021.

AMVAC M Srl is a wholly owned subsidiary of AMVAC BV and was originally formed in 1998 (originally formed as AMVAC M(as Quimica Amvac de Mexico S.A. de C.V and subsequently changed to AMVAC Mexico Srl in 2013)Sociedad de Responsabilidad Limitada “AMVAC M”) to conduct the Company’s business in Mexico.

AMVAC Sgpr is a wholly owned subsidiary of AMVAC BV and was formed on April 12, 2016. This new entity was formed to conduct the Company’s business in the Asia Pacific and China region.

5


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Hong Kong JV is a 50% owned joint venture with Huifeng (Hong Kong) Limited, a wholly owned subsidiary of Huifeng Agrochemical Company, Ltd, (“Huifeng”) a China based basic chemical manufacturer. The Hong Kong JV was formed on August 2, 2016. The purpose of the joint venture is to be a technology transfer platform between the co-owners, including the development of proprietary agrochemical formulations and precision application systems for crop protection. Furthermore, it is intended to be used to develop both partners’ business in the region. This included, in 2017, the acquisition of 100% of the shares of Profeng.

On October 27, 2017, AMVAC BV purchased 100% of the stock of AgriCenter, located in Costa Rica, which owned shares in subsidiaries located in Costa Rica, Panama, Nicaragua, Honduras, the Dominican Republic, Mexico, Guatemala, and El Salvador. These affiliated entities, collectively known as AgriCenter, market, sell and distribute end-use chemicalchemicals, including the Company’s own products, and biological products throughout Central America primarily for crop applications.

On January 10, 2019, AMVAC BV acquired 100% of the stock of Agrovant and Defensive, two distribution companies based in Brazil. Agrovant and Defensive marketed and distributed crop protection products and micronutrients with focus on the fruit and vegetable market segments throughout Brazil. On December 31, 2020, Agrovant and Defensive merged and the Company renamed the resulting entity AMVAC 3p.

On October 8, 2020, American Vanguard Australia Pty Ltd acquired 100% of the stock of AgNova, an Australian company that sources, develops, and distributes specialty crop protection and production solutions for agricultural and horticultural producers, and for selected non-crop users.

On October 2, 2020, the Company’s principal operating subsidiary, AMVAC, completed the purchase of all outstanding shares of Agrinos and certain intellectual property rights. Agrinos is a fully integrated biological input supplier with proprietary technology, manufacturing, and global distribution capabilities and has operating entities in the U.S., Mexico, India, Brazil, China, Ukraine, and Spain.

The Company classifies as international sales all products bearing foreign labeling shipped to a foreign destination.

 

2017

 

 

2016

 

 

2015

 

 

2022

 

 

2021

 

 

2020

 

International sales

 

$

98,905

 

 

$

83,259

 

 

$

77,295

 

 

$

244,282

 

 

$

215,439

 

 

$

186,980

 

Percentage of net sales

 

 

27.9

%

 

 

26.7

%

 

 

26.7

%

 

 

40.1

%

 

 

38.6

%

 

 

40.8

%

9


Risk Management

The Company regularly monitors matters, whether insurable or not, that could pose material risk to its operations,Company’s Environmental, Social and Corporate Governance (“ESG”) strategy is fully described on our website (www.american-vanguard.com); just click on the safety of its employees and neighbors, and its financial performance.“ESG” tab. The Risk Committee of the Board of Directors (“Board”) was formed in 2010, consists of three members of the Board and meets regularly. All members of the Board are invited to and typically attend Risk Committee meetings. Working with senior management, the committee continuously evaluatesreader will also find the Company’s risk profile, identifies mitigation measures and ensures thatupdated Corporate Sustainability Report under the Company is prudently managing these risks. In support of the Risk Committee, senior management has appointed a risk manager and designated several senior executives to lead teams focused on addressing each of the most material risks facing the Company; these groups perform analysis with the benefit of operational knowledge. The top risks identified by management and being addressed by risk teams (in no particular order) include: adverse political and regulatory climate; managing inventory and optimizing manufacturing efficiency; succession planning and bench strength; maintaining a competitive edge in the marketplace; the possibility of an environmental event; undervaluation of the Company; availability of acquisition and licensing targets and cyber-terrorism. Over the course of 2017, the Company continued to implement its enterprise risk management program, which extends to all areas of potential risk and is a permanent feature in the Company’s operation. In addition, the Company continually evaluates insurance levels for product liability, property damage and other potential areas of risk. Management believes its facilities and equipment are adequately insured against loss from usual business risks including cyber-terrorism.same tab.

Available Information

The Company makes available free of charge (through its website, www.american-vanguard.com), its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with the Securities and Exchange Commission (“SEC”). All reports filed with the SEC are available free of charge on the SEC website, www.sec.gov. Also available free of charge on the Company’s website are the Company’s Audit Committee, Compensation Committee, Finance Committee and Nominating and Corporate Governance Committee Charters, the Company’s Corporate Governance Guidelines, the Company’s Code of Conduct and Ethics, and the Company’s Employee Complaint Procedures for Accounting and Auditing Matters andMatters. Beneath the ESG tab at that site, you will also find links to the Company’s policy on Stockholder NominationCorporate Sustainability Reports, Climate Change Commitment and Communication.Human Rights Policy. The Company’s Internet website and the information contained therein or incorporated therein are not intended to be incorporated into this Annual Report on Form 10-K.

6


AMERICAN VANGUARD CORPORATIONITEM 1A. RISK FACTORS

AND SUBSIDIARIESSupply Chain/Regulatory/Geopolitical/Tax Risks

(DollarsDisruption in thousands, except per share data)the global supply chain is creating delays, unavailability and adverse conditions for our industry, including significant price increases especially with regard to ocean bound shipments. Since the inception of the coronavirus pandemic, the global supply chain has been under increased stress stemming from container shortages, a lack of domestic truck drivers and a shift in consumer buying habits. While shipping channels normalized in 2022, freight costs rose to peak levels. Further, the lockdown practices arising from China’s zero-COVID policy, followed by a lifting of those practices and widespread infection have resulted in factory capacity constraints and temporary closures in that country. This disruption interrupted the supply of a certain key intermediate ingredient for the Company’s leading corn soil insecticide during the fourth quarter of 2022, which contributed to lower-than-expected net sales and profit margin of the Company on a consolidated basis during that reporting period. While that supplier has resumed full operations, there is no guarantee that continued supply of raw materials and intermediates will not be impacted by further developments relating to the pandemic in that region. Such disruption could have a material adverse effect on the Company’s operations, financial condition or cash flows.

ITEM 1A.

RISK FACTORS

The regulatory climate remains challenging to the Company’s interests both domestically and internationallyinternationally. Various agencies within the U.S. (both federal and state) and foreign governments continue to exercise increased scrutiny in permitting continued uses (or the expansion of such uses) of oldermany chemistries, including manyseveral of the Company’s products and, in some cases, have initiated or entertained challenges to these uses. The challenge of the regulatory climate is even more pronounced in certain other geographical regions (outside the U.S.) where the Company faces resistance to the continued use of certain of its products. For example, the EUEuropean Union (“EU”) employs a hazard-based analysis when considering whether product registrations can be maintained; under this approach, EU regulatory authorities typically do not weigh benefit against risk in their assessments and routinely cancel products for which a safer alternative is available, notwithstanding the benefit of the cancelled product. There is no guarantee that this regulatory climate will change in the near term or that the Company will be able to maintain or expand the uses of many of its products in the face of thesesuch regulatory challenges.

USEPA has proposed further limitations on10


Several of the continued registration ofCompany’s organophosphates—On September 25, 2015 are subject to a petition to revoke tolerances under the USEPA publishedFFDCA which, if granted, could result in the Federal Register draft human health risk assessmentslimitation and/or cancellation of one or more registrations for foursuch products. Presently, several of the Company’s organophosphate (“OP”) compounds (marketedproducts are under registration review before the USEPA and, at the same time, subject to a petition to revoke tolerances under the names Bidrin®, Counter®, Folex®Federal Food, Drug, and Mocap®Cosmetic Act ("FFDCA"). The Company continues to provide data and other analysis to USEPA in which it recommendssupport of its registrations and in response to that agency’s requests for clarification. However, in the application ofrecent past, USEPA revoked tolerances for chlorpyrifos (an OP not sold by the Company) finding that food residues from that product could not be deemed with reasonable certainty to cause no harm Consequently, the agency cancelled the registrations for chlorpyrifos. There is no guarantee that USEPA will not make a 10X safety factor under the FQPA (Food Quality Protection Act) in lightsimilar finding with respect to one or more of the alleged possibility of neurodevelopmental harm to women and children based on epidemiological data. Since that time, in the face of objection from industry, the agency has applied this safety factor to all registeredCompany’s OPs, as they have come up for review or renewal. The Company, like many in our industry, believes that the basis for applying this safety factor is not based upon sound science and that some or all uses of the Company’s OP products could be limited studies upon which the agency is relying (for which raw data is not available even to the agency) do not establish a causal link between the perceived harm and the use of its products.or cancelled. Accordingly, the Company intends to take all action necessary to defend its registrations. We have been joined in this effort by other companies that are similarly concerned about the potential impact of USEPA’s action. Nevertheless, there is no guarantee that the Company’s actions will alter the course that USEPA has proposed and, if the agency’s position becomes final, some uses of the company’s OP products could be limited Such limitations and/or cancelled. Such actioncancellations could have a material adverse effect upon the Company’s financial performance in future reporting periods.

USEPA has issued a proposed final decision ("PFD") to cancel PCNB. In mid-2022, the USEPA issued a “proposed final decision” (a variety of agency action heretofore unknown to registrants) to cancel the fungicide PCNB, which is registered by the company for use on golf courses and potatoes, among other things. The basis for its PFD was the agency’s initial contention that the product is persistent, bioaccumulative and toxic (“PBT”). The Company disagrees with the agency’s contention and believes that its scientific support for those findings is flawed. In reaching a conclusion that a registered product is a PBT, the agency tends to focus far less on product benefit and far more on product risk. Further, by issuing a PFD, USEPA is, in effect, skipping two steps in the registration review process (namely, the preliminary interim decision and interim decision) during which the Company would otherwise have more time to answer the agency’s concerns and otherwise provide data necessary to support continued registration. In effect, then, the Company must meet a truncated schedule for defending this product, all of which is posted on a public docket, and is doing so under a more stringent standard of review (namely, that of a deemed PBT). Since making its initial determination, the agency has suggested that PCNB may merely have some characteristics of a PBT. There is no guarantee that the Company will succeed in persuading USEPA not to cancel the PCNB registration. AMVAC is the sole registrant of PCNB which it manufactures at its own facility. Loss of this product could have a material adverse negative effect on our operating results.

USEPA has issued a notice of intention to suspend DCPA, the technical ingredient of an important herbicide registered by the company for use on high-value vegetable crops. In April 2022, USEPA issued a notice of intention to suspend ("NOITS") the registration for DCPA based upon the company’s alleged failure to take appropriate steps in responding to an extensive data call in for nearly 90 data studies. The NOITS came as a surprise to AMVAC, as it had been working in good faith to provide dozens of studies over several years, some of which were so complex that it required a review process extending to five years just to define the study protocols. The NOITS is currently pending before an administrative law judge ("ALJ"), who conducted a hearing on the matter in January 2023 and is likely to issue an order within 90-120 days. There is no guarantee that the ALJ will rule in AMVAC’s favor and deny the requested suspension. If AMVAC does not succeed at the NOITS hearing, there is no guarantee that USEPA will not seek to suspend the registration of most any product for which a data call-in is pending, including one or more of AMVAC’s other products. Further, a suspension of DCPA and/or other products could have a material, adverse effect upon the Company’s business operations and financial performance.

Product liability judgments on glyphosate and cases involving other pesticides by domestic courts present a litigation risk to companies in this industry. Multiple judgments have been rendered by domestic courts in product liability cases against Bayer/Monsanto in connection with injuries allegedly arising from exposure to the herbicide product, glyphosate. The basis was purported carcinogenicity based largely upon the findings of a certain international organization, despite significant scientific evidence to the contrary. While the Company does not sell glyphosate, the theory of these results could put one or more of the Company’s products at risk. There is no guarantee that one or more product liability actions would not be brought against the Company on a similar basis, and it is possible that adverse rulings in any such actions could have a material adverse effect upon the Company’s financial performance in future reporting periods.

The trend of passing pesticide “ban-bills” in various states could put one or more of the Company’s products at risk—In certain states, including Maryland and New York, state and/or local legislatures have passed legislation banning the use of specific pesticides, such as chlorpyrifos, or pesticide in general, in spite of valid registrations at USEPA and/or the equivalent state agency. While the Company does not sell chlorpyrifos products, there is no guarantee that one or more of its registered products would not be targeted in state or local legislation of this nature. Further, such legislation could have a material adverse effect upon the Company’s financial performance in future reporting periods.

11


Use of the Company’s products is subject to continuing challenges from activist groupsgroups. Use of agrochemical products, including the Company’s products, is regularly challenged by activist groups in many jurisdictions under a multitude of federal, state and foreign statutes, including FIFRA, the Food Quality Protection Act, Endangered Species Act (“ESA”) and the Clean Water Act, to name a few. These challenges typically take the form of lawsuits or administrative proceedings against the USEPA and/or other federal, state or foreign agencies, the filing of amicus briefs in pending actions, the introduction of legislation that is inimical to the Company’s interests, and/or adverse comments made in response to public comment invited by regulatory agencies in the course of registration, re-registration or label expansion. The most prominent of these actions include a line of cases under which environmental groups have sought to suspend, cancel or otherwise restrict the use of pesticides that have been approved by USEPA on the ground that that agency failed to confer with the National Marine Fishery Service and/or the Fish and Wildlife Service under the ESA with respect to biological opinions relating to the use of such products. While industry has been active in defending registrations and proposing administrative and legislative approaches to address serious resource issues at the affected agencies, these cases continue to be brought. It is possible that one or more of these challenges could succeed, resulting in a material adverse effect upon one or more of the Company’s products.products and consolidated financial statements.

The distribution and sale of the Company’s products are subject to prior governmental approvals and thereafter ongoing governmental regulationregulation. The Company’s products are subject to laws administered by federal, state and foreign governments, including regulations requiring registration, approval and labeling of its products. The labeling requirements restrict the use of, and type of, application for our products. More stringent restrictions could make our products less available, which would adversely affect our revenues and profitability.profitability and cash flows. Substantially all of the Company’s products are subject to the USEPA (and/or similar agencies in the various territories or jurisdictions in which we do business) registration and re-registration requirements and are registered in accordance with FIFRA or similar laws. Such registration requirements are based, among other things, on data demonstrating that the product will not cause unreasonable adverse effects on human health or the environment when used according to approved label directions. All states, where any of the Company’s products are used, also require registration before products, such as the Company sells, can be marketed or used in that state. Governmental regulatory authorities have required, and may require in the future, that certain scientific data requirements be performedfulfilled on the Company’s products. The Company, on its behalf and also in joint efforts with other registrants, has furnished, and is currently furnishing certain required data relative to its products. There can be no assurance, however, that the USEPA or similar agencies will not request that certain tests or studies be repeated, or that more stringent legislation or requirements will not be imposed in the future. The Company can provide no assurance that any testing approvals or registrations will be granted on a timely basis, if at all, or that its resources will be adequate to meet the costs of regulatory compliance.

7


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

The manufacturing of the Company’s products is subject to governmental regulationsregulations.The Company currently owns and operates threesix manufacturing facilities which are located in Los Angeles, California; Axis, Alabama; Hannibal, Missouri; Marsing, Idaho; Clackamas, Oregon; and Marsing, Idaho and owns and has manufacturing services provided in a fourth facility in Hannibal, MissouriEtchojoa, Mexico (the “Facilities”). The Facilities operate under the laws and regulations imposed by relevant country, state and local authorities. The manufacturing of key ingredients for certain of the Company’s products occurs at the Facilities. An inability to renew or maintain a license or permit, or a significant increase in the fees for such licenses or permits, could impede the Company’s manufacture of one or more of its products and/or increase the cost of production; this, in turn, would materially and adversely affect the Company’s ability to provide customers with its products in a timely and affordable manner.

A change in tax laws, treaties or regulations, or their interpretation or application, could have a negative impact on our business and results of operations. We operate in many different countries and in many states within the United States, and we are subject to changes in applicable tax laws, treaties or regulations in the jurisdictions in which we operate. A material change in these tax laws, treaties or regulations, or their interpretation or application, could have a negative impact on our business and results of operations. On August 16, 2022, the Inflation Reduction Act of 2022 (the "IRA") was signed into law. The IRA contains several revisions to the Internal Revenue Code, including a 15% corporate minimum income tax for corporations with average annual adjusted financial statement income over a three-tax-year period in excess of $1 billion and is effective for the tax years beginning after December 31, 2022, a 1% excise tax on stock repurchases made by publicly traded U.S. corporations after December 31, 2022, and business tax credits and incentives for the development of clean energy projects and the production of clean energy. At this time, we do not expect the IRA will have a material impact on our consolidated financial statements. However, any future stock repurchase of our common stock will be subject to the new excise tax law.

12


Pandemic/Climate/Geopolitical Risks

The COVID-19 pandemic is creating risk, uncertainties and adverse conditions in many industries both here and abroad. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic is impacting its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the years ended December 31, 2022, 2021, and 2020 the Company is unable to predict the impact that the pandemic will have on its future financial condition, results of operations and cash flows due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations and cash flows will not be materially adversely affected by the pandemic in future periods.

Climate Change may adversely affect the Company’s business. Over the course of the past several years, global climate conditions have become increasingly inconsistent, volatile and unpredictable. Many of the regions in which the Company does business have experienced excessive moisture, cold, drought and/or heat of an unprecedented nature at various times of the year. In some cases, these conditions have either reduced or obviated the need for the Company’s products, whether pre-plant, at-plant, post-emergent or at harvest. Further, the random nature of climactic change has made it increasingly difficult to forecast market demand and, consequently, financial performance, from year-to-year. There is no guarantee that climate change will abate in the near future, and it is possible that such change will continue to hinder the Company’s ability to forecast its sales performance with accuracy and otherwise adversely affect the Company’s financial performance.

The Company’s business may be adversely affected by weather effects and commodity prices. Demand for many of the Company’s products tends to vary with weather conditions and weather-related pressure from pests. Adverse weather conditions, then, may reduce the Company’s revenues and profitability. In light of the possibility of adverse seasonal effects, there can be no assurance that the Company will maintain sales performance at historical levels in any particular region. Similarly, demand for the Company’s products used in row crops tends to vary with the commodity prices of those crops, for instance, corn, soybeans and cotton. These prices may be driven in part by weather, pest pressure, the domestic farm economy and international markets (e.g., yield and pricing from similar crops grown in Brazil). There is no guarantee that the farm economy and row crop commodity prices will maintain sufficient strength and stability to support the Company’s products at or above historical levels.

The Russian invasion of Ukraine may expand into a broader international conflict that could adversely affect multiple channels of commerce and markets. While business operations relating to Ukraine constitute an immaterial part of the Company’s overall business, there is no guarantee that the current conflict will not draw military intervention from other countries or retaliation from Russia, which, in turn, could lead to a much larger conflict. If such escalation should occur, supply chain, trade routes and markets currently served by the Company could be adversely affected, which, in turn, could materially, adversely affect the Company’s business operations and financial performance.

The Company may be subject to environmental liabilities—While theliabilities. The Company expends substantial funds to minimizeis fully committed toward minimizing the risk of discharge of materials into the environment and to complycomplying with governmental regulations relating to protection of the environment, its neighbors and its workforce,workforce. Nevertheless, federal and state authorities may nevertheless seek fines and penalties for any violation of the various laws and governmental regulations. In addition, while the Company continually adapts its manufacturing processes to the latest environmental control standards of regulatory authorities, it cannot completelyentirely eliminate the risk of accidental contamination or injury from hazardous or regulated materials. Further, these various governmental agencies could, among other things, impose potential civil and criminal liability arising under RCRA for the Company’s importation (transportation, handling, and storage) of depleted Thimet containers (see, “Legal Proceedings” below). In short, the Company may be held liable for significant damages or fines relating to any environmental contamination, injury, or compliance violation which could have a material adverse effect on the Company’s consolidated financial condition, statements of operations and cash flows.

13


Acquisition/Investment Risks

Newly acquired businesses or product lines may not generate forecasted results. While the Company conducts due diligence on acquisitionsusing a combination of internal and employs rigorous investmentthird-party resources and applies what it believes to be appropriate criteria for each transaction before making acquisitions, there is no guarantee that a business or product line acquired by the Company will generate results that meet or exceed results that were forecasted by the Company inwhen evaluating the acquisition. There are many factors that could affect the performance of a newly acquired business or product line. While the Company uses conservative assumptions that are based upon due diligence and other market information in valuing a business or product line prior to concluding an acquisition, actual results generated post-closing could vary widely from the Company’s forecast and, as such, could have a material effect upon the Company’s overall financial performance.

The Company’s investment in foreign businesses may pose additional risks. With the expansion of its footprint internationally, and, in particular, with the business acquired in Central America in 2017, the Company now carries on business at a material level in some jurisdictions that have a history of political, economic or currency-related instability including civil unrest, government takings without reimbursement, and customers with a potentially higher risk profile regarding accounts receivable collectability, as compared to the imposition of penalties without due process of law.Company’s legacy business. While such instability may not be present at the current time, there is no guarantee that conditions will not change in one or more jurisdictions quickly and without notice, nor is there any guarantee that the Company would be able to recoup its investment in such territories in light of such changes.changes and potential losses due to political factors, economic factors, devaluation of local currencies, or the collectability risk from customers. Adverse changes of this nature could have a material effect upon the Company’s overall financial performance.

The Company’s investment in technology may not generate forecasted returns. The Company has had a history of investing in technological innovation, primarily focused on product delivery systemsincluding with respect to precision application technologies (such as SIMPAS and Ultimus), natural oil technology and biologicals, as one of its core strategies. We have focused on technology in closed delivery systems, fumigant application and precision application, to name a few. These investments are based upon the premise that new technology will allow for safer handling or lower overall toxicity profile of the Company’s products,product portfolio, appeal to regulatory agencies and the market we serve, gain commercial acceptance, and command a return that is sufficiently in excess of the investment. However, there is no guarantee that a new technology will be successfully commercialized, generate a material return or maintain market appeal for a substantial period of time.appeal. Further, many types of development costs must be expensed in the period in which they are incurred. This, in turn, tends to put downward pressure on period profitability. There can be no assurance that these expenses will be recovered through successful long-term commercialization of a new technology.

The Company’s businessgrowth has been fueled in part by acquisitions. Over the past few decades, the Company’s growth has been driven by acquisitions and licensing of both established and developmental products from third parties. There is no guarantee that acquisition targets or licensing opportunities meeting the Company’s investment criteria will remain available or will be affordable. If such opportunities do not present themselves, then the Company may be adversely affected by cyclical and seasonal effects—Demand for the Company’s products tendsunable to be seasonal. Seasonal usage follows varying agricultural seasonal patterns, weather conditions and weather related pressure from pests. Weather patterns can have an impact on the Company’s operations. For example, the end user of its products may, because of weather patterns, delay or intermittently disrupt field work during the planting season, which may resultduplicate historical growth rates in a reduction of the use of some products and therefore may, at some point, reduce the Company’s revenues and profitability. In light of the possibility of adverse seasonal effects, there can be no assurance that the Company will maintain sales performance at historical levels in any particular region.future years.

The Company is dependent upon certain sole source suppliers for certain of its raw materials and active ingredientsingredients. There are a limited number of suppliers of certain important raw materials used by the Company in manya number of its products. Certain of these raw materials are available solely from single sources either domestically or overseas. Starting January 1, 2017,In connection with supply chain disruptions in 2021, phosphorus and related compounds were increasingly difficult to source for our entire industry; ensuring a continuous supply required extraordinary efforts both with respect to sourcing and production planning. In the Chinese

8


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

government has placed significant restrictions on chemical manufacturing inlast quarter of 2022, there was a temporary supply chain shortage of one key raw material of the People's Republic of China.  This, in turn, has led to closure of multiple manufacturing plants and scarcity of supply for certain products that are imported by the Company.  In conjunction with the purchase and/or licensing of certain product lines, the Company has entered into multi-year supply arrangements under which such counterparties are the sole source of either active ingredients and/or formulated end-use product and, in some cases, the manufacturer has entered the market as a competitor. The Company is actively pursuing new supply agreements to mitigate the risk of product supply from the People’s Republic of China, by either approving new suppliers outside of China, or conversely by pursuing new Chinese suppliers who have a stronger in situ backward integration position. ThereCompany’s largest corn soil insecticide, Aztec. That said, there is no guarantee that any of our suppliers will be willing or able to supply these products to the Company reliably, continuously and at the levels anticipated by the Company or required by the market. If these sources prove to be unreliable and the Company is not able to supplant or otherwise second source these suppliers,products, it is possible that the Company will not realizeachieve its projected sales which, in turn, could adversely affect the Company's consolidated financial statements.

To the extent that capacity utilization is not fully realized at its manufacturing facilities, the Company may experience lower profitability—While the Company endeavors continuously to maximize utilization of it manufacturing facilities, our success in these endeavors is dependent upon many factors, including fluctuating market conditions, product life cycles, weather conditions, availability of raw materials, equipment failures, and regulatory constraints, among other things. There can be no assurance that the Company will be able to maximize the utilization of capacity at its manufacturing facilities.

The Company’s continued success depends, in part, upon a limited number of key employees—Within certain functions, the Company relies heavily on a small number of key employees to manage ongoing operations and to perform strategic planning. In some cases, there are no internal candidates who are qualified to succeed these key personnel in the short term. In the event that the Company were to lose one or more key employees, there is no guarantee that Company could replace them with people having comparable skills. Further, the loss of key personnel could adversely affect the operation of our business.

The Company faces competition in certain markets from new technologies and demand for organically produced food—The Company faces competition from larger companies that market new chemistries, genetically modified (“GMO”) seeds and other similar technologies (e.g., RNA interference) in certain of the crop protection sectors in which the Company competes, particularly that of corn. In fact, many growers that have chosen to use GMO seeds have reduced their use of the types of pesticides sold by the Company. At the same time, the demand for organically-produced food, which, generally speaking, is made without the use of synthetic chemicals (which constitute most of the Company’s products) continues to increase.  There is no guarantee that the Company will maintain its market share or pricing levels in sectors that are subject to competition from companies that market new technologies.  Further, it is possible that increased demand for organic crops may, over time, reduce the demand for the Company’s products.

The Company faces competition from generic competitors that source product from countries having lower cost structuresstructures. The Company continues to face competition from competitors around the globe that may enter the market through either offers to pay data compensation, or similar means in foreign jurisdictions, and then subsequently source material from countries having lower cost structures (typically India and China). These competitors typically tend to operate at thinner gross margins and, with low costs of goods, tend to drive pricing and profitability of subject product lines downward. There is no guarantee that the Company will maintain market share and pricing overwhen facing such generic competitors, or that such competitors will not offer generic versions of the Company’s products in the future.

14


The Company’s key customers typically carry competing product lines and may be influenced by the Company’s larger competitorscompetitors. A significant portion of the Company’s products are sold to national distributors in the United States,U.S., which also carry product lines of competitors that are much larger than the Company. Typically, revenues from the sales of these competingcompetitor product lines and related program incentives constitute a greater part of our distributors’ income than do revenues from sales and program incentives arising from the Company’s product lines. With the recent consolidation among domestic distribution companies, these considerations have become more pronounced. In light of these facts, there is no assurance that such customers will continue to market our products aggressively or successfully, or that the Company will be able to influence such customers to continue to purchase our products instead of those of our competitors.

Industry consolidation may threaten the Company’s position in various marketsmarkets. The global agricultural chemical industry continues to undergo significant consolidation. Many of the Company’s competitors have grown or are expected to grow through mergers and acquisitions. As a result, these competitors will tend to be in position to realize greater economies of scale, offer more diverse portfolios and thereby exert greater influence throughout the distribution channels. Consequently, the Company may find it more difficult to compete in various markets. While such merger activity may generate acquisition opportunities for the Company,

9


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

there is no guarantee that the Company will benefit from such opportunities. Further, there is a risk that the Company’s future performance may be hindered by the growth of its competitors through consolidation.

The Company is dependent on a limited number of customers, which makes it vulnerable to the continued relationship with and financial health of those customers—In 2017 and 2016,customers. Our top three customers accounted for 33% and 34%, respectively,39% of the Company’s sales.sales in 2022, 2021 and 2020. The Company’s future prospects may depend on the continued business of such customers and on our continued status as a qualified supplier to such customers. The Company cannot guarantee that these key customers will continue to buy products from us at current levels. The loss of a key customer could have a material adverse effect on the Company’s consolidated financial statements.

General Risks

The carrying value of certain assets on the Company’s consolidated balance sheets may be subject to impairment depending upon market trends and other factors—The Company regularly reviews the carrying value of certain assets, including long-lived assets, inventory, fixed assets and intangibles. Depending upon the class of assets in question, the Company takes into account various factors including, among others, sales, trends, market conditions, cash flows, profit margins and the like. Based upon this analysis, where circumstances warrant, the Company may leave such carrying values unchanged or adjust them as appropriate. There is no guarantee that these carrying values can be maintained indefinitely, and it is possible that one or more such assets could be subject to impairment which, in turn, could have an adverse impact upon the Company’s consolidated financial statements.

The Company’s computing systems are subject to cyber security risks – risks. In the course of its operations the Company relies on its computing systems, including access to the internet, the use of third partythird-party applications and the storage and transmission of data through such systems. While the Company has implemented security measures to protect these systems, there is no guarantee that a third party maythird-party will not penetrate these defenses through hacking, phishing or otherwise and either compromise, corrupt or shut down these systems. Further, in the event of such incursion it is possible that confidential business information and private personal data could be confiscated.taken. Such an event could adversely affect both the Company’s ability to operate, its reputation with key stakeholders and its overall financial performanceperformance.

15


Reduced financial performance may limit the Company’s ability to borrow under its credit facilityfacility. The Company has historically grown net sales and net income through boththe expansion of current product lines, the acquisition of product lines from third parties and during 2017, the acquisition of both domestic and international distributors with strong niche market positions. In order to finance such acquisitions, the Company has drawn upon its senior credit facility. However, the Company’s borrowing capacity under the senior credit facility depends, in part, upon its satisfaction of a negative covenant that sets a maximum ratio of borrowed debt to earnings (as measured over the trailing 12 month12-month period). There is no guarantee that the Company will continue to generate earnings necessary to ensure that it has sufficient borrowing capacity to support future acquisitions or that, when necessary, the lender group will amend the senior credit facility to provide for such borrowing capacity.Further, despite the Company’s long-standing relationship with its lenders, in light of the uncertainties in global financial markets, there is no guarantee that the Company’s lenders will be either willing or able to continue lending to the Company at such rates and in such amounts as may be necessary to meet the Company’s working capital needs.

The Company is subject to taxation related risks in multiple jurisdiction. The Company is a U.S. based multinational company subject to tax in multiple U.S. and foreign tax jurisdictions. Significant judgment is required in determining our global provision for income taxes, deferred tax assets or liabilities and in evaluating our tax positions on a worldwide basis. While we believe our tax positions are consistent with the tax laws in the jurisdictions in which we conduct our business, it is possible that these positions may be contested or overturned by jurisdictional tax authorities, which may have a significant impact on our global provision for income taxes. Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. In 2017, the U.S. enacted significant tax reform, and in the long-term certain provisions of the new law may adversely affect us. In addition, governmental tax authorities are increasingly scrutinizing the tax positions of companies. Many countries in the EU, as well as a number of other countries and organizations such as the Organization for Economic Cooperation and Development, are actively considering changes to existing tax laws that, if enacted, could increase our tax obligations in countries where we do business. If U.S. or other foreign tax authorities change applicable tax laws, our overall taxes could increase, and our business, financial condition, results of operations, or cash flows may be adversely impacted.

To the extent that capacity utilization is not fully realized at its manufacturing facilities, the Company may experience lower profitability. While the Company endeavors continuously to maximize utilization of its manufacturing facilities, our success in these endeavors is dependent upon many factors, including fluctuating market conditions, product life cycles, weather conditions in our key markets, availability of raw materials, manufacturing equipment performance, retention of the workforce and regulatory constraints, among other things. There can be no assurance that the Company will be able to maximize the utilization of its manufacturing facilities. Underutilization of such manufacturing resources could have a material adverse effect upon the Company’s financial performance.

The Company’s growth has been fueledcontinued success depends, in part, by acquisition—Overupon a limited number of key employees. Within certain functions, the past few decades,Company relies heavily on a small number of key employees to manage ongoing operations and to perform strategic planning. In some cases, there are no internal candidates who are qualified to succeed these key personnel in the Company’s growthshort term. In the event that the Company were to lose one or more key employees, there is no guarantee that Company could replace them with people having comparable skills. Further, the loss of key personnel could adversely affect the operation of our business.

Domestic and regional inflation trends, increased interest rates and other factors could lead to the erosion of economies and adversely impact the Company. Both the US and many other countries are experiencing inflation, which, in turn, is leading to increased costs in multiple industry segments, including agriculture and related industries. The persistence of inflation has been driven by acquisition and licensing of both established and developmental products from third parties.led central bankers to increase interest rates within their regions. There is no guarantee that acquisition targets or licensing opportunities meetingthese measures will arrest the inflationary trend. Further, these factors, taken together with reduced productivity and constraints on the labor supply could lead to recessionary periods in the regions in which the Company does business. While the Company takes measures within its control to manage the effects of inflation, higher interest rates and other factors, ultimately, they are outside of the Company’s investment criteria will remain available control. Further, the persistence and/or will be affordable. If such opportunities do not present themselves, thenseverity of one or more of them could adversely affect the Company may be unable to record consistent growth in future years.financial performance and/or operations of the Company.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

16


ITEM 1B. UNRESOLVED STAFF COMMENTS

None

ITEM  2

PROPERTIES

ITEM 2 PROPERTIES

AMVAC owns in fee the Facility constituting approximately 152,000 square feet of improved land in Commerce, California (“Commerce”) on which its West Coast manufacturing, some of its warehouse facilities and some of its manufacturing administrative offices are located.

DAVIE owns in fee approximately 72,000 square feet of warehouse, office and laboratory space on approximately 118,000 square feet of land in Commerce, California, which is leased to AMVAC. In 2013, the Company made a significant investment in the Glenn A. Wintemute Research Center, which houses the Company’s primary research laboratory supporting synthesis, formulation and other new product endeavors.

10


AMERICAN VANGUARD CORPORATIONIn 2001, AMVAC completed the acquisition of a manufacturing facility (the “Axis Facility”) from E.I. DuPont de Nemours and Company (“DuPont”). The Axis Facility was one of three such units located on DuPont’s 510-acre complex in Axis, Alabama. The acquisition consisted of a long-term ground lease of 25 acres and the purchase of all improvements thereon. The facility is a multi-purpose plant designed for synthesis of active ingredients and formulation and packaging of finished products. In 2018, FMC Corporation acquired from DuPont a business unit, which held, among other things, the Axis Facility. Prior to expiration of the lease, AMVAC and FMC negotiated the terms of a new lease, which has a term of 15 years and the option to renew for two, 5-year periods.

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

On December 28, 2007, AMVAC purchased certain manufacturing assets relating to the production of Thimet and Counter and located at BASF’s multi-plant facility situated in Hannibal, Missouri (the “Hannibal Site”). Subject to the terms and conditions of the Agreement, AMVAC purchased certain buildings, manufacturing equipment, office equipment, fixtures, supplies, records, raw materials, intermediates and packaging constituting the “T/C Unit” of the Hannibal Site. The parties entered into a ground lease and a manufacturing and shared services agreement, under which BASF continues to supply various shared services to AMVAC for the Hannibal Site.

On March 7, 2008, AMVAC acquired from Bayer CropScience Limited Partnership, (“BCS LP”), a U.S. business of Bayer CropScience GmbH, a facility (the “Marsing Facility”) located in Marsing, ID,Idaho, which consists of approximately 17 acres of improved real property, 15 of which are owned by AMVAC and two of which AMVAC leases from the City of Marsing for a term of 25 years.property. The Marsing Facility is engaged in the blending of liquid and powder raw materials and the packaging of some of the Company’s finished goods inventory in liquid, powder and pelletized formulations which are sold both in the USU.S. and internationally. With this acquisition,In addition, during 2019, the Company purchased approximately three acres of unimproved real estate immediately adjacent to the Marsing Facility for potential storage and operational use in the future.

On October 2, 2020, AMVAC acquired the ability to formulate flowable materials. In connection with the acquisition, AMVAC and BCS LP agreed to enter into a master processor agreement under which AMVAC provides certain third party manufacturing services to BCS LP on an ongoing basis that continued into 2015. Following the termination of the master supply agreement, AMVAC and BCS LP have continued to trade on a normal commercial basis.

In 2001, AMVAC completed the acquisition of a manufacturing facility (the “Axis Facility”) from E.I. DuPont de Nemours and Company (“DuPont”). The Axis Facility is one of three such units located on DuPont’s 510 acre complex in Axis, Alabama. The acquisition consisted of a long-term ground lease of 25 acres and the purchase of all improvements thereon. The facilityoutstanding shares of Agrinos which is a multi-purpose plant designedfully integrated biological input supplier with proprietary technology, internal manufacturing, and global distribution capabilities. Its High Yield Technology® product platform works in conjunction with other nutritional crop inputs to increase crop yield, improve soil health and reduce the environmental footprint of traditional agricultural practices. Agrinos has two primary biological production facilities, a state-of-the-art microbial fermentation facility based in Clackamas, Oregon, and a facility in Sonora, Mexico. The Clackamas and Sonora facilities are used as both manufacturing sites, and operational centers for synthesis of active ingredientsglobal supply chain and formulation and packaging of finished products.logistics.

AMVAC17


AVD regularly adds chemical processing equipment to enhance or expand its production capabilities. AMVACThe Company believes its facilities are in good operating condition, are suitable and adequate for current needs and have flexibility to change products, and can produce at greater rates as required.products. Facilities and equipment are insured against losses from fire as well as other usual business risks. The Company knows of no material defects in title to, or encumbrances on, any of its properties except that substantially all of the Company’s assets are pledged as collateral under the Company’s credit facility agreements with its primary lender group. For further information, refer to note 2Note 3 of the Notes to the Consolidated Financial Statements in Part IV,II, Item 158 of this Annual Report on Form 10-K.

AMVACAVD owns approximately 42 acres of unimproved land in Texas for possible future expansion.

The Company leases approximately 19,953 square feet of office space located at 4695 MacArthur Court in Newport Beach, California. In September 20152020, the lease was amended and was extended to expire on June 30, 2021.2026. The premises have served as the Company’s corporate headquarters since 1994.1995.

The facilities occupied by GemChem, OHP, Envance and TyraTech (Envance and TyraTech are co-located), AMVAC BV’s, GemChem’s, AMVAC M’s,BV, AMVAC M, Srl’s, AMVAC CR Srl’s,Srl, AMVAC Sgpr’s, OHP’sSgpr, AgNova, Agrinos, AMVAC 3p and AgriCenter’s facilitiesAgriCenter, consist of administration, development centers (in the case of Envance and TyraTech) and/or sales offices which are leased. In addition, AMVAC 3p leases warehouse space in Jaboticabal, Brazil.


AMERICAN VANGUARD CORPORATIONITEM 3 LEGAL PROCEEDINGS

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

ITEM  3

LEGAL PROCEEDINGS

A. DBCP Cases

Over the coursePlease refer to Note 5 of the past 30 years, AMVAC and/or the Company have been named or otherwise implicated in a number of lawsuits concerning injuries allegedly arising from either contamination of water supplies or personal exposure to 1, 2-dibromo-3-chloropropane (“DBCP®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the USEPA to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. That suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product.

At present, there are three domestic lawsuits and approximately 85 Nicaraguan lawsuits filed by former banana workers in which AMVAC has been named as a party. Only two of the Nicaraguan actions have actually been served on AMVAC.  With respect to Nicaraguan matters, there was no change in status during 2017. As described more fully below, activity in domestic cases during 2017 is as follows.  The one case remaining in Delaware includes 57 plaintiffs who have appealed a lower court finding that the matter was barred by the statute of limitations; this matter has been stayed pending a ruling by the Delaware Supreme Court on the question of when or if the statute of limitations has run out.  In Hawaii, in the matter of Patrickson, et. al. v. Dole Food Company, following the appellate court’s remandNotes to the trial court for adjudicationConsolidated Financial Statements in 2016, there has been no activity; while in Adams, there has been no activity since 2014, when the court granted dismissal of co-defendant Dole on the basis of a worker’s compensation bar and gave plaintiffs leave to amend their complaint in light of that ruling.

Nicaraguan Matters

A review of court filings in Chinandega, Nicaragua, has found 85 suits alleging personal injury allegedly due to exposure to DBCP and involving approximately 3,592 plaintiffs have been filed against AMVAC and other parties. Of these cases, only two – Flavio Apolinar Castillo et al. v. AMVAC et al., No. 535/04 and Luis Cristobal Martinez Suazo et al. v. AMVAC et al., No. 679/04 (which were filed in 2004 and involve 15 banana workers) – have been served on AMVAC. All but one of the suits in Nicaragua have been filed pursuant to Special Law 364, an October 2000 Nicaraguan statute that contains substantive and procedural provisions that Nicaragua’s Attorney General previously expressed as unconstitutional. Each of the Nicaraguan plaintiffs’ claims $1 million in compensatory damages and $5 million in punitive damages. In all of these cases, AMVAC is a joint defendant with Dow Chemical Company and Dole Food Company, Inc. AMVAC contends that the Nicaragua courts do not have jurisdiction over it and that Public Law 364 violates international due process of law. AMVAC has objected to personal jurisdiction and demanded under Law 364 that the claims be litigated in the United States. In 2007, the court denied these objections, and AMVAC appealed the denial. It is not presently known as to how many of these plaintiffs actually claim exposure to DBCP at the time AMVAC’s product was allegedly used nor is there any verification of the claimed injuries. Further, to date, plaintiffs have not had success in enforcing Nicaraguan judgments against domestic companies before U.S. courts. With respect to these Nicaraguan matters, AMVAC intends to defend any claim vigorously. Furthermore, the Company does not believe that a loss is either probable or reasonably estimable and has not recorded a loss contingency for these matters.

Delaware DBCP Cases

Abad Castillo and Marquinez.  On or about May 31, 2012, two cases (captioned Abad Castillo and Marquinez) were filed with the United States District Court for the District of Delaware (USDC DE No. 1:12-CV-00695-LPS) involving claims for physical injury arising from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala, and Panama.  Defendant Dole brought a motion to dismiss 22 plaintiffs from Abad Castillo on the ground that they were parties in cases that had been filed by HendlerLaw, P.C. in Louisiana.  On September 19, 2013, the appeals court granted, in part, and denied, in part, the motion to dismiss, holding that 14 of the 22 plaintiffs should be dismissed.  On May 27, 2014, the district court granted Dole’s motion to dismiss the matter without prejudice on the ground that the applicable statute of limitations had expired in 1995.  Then, on August 5, 2014, the parties stipulated to summary judgment in favor of defendants (on the same ground as the earlier motion) and the court entered judgment in the matter.  Plaintiffs were given an opportunity to appeal; however, only 57 of the 2,700 actually entered an appeal.  Thus, at this stage, only 57 plaintiffs remain in the action.  On or about June 18, 2017, the Third Circuit Court submitted a certified question of law to the Delaware Supreme Court on the question of when the tolling period ended. The Delaware Supreme Court heard oral argument on January 17, 2018 and is expected to issue a ruling within 90 days. During the pendencyPart II, item 8 of this question, these matters will be effectively stayed.  At any rate, the Company believes that a loss is neither probable nor reasonably estimable in these matters and has not recorded a loss contingency.  Annual Report on Form 10-K.

12ITEM 4 MINE SAFETY DISCLOSURES

Not Applicable.

18


AMERICAN VANGUARD CORPORATION

PART II

ITEM 5 MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND SUBSIDIARIESISSUER PURCHASES OF EQUITY SECURITIES

(Dollars in thousands, except per share data)

Hawaiian DBCP Matters

Patrickson, et. al. v. Dole Food Company, et al. In October 1997, AMVAC was served with two complaints in which it was named as a defendant, filed in the Circuit Court, First Circuit, State of Hawai’i and in the Circuit Court of the Second Circuit, State of Hawai’i (two identical suits) entitled Patrickson, et. al. v. Dole Food Company, et. al (“Patrickson Case”) alleging damages sustained from injuries (including sterility) to banana workers caused by plaintiffs’ exposure to DBCP while applying the product in their native countries. Other named defendants include: Dole Food Company, Shell Oil Company and Dow Chemical Company. After several years of law and motion activity, the court granted judgment in favor of the defendants based upon the statute of limitations on July 28, 2010. On August 24, 2010, the plaintiffs filed a notice of appeal. On October 21, 2015, the Hawai’i Supreme Court granted the appeal and overturned the lower court decision, ruling that the State of Hawai’i now recognizes cross-jurisdictional tolling, that plaintiffs filed their complaint within the applicable statute of limitations and that the matter is to be remanded to the lower court for further adjudication. No discovery has taken place in this matter, and, at this stage in the proceedings, the Company does not believe that a loss is either probable or reasonably estimable and, accordingly, has not recorded a loss contingency for this matter.

Adams v. Dole Food Company et al. On approximately November 23, 2007, AMVAC was served with a suit filed by two former Hawaiian pineapple workers (and their spouses), alleging that they had testicular cancer due to DBCP exposure; the action is captioned Adams v. Dole Food Company et al in the First Circuit for the State of Hawaii. Plaintiff alleges that they were exposed to DBCP between 1971 and 1975. AMVAC denies that any of its product could have been used at the times and locations alleged by these plaintiffs. Following the dismissal of Dole Food Company on the basis of the exclusive remedy of worker’s compensation benefits, plaintiffs appealed the dismissal. The court of appeals subsequently remanded the matter to the lower court in February 2014, effectively permitting plaintiffs to amend their complaint to circumvent the workers’ compensation bar. There has been no activity in the case since that time. The Company does not believe that a loss is either probable or reasonably estimable and has not recorded a loss contingency for this matter.

B. Other Matters

EPA FIFRA/RCRA Matter.  On November 10, 2016, the Company was served with a grand jury subpoena out of the U.S. District Court for the Southern District of Alabama in which the U.S. Department of Justice (“DoJ”) sought production of documents relating to the Company’s reimportation of depleted Thimet containers from Canada and Australia.  The Company has retained defense counsel and has substantially completed the production during the course of which it incurred approximately $2,350 in legal costs and fees responding to this subpoena.  During the third quarter of 2017, the Company received a request from DoJ to interview several individuals who may be knowledgeable of the matter.  Those interviews are likely to take place during the second quarter of 2018. At this stage, DoJ has not made clear its intentions with regard to either its theory of the case or potential criminal or civil enforcement.  Thus, it is too early to tell whether a loss is probable or reasonably estimable. Accordingly, the Company has not recorded a loss contingency on this matter.

Walker v. AMVAC.  On or about April 10, 2017, the Company was served with a summons and complaint that had been filed with the United State District Court for the Eastern District of Tennessee under the caption Larry L. Walker v. AMVAC (as No. 4:17-cv-00017).  Plaintiff seeks contract damages, correction of inventorship, accounting and injunctive relief arising from for the Company’s alleged misuse of his confidential information to support a patent application (which was subsequently issued) for a post-harvest corn herbicide that the Company has not commercialized.  Plaintiff claims further that he, not the Company, should be identified as the inventor in such application.  The Company believes that these claims are without merit and intends to defend vigorously.  On May 24, 2017, the Company filed a motion to dismiss this action, or in the alternative, for transfer of venue, on the ground that (i) the complaint fails to state claim upon which relief can be granted, (ii) the contracts cited by plaintiff in his complaint include a forum selection clause requiring that disputes are to be adjudicated in the U.S. District Court for the Central District of California, and (iii) the doctrine of forum non conveniens applies.  The District Court in Tennessee has yet to rule on the motion. At this stage in the proceedings, it is too early to determine whether a loss is probable or reasonably estimable; accordingly, the Company has not recorded a loss contingency.  

Harold Reed v. AMVAC et al.  During January 2017, the Company was served with two Statements of Claim that had been filed on March 29, 2016 with the Court of Queen’s Bench of Alberta, Canada (as case numbers 160600211 and 160600237) in which plaintiffs Harold Reed (an applicator) and 819596 Alberta Ltd. dba Jem Holdings (an application equipment rental company) allege physical injury and damage to equipment, respectively, arising from a fire that occurred during an application of the Company’s potato sprout inhibitor, SmartBlock, at a potato storage facility in Coaldale, Alberta on April 2, 2014.  Plaintiffs allege, among other things, that AMVAC was negligent and failed to warn them of the risks of such application.  Reed seeks damages of $250 for pain and suffering, while Jem Holdings seeks $60 in lost equipment; both plaintiffs also seek unspecified damages as well.  Also during

13


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

January 2017, the Company received notice that four related actions relating to the same incident were filed with the same court: (i) Van Giessen Growers, Inc. v Harold Reed et al (No. 160303906)(in which grower seeks $400 for loss of potatoes); (ii) James Houweling et al. v. Harold Reed et al. (No. 160104421)(in which equipment owner seeks damages for lost equipment); (iii) Chin Coulee Farms, etc. v. Harold Reed et al. (No. 150600545)(in which owner of potatoes and truck seeks $530 for loss thereof); and (iv) Houweling Farms v. Harold Reed et al. (No. 15060881)(in which owner of several Quonset huts seeks damages for lost improvements, equipment and business income equal to $4,300).  The Company was subsequently named as cross-defendant in those actions by Reed. During the third quarter of 2017, counsel for the Company filed a Statement of Defence (the Canadian equivalent of an answer), alleging that Reed was negligent in his application of the product and that the other cross-defendants were negligent for using highly flammable insulation and failing to maintain sparking electrical fixtures in the storage units affected by the fire.  The Company believes that the claims against it in these matters are without merit and intends to defend them vigorously.  At this stage in the proceedings, however, it is too early to determine whether a loss is probable or reasonably estimable; accordingly, the Company has not recorded a loss contingency.

Galvan v. AMVAC In an action entitled Graciela Galvan v. AMVAC filed on April 7, 2014 with the Superior Court for the State of California for the County of Orange (No. 00716103CXC), plaintiff, a former employee, alleges violations of wages and hours requirements under the California Labor Code. The Company completed the deposition of putative class representative and participated in mediation on the matter. In February 2016, the court granted plaintiff’s motion for class certification with respect to only one of the seven original claims (namely, that allegedly discretionary bonus payments made to class members during the subject period should have been taken into account when calculating overtime).  The Company believes that such bonus payments were discretionary and, as such, were properly excluded from overtime calculations.  Nevertheless, in the interest of saving defense costs, the Company engaged in settlement discussions with plaintiff’s counsel over the course of several months.  During the third quarter of 2016, the Company recorded a loss contingency to cover the estimated amount of settlement.  During December 2016, the parties reached agreement on terms of settlement, and, on February 9, 2018, the court gave its final approval to the terms of the class settlement.  The settlement was not material to the Company’s consolidated financial statements and the Company is to provide the court with a report of administration of the settlement proceeds to the class in August 2018, after which the Company expects that the matter will be dismissed with prejudice.

ITEM 4

MINE SAFETY DISCLOSURES

Not Applicable

14


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

PART II

ITEM  5

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Effective March 7, 2006, the Company listed its $0.10 par value common stock (“Common Stock”) on the New York Stock Exchange under the ticker symbol AVD. From January 1998 through March 6, 2006, the Common Stock was listed on the American Stock Exchange under the ticker symbol AVD. The Company’s Common Stock traded on The NASDAQ Stock Market under the symbol AMGD from March 1987 through January 1998.

The following table sets forth the range of high and low sales prices as reported for the Company’s Common Stock for the calendar quarters indicated.Holders

 

 

High

 

 

Low

 

Calendar 2017

 

 

 

 

 

 

 

 

First quarter

 

$

19.35

 

 

$

14.65

 

Second quarter

 

 

18.80

 

 

 

15.20

 

Third quarter

 

 

23.35

 

 

 

17.10

 

Fourth quarter

 

 

24.00

 

 

 

18.01

 

Calendar 2016

 

 

 

 

 

 

 

 

First quarter

 

$

17.07

 

 

$

9.63

 

Second quarter

 

 

17.41

 

 

 

12.60

 

Third quarter

 

 

17.92

 

 

 

14.45

 

Fourth quarter

 

 

20.00

 

 

 

14.20

 

Holders

As of February 16, 2018,March 6, 2023, the number of stockholders of the Company’s Common Stock was approximately 4,744,12,533, which includes beneficial owners with shares held in brokerage accounts under street name and nominees.

Dividends

The Company has issued a cash dividend in each of the last twenty-twotwenty-four years dating back to 1996. Cash dividends declared during the past three years are summarized in the table below.

Declaration Date

 

Distribution Date

 

Record Date

 

Dividend

Per Share

 

 

Total

Paid

 

December 12, 2017

 

January 10, 2018

 

December 27, 2017

 

$

0.015

 

 

$

438

 

September 18, 2017

 

October 19, 2017

 

October 5, 2017

 

 

0.015

 

 

 

439

 

June 15, 2017

 

July 14, 2017

 

June 30, 2017

 

 

0.015

 

 

 

437

 

March 16, 2017

 

April 15, 2017

 

March 31,2017

 

 

0.015

 

 

 

435

 

Total 2017

 

 

 

 

 

$

0.060

 

 

$

1,749

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 8, 2016

 

January 6, 2017

 

December 23, 2016

 

$

0.010

 

 

$

289

 

October 11, 2016

 

November 11, 2016

 

October 28, 2016

 

 

0.010

 

 

 

289

 

June 13, 2016

 

July 12, 2016

 

June 30, 2016

 

 

0.010

 

 

 

289

 

Total 2016

 

 

 

 

 

$

0.030

 

 

$

867

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 16, 2015

 

April 17, 2015

 

April 3, 2015

 

$

0.020

 

 

$

572

 

Total 2015

 

 

 

 

 

$

0.020

 

 

$

572

 

Declaration Date

 

Record Date

 

Distribution Date

 

Dividend
Per Share

 

 

Total
Paid

 

December 12, 2022

 

December 28, 2022

 

January 11, 2023

 

$

0.030

 

 

$

851

 

September 12, 2022

 

September 23, 2022

 

October 7, 2022

 

 

0.025

 

 

 

715

 

June 6, 2022

 

June 24, 2022

 

July 8, 2022

 

 

0.025

 

 

 

742

 

March 14, 2022

 

March 25, 2022

 

April 15, 2022

 

 

0.025

 

 

 

736

 

Total 2022

 

 

 

 

 

$

0.105

 

 

$

3,044

 

December 13, 2021

 

December 27, 2021

 

January 10, 2022

 

$

0.020

 

 

$

594

 

September 13, 2021

 

October 1, 2021

 

October 15, 2021

 

 

0.020

 

 

 

594

 

June 8, 2021

 

June 24, 2021

 

July 8, 2021

 

 

0.020

 

 

 

600

 

March 10, 2021

 

March 15, 2021

 

April 15, 2021

 

 

0.020

 

 

 

596

 

Total 2021

 

 

 

 

 

$

0.080

 

 

$

2,384

 

December 7, 2020

 

December 23, 2020

 

January 6, 2021

 

$

0.020

 

 

$

592

 

March 9, 2020

 

March 26, 2020

 

April 16, 2020

 

 

0.020

 

 

 

586

 

Total 2020

 

 

 

 

 

$

0.040

 

 

$

1,178

 

15


AMERICAN VANGUARD CORPORATIONShare Repurchase Programs

AND SUBSIDIARIESThe Company periodically repurchases shares of its common stock under board-authorized repurchase programs through a combination of open market transactions and accelerated share repurchase (“ASR”) arrangements.

(DollarsOn August 22, 2022, pursuant to a Board of Directors resolution, the Company entered into an ASR to repurchase $20,000 of its common stock. Under the ASR agreement, the Company paid $20,000 and immediately received an initial delivery of 802,810 shares in thousands, exceptthe amount of $16,000, based on a price of $19.93 per share, data)which represented 80% of the notional amount of the ASR based on the closing price of the Company’s common stock on the New York Stock Exchange ("NYSE") on August 22, 2022. On December 14, 2022, the ASR was completed, and pursuant to the settlement terms of the ASR, the Company received an additional 131,892 shares of its common stock. The average price paid for all of the shares delivered under the ASR was $21.40 per share.

On March 8, 2022, pursuant to a Board of Directors resolution, the Company announced its intention to repurchase an aggregate number of up to 1,000,000 shares of its common stock under a 10b5-1 plan, par value $0.10 per share, in the open market over the succeeding one year, subject to limitations and restrictions under applicable securities laws. During 2022, the Company purchased 734,150 shares of its common stock for a total of $14,002 at an average price of $19.07 per share.

Purchases

19


On August 30, 2021, pursuant to a Board of Equity Securities byDirectors resolution, the IssuerCompany announced its intention to repurchase an aggregate number of 300,000 shares of its common stock under a 10b5-1 plan, par value $0.10 per share, in the open market over the succeeding six months. During 2021, the Company purchased 300,000 shares of its common stock for a total of $4,579 at an average price of $15.26 per share.

NoneThe table below summarized the number of shares of our common stock that were repurchased during the years ended December 31, 2022 and 2021. The Company did not repurchase any of its common stock in 2020.

Year ended

 

Total number of
shares purchased

 

 

Average price paid
per share

 

 

Total amount paid

 

December 31, 2022

 

 

1,668,852

 

 

$

20.37

 

 

$

34,002

 

December 31, 2021

 

 

300,000

 

 

$

15.26

 

 

$

4,579

 

Securities Authorized for Issuance Underunder Equity Compensation Plans

Plan Category

 

Number of securities to be issued upon exercise

of outstanding options,

warrants, and rights

 

 

Weighted-average

exercise price of

outstanding options,

warrants, rights

 

 

Number of securities

remaining available for

future issuance

under equity

compensation plans

 

 

Number of securities to
be issued upon exercise
of outstanding options,
warrants, and rights

 

 

Weighted average
exercise price of
outstanding options,
warrants, rights

 

 

Number of securities
remaining available for
future issuance under
equity compensation plans

 

Equity compensation plans approved

by security holders

 

 

554,449

 

 

$

9.60

 

 

 

2,000,579

 

 

 

150,704

 

 

$

11.49

 

 

 

1,524,567

 

Total

 

 

554,449

 

 

$

9.60

 

 

 

2,000,579

 

 

 

150,704

 

 

$

11.49

 

 

 

1,524,567

 

16


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Stock Performance Graph

The following graph presents a comparison of the cumulative, five-year total return for the Company, the S&P 500Russell 2000 Stock Index, and a peer group (Specialty(S&P 400 Specialty Chemical Industry). The graph assumes that the beginning values of the investments in the Company, the S&P 500Russell 2000 Stock Index, and the S&P 400 Specialty Chemical Index (a peer group of companiescompanies) each was $100 on December 31, 2012.2017. All calculations assume reinvestment of dividends. Returns over the indicated period should not be considered indicative of future returns.

img96571259_0.jpg 


17

20


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIESITEM 6 RESERVED

(Dollars in thousands, except per share data)

ITEM 6

SELECTED FINANCIAL DATA

The selected consolidated financial data set forth below with respect to each of the calendar years in the five-year period ended December 31, 2017, have been derived from the Company’s consolidated financial statements and are qualified in their entirety by reference to the more detailed consolidated financial statements and the independent registered public accounting firm’s reports thereon, which are included elsewhere in this Report on Form 10-K as of December 31, 2017 and 2016 and for each of the three years in the period ended December 31, 2017. See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”Not applicable

 

 

2017

 

 

2016

 

 

2015

 

 

2014

 

 

2013

 

Net sales

 

$

355,047

 

 

$

312,113

 

 

$

289,382

 

 

$

298,634

 

 

$

381,021

 

Gross profit

 

$

147,392

 

 

$

128,288

 

 

$

111,902

 

 

$

114,496

 

 

$

171,347

 

Operating income

 

$

26,794

 

 

$

20,540

 

 

$

11,524

 

 

$

6,710

 

 

$

55,735

 

Income before provision for income taxes and loss on

   equity investments

 

$

24,853

 

 

$

18,917

 

 

$

8,962

 

 

$

3,644

 

 

$

53,834

 

Net income attributable to American Vanguard

 

$

20,274

 

 

$

12,788

 

 

$

6,591

 

 

$

4,841

 

 

$

34,449

 

Earnings per common share

 

$

0.70

 

 

$

0.44

 

 

$

0.23

 

 

$

0.17

 

 

$

1.22

 

Earnings per common share—assuming dilution

 

$

0.68

 

 

$

0.44

 

 

$

0.23

 

 

$

0.17

 

 

$

1.19

 

Total assets (1)

 

$

535,592

 

 

$

429,956

 

 

$

435,270

 

 

$

463,590

 

 

$

439,917

 

Working capital (1)

 

$

128,681

 

 

$

130,001

 

 

$

139,850

 

 

$

197,073

 

 

$

132,486

 

Long-term debt, excluding current installments

 

$

77,486

 

 

$

40,951

 

 

$

68,321

 

 

$

98,605

 

 

$

50,671

 

Stockholders’ equity

 

$

305,314

 

 

$

282,357

 

 

$

268,326

 

 

$

261,003

 

 

$

257,795

 

Weighted average shares outstanding—basic

 

 

29,100

 

 

 

28,859

 

 

 

28,673

 

 

 

28,436

 

 

 

28,301

 

Weighted average shares outstanding—assuming dilution

 

 

29,703

 

 

 

29,394

 

 

 

29,237

 

 

 

28,912

 

 

 

28,899

 

Dividends per share of common stock

 

$

0.06

 

 

$

0.03

 

 

$

0.02

 

 

$

0.17

 

 

$

0.22

 

(1)

The Company’s consolidated balance sheets as of December 31, 2015, 2014, and 2013 reflects certain reclassifications for deferred income taxes and income taxes payables.  

1821


AMERICAN VANGUARD CORPORATION

ITEM 7 MANAGEMENT’S DISCUSSION AND SUBSIDIARIESANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share data)

ITEM  7

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. Generally, “may,” “could,” “will,” “would,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “continue” and similar words identify forward-looking statements. Forward-looking statements appearing in this Report are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on our current expectations and are subject to risks and uncertainties that can cause actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. SEC.Security and Exchange Commission (“SEC”). It is not possible to foresee or identify all such factors. We urge you to consider these factors carefully in evaluating the forward-looking statements contained in this Report.

The discussion and analysis of our financial condition and results of operations for 2022, as compared to 2021 appears below. As permitted by SEC rules, we have omitted the discussion and analysis of our financial condition and results of operations for 2021 compared to 2020. See Item 7, “Management’s Discussions and Analysis of Financial Condition and Results of Operations”, in our Annual Report on Form 10-K for the year ended December 31, 2021, for this discussion.

MANAGEMENT OVERVIEW

The Company’s operating resultsperformance in 2017 were2022 was stronger in most all respects as compared to the prior year. The domestic agricultural economy continued its second upcycle year following a multi-year downcycle that concluded at the end of 2020. With that trend, commodity prices for many crops, including corn, soybeans and cotton, rose and remained strong. Further, with greater confidence in the post-pandemic agricultural and chemical market and improved overavailability within the shipping industry, growers and distribution relaxed their procurement patterns from a mode of ordering months in advance of the planting season (in 2021) to more of a just-in-time approach (in 2022). While the Company had enjoyed a strong growth trajectory for the first three quarters of 2022, that curve flattened during the fourth quarter, as temporary supply chain disruptions (described below) prevented the production and sale of the Company’s leading corn soil insecticide during that period. It is also worth noting that, while shipping services had become more readily available during 2022, the cost of freight rose to its highest point since the start of the pandemic. We expect that those of 2016, withcosts will recede to more normalized levels in 2023.

In summary, net sales up 14% ($355,047for 2022 rose 9%, as compared to $312,113, year over year)2021 (to $609,615 from $557,676), and net income attributablewas up about 43% (to $26,618 from $18,587). Operating income rose 31% (to $40,651 in 2022 from $30,946 in 2021). With respect to American Vanguard up 58% ($20,274 v. $12,788)our businesses, net sales of our U.S. Crop rose by 9%, while gross profit up about 15% ($147,392 v. $128,288)rose 22%. In the U.S., gross margin slightly up to 42% ofnon-Crop net sales declined by 2%, while gross profit dropped by 6%. Our international business increased net sales by 13% and operating expenses up about 12%gross profit by 9%.

As a result of the sales dynamics just described, gross profit during 2022 was approximately 13% above that of 2021 ($120,598 v. $107,748), but down241,352 vs. $214,047). Further, gross profit when expressed as a percentage of sales to 34% in 2017was 40%, as compared to 35% in 2016.  

Top line sales performance was driven in part by growth of certain existing product lines, particularly domestic cotton products (in light of increase cotton acreage and pest pressure) and vector control products (following heightened hurricane activity), and the addition of new sales from the four acquisitions that the Company completed largely38% in the second half of 2017. Gross profit increased as a result of continued improvement in factory performance, organic growth in the Company’s sales and the addition of products and businesses acquired during 2017.prior year. Operating expenses rose on an absolute basis, as the Company continued to invest in the maintenance of registrations of several important products, professional fees related to acquisitions, continued development of our SIMPAS precision application technology and litigation related to the DoJ proceedings against us, but dropped as a percentage of sales. Due to our acquisition activities, our borrowings increased in 2017by 10% ending at $200,701 as compared to 2016. As$183,272 in 2021. Further, operating expenses (which include outbound freight) as a result,percent of net interest expense was $1,941 in 2017,sales remained flat at 33%, as compared to $1,6232021.

Despite numerous increases in 2016.  Our provision for income taxes included a one-time benefit of $3,433 in connection with the enactmentinterest rate by the Federal Open Market Committee over the course of the Tax Cutsyear, our interest expense remained approximately even with that of the prior year ($3,954 in 2022 vs. $3,687 in 2021). This performance was due to timing of our borrowings, continued strong cash generated from increased sales, continued focus on working capital management and Jobs Act (“Tax Reform Act”) on December 22, 2017. Oura high level of participation by customers in our prepayment programs. For 2022, our effective tax rate decreased to 18%(at 23.8% in 2017,2022 vs. 30.1% in 2021). Our net income was $27,404 in 2022, as compared to 30%$18,587 in 2016. Net income increased to $0.68 per diluted share ($0.70 per basic share), as compared to $0.44 per diluted (and basic) share in 2016.  2021, which represents an increase of about 47%.

22


When considering the consolidated balance sheet,sheets, long-term debt increased by $36,535decreased to $77,486 at$51,477 as of December 31, 2017,2022, from $52,240 as compared to $40,951 this time last year.of December 31, 2021. The increaseddecreased level of debt was driven by four acquisitions completedthe Company’s strong cash management during 2022, including a continued strong response from the financial year and particularly inCompany’s largest customers to our early-pay programs, offset by the final quarterdecision to repurchase $34,002 of the year. Notwithstanding the increase in long term debt, theCompany's stock. The Company’s borrowing capacity increasedliquidity position improved to $139,241$200,372 as of December 31, 20172022, as compared to $104,853 at the same time in 2016, and inventory, including goods purchased with our acquisitions, increased only slightly ($123,124 v. $120,576) at year-end.$178,705 as of December 31, 2021.

19


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Results of Operations

20172022 Compared with 2016:2021:

 

 

2017

 

 

2016

 

 

$ Change

 

 

% Change

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

132,137

 

 

$

119,226

 

 

$

12,911

 

 

 

11

%

Herbicides/soil fumigants/fungicides

 

 

121,581

 

 

 

123,540

 

 

 

(1,959

)

 

 

-2

%

Other, including plant growth regulators

 

 

47,691

 

 

��

29,438

 

 

 

18,253

 

 

 

62

%

Total crop

 

 

301,409

 

 

 

272,204

 

 

 

29,205

 

 

 

11

%

Non-crop

 

 

53,638

 

 

 

39,909

 

 

 

13,729

 

 

 

34

%

Total net sales

 

$

355,047

 

 

$

312,113

 

 

$

42,934

 

 

 

14

%

Cost of sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

84,008

 

 

$

78,945

 

 

$

5,063

 

 

 

6

%

Herbicides/soil fumigants/fungicides

 

 

67,558

 

 

 

66,299

 

 

 

1,259

 

 

 

2

%

Other, including plant growth regulators

 

 

31,951

 

 

 

19,139

 

 

 

12,812

 

 

 

67

%

Total crop

 

 

183,517

 

 

 

164,383

 

 

 

19,134

 

 

 

12

%

Non-crop

 

 

24,138

 

 

 

19,442

 

 

 

4,696

 

 

 

24

%

Total cost of sales

 

$

207,655

 

 

$

183,825

 

 

$

23,830

 

 

 

13

%

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

48,129

 

 

$

40,281

 

 

$

7,848

 

 

 

19

%

Herbicides/soil fumigants/fungicides

 

 

54,023

 

 

 

57,241

 

 

 

(3,218

)

 

 

-6

%

Other, including plant growth regulators

 

 

15,740

 

 

 

10,299

 

 

 

5,441

 

 

 

53

%

Gross profit crop

 

 

117,892

 

 

 

107,821

 

 

 

10,071

 

 

 

9

%

Gross profit non-crop

 

 

29,500

 

 

 

20,467

 

 

 

9,033

 

 

 

44

%

Total gross profit

 

$

147,392

 

 

$

128,288

 

 

$

19,104

 

 

 

15

%

Gross margin crop

 

 

39

%

 

 

40

%

 

 

 

 

 

 

 

 

Gross margin non-crop

 

 

55

%

 

 

51

%

 

 

 

 

 

 

 

 

Total gross margin

 

 

42

%

 

 

41

%

 

 

 

 

 

 

 

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S

 

$

256,142

 

 

$

228,854

 

 

$

27,288

 

 

 

12

%

International

 

 

98,905

 

 

 

83,259

 

 

 

15,646

 

 

 

19

%

Total net sales

 

$

355,047

 

 

$

312,113

 

 

$

42,934

 

 

 

14

%

 

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

Net sales:

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

288,624

 

 

$

263,632

 

 

$

24,992

 

 

9%

U.S. non-crop

 

 

76,709

 

 

 

78,605

 

 

 

(1,896

)

 

-2%

Total U.S.

 

 

365,333

 

 

 

342,237

 

 

 

23,096

 

 

7%

International

 

 

244,282

 

 

 

215,439

 

 

 

28,843

 

 

13%

Total net sales

 

$

609,615

 

 

$

557,676

 

 

$

51,939

 

 

9%

Cost of sales:

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

156,115

 

 

$

154,064

 

 

$

2,051

 

 

1%

U.S. non-crop

 

 

41,452

 

 

 

41,162

 

 

 

290

 

 

1%

Total U.S.

 

 

197,567

 

 

 

195,226

 

 

 

2,341

 

 

1%

International

 

 

170,696

 

 

 

148,403

 

 

 

22,293

 

 

15%

Total cost of sales

 

$

368,263

 

 

$

343,629

 

 

$

24,634

 

 

7%

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

132,509

 

 

$

109,568

 

 

$

22,941

 

 

21%

U.S. non-crop

 

 

35,257

 

 

 

37,443

 

 

 

(2,186

)

 

-6%

Total U.S.

 

 

167,766

 

 

 

147,011

 

 

 

20,755

 

 

14%

International

 

 

73,586

 

 

 

67,036

 

 

 

6,550

 

 

10%

Total gross profit

 

$

241,352

 

 

$

214,047

 

 

$

27,305

 

 

13%

Gross margin:

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

46%

 

 

42%

 

 

 

 

 

 

U.S. non-crop

 

46%

 

 

48%

 

 

 

 

 

 

Total U.S.

 

46%

 

 

43%

 

 

 

 

 

 

International

 

30%

 

 

31%

 

 

 

 

 

 

Total gross margin

 

40%

 

 

38%

 

 

 

 

 

 

Following is a more detailed discussionNet sales of our sales performance by category.  Domestic sales finishedU.S. crop business were about 9% higher than those of the prior year at $256,142, as compared to $228,854 in 2016, an increase($288,624 vs. $263,632). With the second full year of 12%. Sales were positively impacted byhigh commodity prices and a strong growth in our US cotton products Bidrin® and Folex®; a stable Midwest corn soil insecticide market wherefarm economy, the Company experienced strong demand for its crop protection products. The pacing of procurement practices in the distribution channel, appearshowever, relaxed from advance purchasing in 2021 (for the 2021-2022 season) to have normalized; hurricane-drivenmore of a just-in-time approach in 2022 (for the 2022-2023 season). The Company experienced strong sales of its corn products, particularly soil insecticides and post-emergent herbicides (Impact, Impact Core, Sinate, and Impact Z) notwithstanding a 20% drop in sales of our leading corn soil insecticide, Aztec, which we were unable to make and sell in the fourth quarter of 2022, due to unavailability of a key intermediate from both a domestic supplier (which experienced capacity constraints) and a China-based supplier (which experienced widespread COVID infection followed by a temporary shutdown). With respect to our cotton products, strong commodity prices stimulated demand for our superior mosquito adulticide, Dibrom®;Bidrin foliar insecticides and $21,978 in incrementalFolex harvest defoliant, which together generated sales of newly acquired products and businesses primarily in the second half of the year. Offsetting these increases, we experienced significant competitive pricing pressure in the US post-emergent corn herbicide market for our product Impact®that were up 33%, and slightly lower annual sales from our soil fumigant products mainly driven by wet weather in the early part of the year in the western states.

International sales increased 19% year-over year ($98,905 in 2017 as compared to $83,259 in 2016), driven by increased sales associated with the key AgriCenter acquisition, made in October 2017, strong tolling revenues, and increased salesthose of Counter and Aztec. These gains were offset by slower2021. We also recorded stronger sales of our Mocap®soil fumigants (for use on a wide range of fruit and Nemacur® insecticides.vegetables), Thimet (for use of peanuts and sugar beets), our herbicide, Dacthal (for use on high-value crops, including onions) and our soybean herbicide products.

The relativeCost of sales performance of our crop and non-crop businesses is as follows: Net sales of ourwithin the domestic crop business in 2017 were $301,409, which constitutes an increase of 11% aswas flat compared to net2021, on sales of $272,204 in 2016. Net sales of our non-crop products in 2017 were $53,638, which is an increase of approximately 34% as compared to $39,909 in 2016. A more detailed discussion of product groups and products having an effect on net sales for each of the crop and non-crop businesses appears below.

In our crop business, net sales of insecticides in 2017 ended at $132,137, which was an 11% increase as compared to sales of $119,226 in 2016. For the same period, annual net sales of our granular soil insecticides were up 8% above 2016. We sawthat increased

20


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

year-over-year sales from our Thimet® used in peanuts, sugar cane and potatoes, along with increased domestic sales of our cotton foliar insecticide, Bidrin®. We saw modest sales increases in our domestic corn soil insecticides Aztec® 9%, SmartChoice® and Counter® offset by some modest sales declines in our international sales of Mocap® and Nemacur®.  We also benefitted from the mid-year acquisition of abamectin which added net sales of approximately $2,000 to our results. In general, our overall agricultural insecticide business showed a solid performance in 2017.

Within the product group of herbicides/soil fumigants/fungicides, our crop net sales in 2017 ended at $121,581, as compared to $123,540 in 2016. Our fumigant product line continued to perform well despite a slight year-over-year decline in revenue caused by wet weather in both the Western and Southeastern regions of the US which inhibited some on-ground application of this liquid product. In the midwest, we experienced an intensely competitive environment during the year in the post-emergent corn herbicide market and sales of our Impact® herbicide declined when compared to the prior year. This performance was substantially offset by strong performances of both our newly acquired paraquat herbicide and our chlorothalonil fungicide. These products were acquired in mid-year and contributed over $14,000 to this category.

Within our other product group (which includes plant growth regulators, molluscicides and third party manufacturing activity) we experienced an increase of 62% in net sales, ending at $47,691 in 2017, as compared to $29,438 in 2016. The main drivers of this performance were stronger year-over-year sales of our cotton defoliant Folex® due to the 20% increase in U.S. cotton acreage in 2017 as compared to the prior year, an increase in toll manufacturing activity, and the inclusion of sales in Latin America by our newly acquired AgriCenter business.

Within our non-crop business, 2017 net sales increased by 34% to $53,638 as compared to $39,909 in 2016.  The sales increase resulted from sales in the last three months of the year following the acquisition of OHP, our new niche horticultural distribution business. In addition, our core non crop product portfolio had a very solid year led by naled sales (our Dibrom® brand mosquito adulticide) which rose 69% in 2017, as a result of the intense hurricane season, headlined by the persistent torrential rains of Harvey over the eastern Texas coastal region. In response to the emergency, AMVAC ramped up production significantly, FEMA utilized all available Dibrom inventories (both from the Company and in the market) and the resulting mosquito control operation was successful. We also recorded a 92% increase in our PCNB product sales as we continue to build our market position, an 18% increase in our Pest Strip® products, and modest increases in several of our other commercial pest control products.  This performance was offset by the short-term decline in our pharmaceutical products arising from customers having ordered additional product in 2016 in light of uncertain supply conditions.

Our cost of sales for 2017 was $207,655 or 58% of sales. This compared to $183,825 or 58% of sales for 2016. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales.  The raw materials element of our cost of sales remained approximately flat as compared to last year. During the year, our Impact product line endured increased competition resulting in some weakening of market price and accordingly, increased cost of sales when compared to sales revenue as a result. Furthermore, the distribution businesses acquired in the final quarter performed well and added to net sales, as indicated above. In general terms the cost of sales related to distribution activities tends to be higher than those of our core business portfolio because those businesses are selling fully marked up third party products while the Company’s core portfolio benefits from the upstream manufacturing activity. Our manufacturing performance for the year was strong and in-line with our targets; specifically, our factory underabsorption costs dropped to $12,865 or 3.6% of net sales in 2017 as compared to $17,739 or 5.7% of net sales in 2016.  

Grossgross profit for 2017 improved by $19,104 or 15% to end at $147,392 for the year ended December 31, 2017, as compared to $128,288 for the prior year. Gross21% ($132,509 in 2022 vs. $109,568 in 2021), and gross margin as a percent of net sales, however, was 42% for 2017 as compared to 41% in 2016. While the Company experienced continuous improvement in factory performance and factory cost recovery and strong performance on raw material purchasing, these benefits were offset by competitive pricing pressure in the Midwest herbicide market and a larger volume of lower-margin sales through newly acquired distribution businesses.

21


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Operating expenses in 2017 increased by $12,850 to $120,598 or 34%46% of sales as compared to $107,74842% last year.

23


Net sales of our U.S. non-crop business were down about 2% ($76,709 in 2022 vs. $78,605 in 2021). This decline was driven primarily by the nationwide consumer pest-control market, which dropped by 30% year-over-year, due to US workers returning to the workplace post-COVID. Net sales from our OHP nursery and ornamental business were about even with those of 2021, as US consumer demand for plant materials remained level. During 2022, we posted relatively flat Dibrom® mosquito adulticide sales. By contrast, sales of insecticides for commercial applications rose during the year, as the professional pest-control market began to regain its footing. Finally, TyraTech/Envance extended the scope of a license agreement in 2021 and benefited from a one-time non-refundable up-front fee.

Cost of sales in our U.S. non-crop business remained flat with the prior year and gross profit decreased by 6% (to $35,257 in 2022 from $37,443 in 2021), and gross margin percentage decreased to 46% in 2022, as compared to 48% in 2021.

Net sales of our international businesses increased by 13% in 2022 ($244,282 vs. $215,439 in 2021). During 2022, our international group continued to successfully integrate two important new businesses, AgNova in Australia, and Agrinos biological products in more than a half dozen countries worldwide. We enjoyed strong demand for our soil fumigants, particularly in Mexico and Australia, and experienced increased sales of our Counter nematicide in Brazil. Further, we experienced higher sales in our AgriCenter Central American distribution business and achieved a record $100 million in net sales from our LATAM region. Expansion of our Green Solutions product portfolio has significantly enhanced our penetration of international markets and drawn us much closer to many key customers.

Cost of sales in our international business increased by 15% (to $170,696 in 2022 from $148,403 in 2021) on sales that increased 13%, gross profit rose 10% from the prior year (to $73,586 in 2022 from $67,036 in 2021), and gross margin percentage ended at 30% in 2022, as compared to 31% in 2021.

Operating expenses (which include outbound freight costs) increased by $17,429 in 2022, to $200,701 or 35%33% of net sales, as compared to $183,272 or 33% in 2016.2021. The differences in operating expenses by department are as follows:

 

 

2022

 

 

2021

 

 

Change

 

 

% Change

 

Selling

 

$

52,512

 

 

$

49,409

 

 

$

3,103

 

 

 

6

%

General and administrative:

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

51,671

 

 

 

47,971

 

 

 

3,700

 

 

 

8

%

Proxy contest activities

 

 

1,785

 

 

 

 

 

 

1,785

 

 

 

100

%

Amortization

 

 

13,953

 

 

 

13,713

 

 

 

240

 

 

 

2

%

Research, product development and regulatory

 

 

31,816

 

 

 

28,855

 

 

 

2,961

 

 

 

10

%

Freight, delivery and warehousing

 

 

48,964

 

 

 

43,324

 

 

 

5,640

 

 

 

13

%

Total Operating Expenses

 

$

200,701

 

 

$

183,272

 

 

$

17,429

 

 

 

10

%

 

 

2017

 

 

2016

 

 

Change

 

 

% Change

 

Selling

 

$

29,112

 

 

$

27,442

 

 

$

1,670

 

 

 

6

%

General and administrative

 

 

37,660

 

 

 

32,128

 

 

 

5,532

 

 

 

17

%

Research, product development and regulatory

 

 

26,076

 

 

 

21,298

 

 

 

4,778

 

 

 

22

%

Freight, delivery and warehousing

 

 

27,750

 

 

 

26,880

 

 

 

870

 

 

 

3

%

 

 

$

120,598

 

 

$

107,748

 

 

$

12,850

 

 

 

12

%

Selling expenses increased by $1,6706% to $29,112$52,512 for the year ended December 31, 2017,2022, as compared to $27,442$49,409 in 2016. The main drivers for2021. This included increased costs associated with travel expenses (as the in-person business interactions with customers continue to increase), inflation related increased expenses are expanded activitieswages, increased spending on advertising and promoting the Company’s products, and the cost of commissions associated with sales growth in both international and domestic sales operations resulting from acquisitions.  However, selling expenses as a percent of net sales actually decreased from 8.8%Brazil. These increased costs were somewhat offset by beneficial exchange rate movement in 2016 to 8.2% in 2017.

key currencies.

General and administrative expenses increased by $5,5328% to $37,660$51,671 for the year ended December 31, 2017,2022, as compared to $32,128$47,971 in 2016.2021. The main drivers forwere the increase are driven by annet increase in legal expenses related to the DoJ proceedings against the Company of approximately $1,200, expenses of $1,821 incurred in professional fees in connection with the productshort-term and business acquisitions completed in 2017 including; the expense of the acquisition process, increased amortization expenseslong-term incentive compensation, as a result of improved financial performance and increased bad debt expenses related to our businesses in Central America. In addition, wages, travel expense and other administrative costs increased in support of our growing business.

The Company spent $1,785 in fees associated with our Proxy defense activities; there were no such fees in the valuationcomparative period of the acquisitions, and the administrative operating expenses of such acquisitions from the closing date of the respective acquisitions.  

prior year.

Research, product development and regulatory expenses increased by $4,77810% to $26,076 for the year ended December 31, 2017,$31,816 in 2022, as compared to $21,298$28,855 in 2016.2021. The increase is driven by additional regulatory activity defendingmain drivers were increases in our expanded portfolio of products, product development studies, driven by our expanded portfoliocosts, primarily resulting from increased international regulatory activities and continued progress on the developmentwork in support of our SIMPAS technology.

SIMPAS/ULTIMUS technology platform. In addition, wages and travel expenses increased in support of our growing business.

24


Freight, delivery and warehousing costs for the year ended December 31, 20172022, increased by $87013% (on sales up 9%) to $27,750,$48,964, as compared to $26,880$43,324 in 2016.2021. This is mainly due to increases in freight rates, and changes in volume, product mix and customer destinations. When expressed as a percentage of sales, freight costs decreased slightlyremained essentially flat at 8% of net sales.

In July 2020, the Company made a strategic investment in Clean Seed Inc. (Clean Seed) in the amount of $1,190. The investment is carried at fair value on the Company’s consolidated balance sheets. The Company recorded losses to Clean Seed’s fair value in the amount of $732 and $391 in 2022 and 2021, respectively.

In February 2016, AMVAC BV made an equity investment of $3,283 in Biological Products for Agriculture (“Bi-PA”). The Company has elected to measure the investment at cost less impairment, if any, and to record an increase or decrease for changes resulting from observable price changes in orderly transactions for the identical or a similar investment of Bi-PA. The Company recorded an impairment in the amount of $399 during the year overended December 31, 2021. No impairment was recorded for the year to 7.8% in 2017, as compared to 8.6% in 2016.  This is mainly due to product mix and locations of customers.ended December 31, 2022.

Net interest expense was $1,941$3,954 in 2017,2022, as compared to $1,623$3,687 in 2016.2021. Interest costs are summarized in the following table:

 

2017

 

 

2016

 

 

2022

 

 

2021

 

Average Indebtedness and Interest expense

 

Average

Debt

 

 

Interest

Expense

 

 

Interest

Rate

 

 

Average

Debt

 

 

Interest

Expense

 

 

Interest

Rate

 

 

Average
Debt

 

 

Interest
Expense

 

 

Interest
Rate

 

 

Average
Debt

 

 

Interest
Expense

 

 

Interest
Rate

 

Working capital revolver

 

$

51,103

 

 

$

1,547

 

 

 

3.0

%

 

$

59,897

 

 

$

1,382

 

 

 

2.3

%

 

$

134,158

 

 

$

3,921

 

 

 

2.9

%

 

$

142,238

 

 

$

3,414

 

 

 

2.4

%

Notes payable

 

 

 

 

 

 

 

 

 

 

 

20

 

 

 

1

 

 

 

5.0

%

Interest income

 

 

 

 

 

(41

)

 

 

 

 

 

 

 

 

(7

)

 

 

 

 

 

 

 

 

(167

)

 

 

 

 

 

 

 

 

(65

)

 

 

 

Amortization of debt issuance costs

 

 

 

 

 

293

 

 

 

 

 

 

 

 

 

250

 

 

 

 

Amortization of deferred loan fees

 

 

 

 

 

261

 

 

 

 

 

 

 

 

 

367

 

 

 

 

Amortization of other deferred liabilities

 

 

 

 

 

82

 

 

 

 

 

 

 

 

 

37

 

 

 

 

 

 

 

 

 

28

 

 

 

 

 

 

 

 

 

(4

)

 

 

 

Other interest expense

 

 

 

 

 

143

 

 

 

 

 

 

 

 

 

44

 

 

 

 

 

 

 

 

 

228

 

 

 

 

 

 

 

 

 

218

 

 

 

 

Subtotal

 

 

51,103

 

 

 

2,024

 

 

 

4.0

%

 

 

59,917

 

 

 

1,707

 

 

 

2.8

%

 

 

134,158

 

 

 

4,271

 

 

 

3.2

%

 

 

142,238

 

 

 

3,930

 

 

 

2.8

%

Capitalized interest

 

 

 

 

 

(83

)

 

 

 

 

 

 

 

 

(84

)

 

 

 

 

 

 

 

 

(317

)

 

 

 

 

 

 

 

 

(243

)

 

 

 

Total

 

$

51,103

 

 

$

1,941

 

 

 

3.8

%

 

$

59,917

 

 

$

1,623

 

 

 

2.7

%

 

$

134,158

 

 

$

3,954

 

 

 

2.9

%

 

$

142,238

 

 

$

3,687

 

 

 

2.6

%

The Company’s average overall debt for the year ended December 31, 20172022, was $51,103$134,158, as compared to $59,917$142,238 for the year ended December 31, 2016.2021. The decrease in average debt can be attributed to improved cash management, partially offset by the Company repurchasing $34,002 of its common stock. On a gross basis, our effective interest rate increased on our working capital revolver to 3.0%, as compared to 2.3% in 2016. This increase was driven by increases in the LIBOR rate. Afterafter adjustments related to capitalized interest and including expenses related to the amortization of deferred liabilities, the overallour effective interest rate was 3.8% for 2017on our working capital revolver increased to 2.9%, as compared to 2.7%2.4% in 2016.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Reform Act”) was signed into law.  The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system and imposing a tax on deemed repatriated earnings of foreign subsidiaries.  The Tax Reform Act reduces the U.S. corporate income tax rate from a maximum of 35%2021 due to a flat 21% rate, effective January 1, 2018. As a result of the reductionincreases in the LIBOR rate driven by U.S. corporate income tax rate, wefiscal policy.

22


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

revalued our ending net deferred tax assets and liabilities at December 31, 2017, provisionally resulting in a deferred tax benefit of $4,683 that is included in the provision for income taxes for the year ended December 31, 2017. The Tax Reform Act also provided for a one-time deemed mandatory repatriation of Post-1986 undistributed foreign subsidiary earnings and profits (“E&P”) through the year ended December 31, 2017.  We have performed a review of our foreign entities and have estimated that the amount of deemed repatriated income amounts to $30,085, on which the Company has estimated that there will be a tax expense of $1,250. That amount is also included in the provision for income taxes for the year ended December 31, 2017.  The net tax benefits from the Tax Reform Act are reflected in our financial results in accordance with Staff Accounting Bulletin No. 118 (SAB 118), which was issued to address the application of US GAAP in situations when the registrant does not have the necessary information available, prepared or analyzed (including computation) in reasonable detail to complete the accounting for uncertain income tax effects of the Tax Reform Act. Additional work is necessary for a more detailed analysis of our deferred tax assets and liabilities and of the impact of the deemed repatriation. Any subsequent adjustment to these amounts will be recorded to income tax expense in the quarter of 2018 when the analysis is complete.

Our provision for income taxes for 20172022 was $4,443,$8,561, as compared to $5,540$8,166 for 2016.2021. The effective tax rate for 20172022 was 18%23.8%, as compared to 30%30.1% in 2016.2021. The decrease inof the effective tax rate in 2022, as compared to 2021, was primarily driven by the inclusiondue to a non-cash charge related to a valuation allowance associated with a deferred tax asset in Brazil established in 2021.

The Company is subject to U.S. federal income tax as well as to income tax in multiple state jurisdictions. Federal income tax returns of the one-time net tax benefit associated with the Tax Reform Act enacted on December 22, 2017, in the amount of $3,433. The decrease is partially offset by lower percentage of earnings in jurisdictions with lower income tax rate.

The Company has effectively settled its examination with theare subject to Internal Revenue Service (“IRS”) examination for the 2019 through 2021 tax years ended December 31, 2012 through 2014.  The Company’s 2015 and 2016 federalyears. State income tax returns are still subject to IRS examination.examination for the 2018 through 2021 tax years. The Company has other state and foreign income tax returns subject to examination.

For the year ended December 31, 2017, the Company recorded losses on its equity investment of $49. For the same period of 2016, the Company recorded losses on its equity investment of $353. In 2017, our netNet income was reduced by $87, as compared to $236 in 2016, representing the$27,404 or $0.94 per basic share of net income of our majority owned subsidiary that was charged to the non-controlling interest.  

Net income attributable to American Vanguard ended at $20,274 or $0.68and $0.92 per diluted share in 20172022, as compared to $12,788$18,587 or $0.44$0.62 per basic share and $0.61 per diluted share in 2016.2021.

25


Liquidity and Capital Resources

The Company generated $59,001$57,105 of cash from operating activities provided during the year ended December 31, 2017,2022, as compared to $46,406$86,361 in the prior year. Included in the $59,001$57,105 are net income of $20,361,$27,404, plus non-cash depreciation, amortization of intangibles and other long-term assets and discounted future liabilities, in the amount of $22,290.  Stock based$25,711, loss on disposal of property, plant and equipment of $268, amortization of deferred loan fees and discounted liabilities of $289, provision for bad debts in the amount of $1,171, provision for inventory obsolescence in the amount of $340,and revisions of contingent consideration of $610. In addition, stock-based compensation of $4,714, loss from equity method investment$5,684, change in fair value of $49 andinvestments of $732, change in value of deferred income taxes of $398, provided$5,278, change in liabilities for certain tax positions or unrecognized tax benefits of $1,441, non-cash lease expense of $68 and net foreign currency adjustment of $29, resulted in net cash inflowsprovided by operating activities (prior to changes in assets and liabilities associated with operations, net of $47,812,business combinations) of $55,529 as compared to $37,843$50,989 for the same period of 2016.2021.

During 2017 the Company generated $11,189 from reducingThe Company’s working capital increased by $3,027 at December 31, 2022, as comparted to the prior year ($121,966 compared to generating $8,563 during 2016. This change excluded increases in working capital related to the products$118,939). Accounts receivables increased by $6,447, inventories increased by $29,560, tax receivable, net increased by $4,910, and businesses acquired during 2017. Included in this change; inventories reducedprepaid expenses increased by $16,183 as a result of consistent efforts from our sales, inventory and operations planning team to balance manufacturing cost recovery, plant capacity and customer needs.$3,082. Deferred revenue as of December 31, 2017 increased by $10,726, as compared to December 31, 2016 primarily as a result of$47,551, driven by customer decisions to make early payments in return for early cash incentive programs. Our accounts payable balances increased by $3,322 driven$1,704, program accruals decreased by increased manufacturing activity$2,449 and capital spending in the final quarter of the year.  In addition accounts receivables and prepaid expenses reduced by $754 and $647 respectively. Offsetting these positive changes, the Company made payments to the IRS following the concluding of the 2012 to 2014 audit in the amount of $12,073other payables and accrued programs reduced year-on-yearexpenses increased by $4,529. Finally other payables decreased by $3,841.$90. The Company also paid $1,321 in contingent consideration (in addition to $68 included in cash used in financing activities).

With regard to our program accrual, these reduced as noted above,the year-over-year change is primarily reflecting ourdriven by the mix of product line sales and customers in 20172022, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Most of our programs relate to domestic sales. Typically, crop productsdomestic crops have a growing season that ends on September 30th August 31st of each year. During 2017, the Company made accruals for programs in the amount of $59,806 and made payments in the amount of $63,682. During the prior year,2022, the Company made accruals in the amount of $70,448$111,649 and made payments in the amount of $71,889.$114,151. During 2021, the Company made accruals in the amount of $99,482 and made payments in the amount of $81,678.

In 2016, inventory reduced by $15,901, accounts payables increased by $9,015, other payables increased by $4,631Because the estimate for the program accrual is a material component of the Company’s overall financial performance, the Company believes that the process it uses is critical in setting the accrual at the appropriate level. The Company’s process for developing the estimate involves a detailed review of each related transaction and income tax receivable reduced by $1,186.  Offsetting these positive changes, accounts receivables increased by $11,817, prepaid expenses increased by $3,872, deferred revenues decreased by $5,040 and program costs by $1,441.  includes the input of a significant number of senior employees to enable the Company to set the accrual using consistently applied judgements, subject to the particular circumstances of any individual transaction.

23


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Cash used for investing activities was $89,512amounted to $14,470 for the year ended December 31, 20172022, as compared to $14,137$20,042 in 2016. The2021. In 2022, the Company spent $81,896$13,261 on capital expenditures primarily focused on continuing to invest in manufacturing infrastructure to expand production efficiency and capabilities. In addition, the Company made a payment of $1,000 to Clean Seed to amend a license agreement under which royalty-bearing license rights were converted to fully paid-up, royalty-free, perpetual license rights, and spent $293 on registrations and patents. In 2021, the Company spent $10,524 in business and product acquisitions including intangible assets, goodwill, working capital and fixed assets.  In addition, $6,666 was spentassets as well as patent application costs, and $9,518 on fixed assetscapital expenditures primarily focused on continuing to invest inour manufacturing infrastructure and $950 on an investment.facilities.

During the year ended December 31, 20172022, financing activities provided $33,935, principally fromused $38,260, as compared to $65,871 during the prior year. This included making repayments of $254,000 and borrowings of $253,000 on the Company’s senior credit facility as compared to utilizing $28,545 forduring the year ended December 31, 2016. This included a net borrowing2022. During 2021, the Company made repayments in the amount of $37,025 from our credit facility in 2017, as compared to a net repayment$186,569 and borrowings of $27,600 in 2016.  We paid $751 in debt issuance costs related to$131,000. During 2022, the amendment of our credit facility.  In 2017, weCompany paid dividends to stockholders amounting to $1,600,$2,787, as compared to $578$2,382 in 2016.  2021. Furthermore, the Company paid contingent consideration in the amount of $68 (in addition to the $1,321 included in cash provided by operating activities) and $1,301 for the years ended December 31, 2022 and 2021, respectively. Finally, the Company used $34,002 to repurchase common stock in 2022, as compared to $4,579 in 2021.

The Company has various loans in place that together constitute the long-term loan balances shown in the consolidated balance sheetsdebt as atof December 31, 20172022 and 2016. These are2021 relating to a revolving line of credit as summarized in the following table:

Indebtedness

 

2017

2016

 

 

 

2022

 

 

2021

 

$000’s

 

Long-term

 

 

Long-term

 

 

Revolving line of credit

 

$

78,425

 

 

$

41,400

 

 

 

$

52,300

 

 

$

53,300

 

Debt issuance costs

 

 

(939

)

 

 

(449

)

 

 

 

(823

)

 

 

(1,060

)

Total indebtedness

 

$

77,486

 

 

$

40,951

 

 

 

$

51,477

 

 

$

52,240

 

26


The Company’s main bank is Bank of the West, a wholly-ownedwholly owned subsidiary of the French bank, BNP Paribas.BMO Financial Group. Bank of the West has been the Company’s bank for more than 30 years and is the syndication manager for the Company’s loans.

AsThe Company and certain of June 30, 2017,its affiliates are parties to a revolving line of credit agreement entitled the “Third Amended and Restated Loan and Security Agreement” dated as of August 5, 2021 (the “Credit Agreement”), which is a senior secured lending facility among AMVAC, Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliatesBorrower Agent (including the Company AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second AmendedBorrowers, on the one hand, and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West as administrative agent, swing line lenderdocumentation agent, syndication agent, collateral agent and Letter of Credit (“L/C”) issuer.sole lead arranger, on the other hand. The Credit Agreement is a senior secured lending facility, consistingconsists of a line of credit of up to $250,000,$275,000, an accordion feature of up to $100,000$150,000, a letter of credit and swingline sub-facility (each having limits of $25,000) and has a maturity date of August 5, 2026. The Credit Agreement amends and restates the previous credit facility, which had a maturity date of June 30, 2022. TheWith respect to key financial covenants, the Credit Agreement contains two key financial covenants;two: namely, borrowers are required to maintain a Consolidated Funded DebtTotal Leverage (“TL”) Ratio of no more than 3.5-to-1, during the first three years, stepping down to 3.25-to-1 as of September 30, 2024, and a Consolidated Fixed Charge CovenantCoverage Ratio of at least 1.25-to-1. In addition, to the extent that it completes acquisitions totaling $15 million or more in any 90-day period, AMVAC may step-up the TL Ratio by 0.5-to-1, not to exceed 4.00-to-1, for the next three full consecutive quarters. Acquisitions below $50 million do not require Agent consent.

The Company’s borrowing capacity varies with its financial performance, measured in terms of Consolidated EBITDA as defined in the Credit Agreement, for the trailing twelve monthtwelve-month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate”Margin” which is based upon the Consolidated Funded DebtTotal Leverage (“TL”) Ratio (“Eurocurrency RateLIBOR Revolver Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable RateMargin (“AlternateAdjusted Base Rate Revolver Loan”). Interest payments for Eurocurrency RateLIBOR Revolver Loans are payable on the last day of each interest period (either one, two, threeone-, three- or sixsix- months, as selected by the borrower) and the maturity date, while interest payments for AlternateAdjusted Base Rate Revolver Loans are payable on the last business day of each month and the maturity date. The interest rate on December 31, 2022, was 5.67%.

At December 31, 2017,2022, according to the terms of the Credit Agreement, as amended, and based on our performance against the most restrictive covenantscovenant listed above, the Company had the capacity to increase its borrowings by up to $139,241.$200,372. This compares to an available borrowing capacity of $104,853$178,705 as of December 31, 2016.2021. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve monthtwelve-month period, which has improved, (2) the inclusion of proforma EBITDA related to acquisitions completed during 2017the preceding twelve months and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

The Company and the Lenders entered into an amendment to the Credit Agreement (“Amendment”), effective March 9, 2023, whereby LIBOR was replaced by SOFR with a credit spread adjustment of 10.0 bps for all SOFR periods. The revolving loans now bear interest at a variable rate based at borrower’s election with proper notice, on either (i) SOFR plus 0.1% per annum and the “Applicable Margin” or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month SOFR Rate plus 1.10%, plus, in the case of (x), (y) or (z) the Applicable Margin (“Adjusted Base Rate Revolver Loan”). In addition, the Amendment waived the minimum fixed charge coverage ratio (“FCCR”) requirement for the year ended December 31, 2022, and adjusted the terms of the FCCR for the periods ending March 31, 2023 and June 30, 2023. The Company was in compliance with all theother debt covenants as of December 31, 2017.2022.

Contractual Obligations and Off-Balance Sheet Arrangements

We believe that the combination of our cash flows from future operations, current cash on hand and the availability under the Company’s credit facility will be sufficient to meet our working capital and capital expenditure requirements and will provide us with adequate liquidity to meet our anticipated operating needs for at least the next 12 months.months from the issuance of the Annual Report. Although operating activities are expected to provide cash, to the extent of growth in the future, our operating and investing activities will use cash and, consequently, this growth may require us to access some or all of the availability under the credit facility. It is also possible that additional sources of finance may be necessary to support additional growth.

24


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

The following summarizes our contractual obligations at December 31, 2017, and the effects such obligations are expected to have on cash flows in future periods:

 

 

Payments Due by Period

 

 

 

Total

 

 

Less than

1 Year

 

 

1—3

Years

 

 

4—5

Years

 

 

After

5 Years

 

Long-term debt

 

$

78,425

 

 

$

 

 

$

 

 

$

78,425

 

 

$

 

Estimated interest liability (1)

 

 

8,118

 

 

 

1,804

 

 

 

3,608

 

 

 

2,706

 

 

 

 

Licensing obligations

 

 

589

 

 

 

127

 

 

 

240

 

 

 

222

 

 

 

 

Deferred earn outs on business acquisitions

 

 

10,741

 

 

 

5,263

 

 

 

5,478

 

 

 

 

 

 

 

Employment agreements

 

 

2,427

 

 

 

896

 

 

 

1,531

 

 

 

 

 

 

 

Operating leases—rental properties

 

 

6,762

 

 

 

1,520

 

 

 

2,984

 

 

 

1,608

 

 

 

650

 

Operating leases—vehicles

 

 

1,361

 

 

 

730

 

 

 

615

 

 

 

16

 

 

 

 

Transition taxes (2)

 

 

1,250

 

 

 

100

 

 

 

200

 

 

 

200

 

 

 

750

 

 

 

$

109,673

 

 

$

10,440

 

 

$

14,656

 

 

$

83,177

 

 

$

1,400

 

(1)

Estimated interest liability has been calculated using the current effective rate for each category of debt over the remaining term of the debt and taking into account scheduled repayments. The revolving line has been assumed to be constant (i.e. $78,425) throughout the remaining term. All of our debt is linked to LIBOR rates.

There were no other off-balance sheet arrangements as of December 31, 2017.

Under the terms of the credit facility,Substantially all debt outstanding is due when the agreement expires on June 30, 2022.

In addition to the above contractual obligations, $2,118 of unrecognized tax benefits and $2,257 of accrued penalties and interest have been recorded as long term liabilities as of December 31, 2017. We are uncertain as to if or when such amounts may be settled or any tax benefits may be realized.

(2)

The Company elected to pay the transition tax in an eight-year period.

25


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Results of Operations

2016 Compared with 2015:

 

 

2016

 

 

2015

 

 

$ Change

 

 

% Change

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

119,226

 

 

$

117,180

 

 

$

2,046

 

 

 

2

%

Herbicides/soil fumigants/fungicides

 

 

123,540

 

 

 

111,897

 

 

 

11,643

 

 

 

10

%

Other, including plant growth regulators

 

 

29,438

 

 

 

29,013

 

 

 

425

 

 

 

1

%

Total crop

 

 

272,204

 

 

 

258,090

 

 

 

14,114

 

 

 

5

%

Non-crop

 

 

39,909

 

 

 

31,292

 

 

 

8,617

 

 

 

28

%

Total net sales

 

$

312,113

 

 

$

289,382

 

 

$

22,731

 

 

 

8

%

Cost of sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

78,945

 

 

$

77,288

 

 

$

1,657

 

 

 

2

%

Herbicides/soil fumigants/fungicides

 

 

66,299

 

 

 

65,507

 

 

 

792

 

 

 

1

%

Other, including plant growth regulators

 

 

19,139

 

 

 

18,097

 

 

 

1,042

 

 

 

6

%

Total crop

 

 

164,383

 

 

 

160,892

 

 

 

3,491

 

 

 

2

%

Non-crop

 

 

19,442

 

 

 

16,588

 

 

 

2,854

 

 

 

17

%

Total cost of sales

 

$

183,825

 

 

$

177,480

 

 

$

6,345

 

 

 

4

%

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

40,281

 

 

$

39,892

 

 

$

389

 

 

 

1

%

Herbicides/soil fumigants/fungicides

 

 

57,241

 

 

 

46,390

 

 

 

10,851

 

 

 

23

%

Other, including plant growth regulators

 

 

10,299

 

 

 

10,916

 

 

 

(617

)

 

 

-6

%

Gross profit crop

 

 

107,821

 

 

 

97,198

 

 

 

10,623

 

 

 

11

%

Gross profit non-crop

 

 

20,467

 

 

 

14,704

 

 

 

5,763

 

 

 

39

%

Total gross profit

 

$

128,288

 

 

$

111,902

 

 

$

16,386

 

 

 

15

%

Gross margin crop

 

 

40

%

 

 

38

%

 

 

 

 

 

 

 

 

Gross margin non-crop

 

 

51

%

 

 

46

%

 

 

 

 

 

 

 

 

Total gross margin

 

 

41

%

 

 

39

%

 

 

 

 

 

 

 

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S

 

$

228,854

 

 

$

212,087

 

 

$

16,767

 

 

 

8

%

International

 

 

83,259

 

 

 

77,295

 

 

 

5,964

 

 

 

8

%

Total net sales

 

$

312,113

 

 

$

289,382

 

 

$

22,731

 

 

 

8

%

Net sales in 2016 increased by approximately 8%, as compared to the prior year. This is largely attributable to lower sales of our cotton insecticide caused by fewer planted acres in several key selling geographies and lighter foliar pest pressure. We experienced another year of solid performance from our soil fumigant products, which are used in the potato and various vegetable/fruit markets. Sales also benefited from the introduction of several new High Concentration (HC) soil insecticides, and from increased international sales of our insecticides Mocap® and Nemacur® along with first year sales of our recently acquired bromacil herbicide products.

Our international business continued to perform well during the twelve months ended December 31, 2016 with net sales of $83,259 which was a 8% improvement over the prior year. Sales benefited from our April, 2015 acquisition of two product lines – European Nemacur® purchased from Adama and the Hyvar/Krovar (bromacil) products purchased from DuPont. In 2015, the Company recorded stronger sales in Mexico and the Asian market, somewhat lower sales in Europe and Canada, and relatively flat sales in other geographic regions.

In the Midwest corn market, distributors and retailers continued to work down inventories of many crop protection products and growers remained cautious regarding input purchases due to the low corn commodity price. During the year, we have seen excess inventories decline significantly and corn commodity price stabilize, both of which should provide a basis for more normal buying patterns to resume. Despite conservative procurement described above and continued reduced insect pressure as a result of two years of harsh winter weather, the Company’s 2015 sales of insecticide and herbicide products for corn remained essentially flat withassets are pledged as collateral under the prior year.Credit Agreement, as amended.

2627


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

The Company’s total net sales for the year ended December 31, 2016 were up 8% to $312,113, as compared to $289,382 for the year ended December 31, 2015. Net sales of our crop business in 2016 were $272,204, which constitutes an increase of nearly 5% as compared to net sales of $258,090 for that business in 2015. Net sales of our non-crop products in 2016 were $39,909, which is an increase of approximately 28% as compared to $31,292 in 2015. A more detailed discussion of product groups and products having a material effect on net sales for each of the crop and non-crop businesses appears below.

In our Crop business, net sales of insecticides in 2016 ended at $119,226, which was a 2% increase as compared to $117,180 in 2015. For the same period, annual net sales of our granular soil insecticides were up 4% from 2015, primarily driven by reduced equipment sales, while sales of our corn soil insecticides remained relatively flat. We had increased year-over-year performance from our Nemacur® and Mocap® products in international markets offset by a decline in domestic Thimet® sales due to seasonally delayed purchasing which are likely to shift to later in the 2016-2017 season. Among our non-granular insecticide products for crop applications, net sales of our cotton foliar insecticide Bidrin® were down due to fewer planted acres in several prime/high usage areas of the Southeast region and lighter pest pressure.

Within the product group of herbicides/soil fumigants/fungicides, our crop net sales in 2016 were up 10% to $123,540 as compared to $111,897 in 2015. Our fumigant product line continued to perform well. Midwest restocking demand for our post-emergent corn herbicide Impact resulted in increased sales and the addition of newly acquired bromacil products Hyvar® and Krovar® contributed to an overall increase in our herbicide category. Within this group, fungicides were essentially flat with the prior year.

Within our other products group (which includes plant growth regulators, molluscicides and third party manufacturing activity), we experienced an increase of approximately 1% in net sales, ending at $29,438 in 2016, as compared to $29,013 in 2015. The major drivers of this performance were flat year-over-year sales of our cotton defoliant Folex®; a decline in our specialty fruit product NAA® and toll manufacturing; offset by an increase in sales of our potato sprout inhibitor SmartBlock® and our molluscicide Metaldehyde.

Within our non-crop business, 2016 net sales increased by 28% to $39,909 as compared to $31,292 recorded in 2015. Naled sales (our Dibrom® brand mosquito adulticide) rose 8% in 2016, and we saw slight increases in several of our products that have faced generic competition. Offsetting those gains, we posted either flat or lower year-over-year sales in our consumer bug/insect sprays, pest strips and pharmaceutical product lines.

Our cost of sales for 2016 was $183,825 or 59% of net sales. This compared to $177,480 or 61% of net sales for 2015. The decrease in cost of sales as a percentage of net sales in 2016 was driven primarily as a result of reduced factory costs, which reduced cost of sales by approximately 2.4%. This was partially offset by inflation in raw material prices, which on average amounted to an increase in cost of sales approximately ¾ of one percent. Together these factors resulted in the reduction in cost of sales by 1%.

Gross profit for 2016 increased by $16,386 to end at $128,288 for the year ended December 31, 2016, as compared to $111,902 for the prior year. Gross margin percentage for 2016 improved by 2% and ended at 41%, as compared to 39% for 2015. The improvement was driven by improved factory cost recovery.

Operating expenses in 2016 increased by $7,370 to $107,748 or 34.5% of sales as compared to $100,378 or 34% in 2015. The differences in operating expenses by department are as follows:

 

 

2016

 

 

2015

 

 

Change

 

 

Change

 

Selling

 

$

27,442

 

 

$

27,052

 

 

$

390

 

 

 

1

%

General and administrative

 

 

32,128

 

 

 

28,516

 

 

 

3,612

 

 

 

13

%

Research, product development and regulatory

 

 

21,298

 

 

 

19,116

 

 

 

2,182

 

 

 

11

%

Freight, delivery and warehousing

 

 

26,880

 

 

 

25,694

 

 

 

1,186

 

 

 

5

%

 

 

$

107,748

 

 

$

100,378

 

 

$

7,370

 

 

 

7

%

Selling expenses increased by $390 to end at $27,442 for the year ended December 31, 2016, as compared to $27,052 in 2015. The main drivers for the decrease are cost reduction actions in our advertising and marketing efforts and reductions in costs associated with both international and domestic field sales operations.

General and administrative expenses increased by $3,612 to $32,128 for the year ended December 31, 2016, as compared to $28,516 in 2015. The main drivers for the increase are primarily due to increase in legal expense, amortization expense from the product line acquisitions completed during the early part of 2016 and incentive compensation costs.

27


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Research, product development and regulatory expenses increased by $2,182 to $21,298 for the year ended December 31, 2016, as compared to $19,116 in 2015. This was driven by timing of product defense studies and from the benefits of the consolidation of two industry wide task force groups.

Freight, delivery and warehousing costs for the year ended December 31, 2016 increased by $1,186 to $26,880, as compared to $25,694 in 2015. As a percentage of sales, freight costs reduced slightly year over year, at 8.6% in 2016, as compared to 8.9% in 2015.

Net interest expense was $1,623 in 2016, as compared to $2,562 in 2015. Interest costs are summarized in the following table:

 

 

2016

 

 

2015

 

Average Indebtedness and Interest expense

 

Average

Debt

 

 

Interest

Expense

 

 

Interest

Rate

 

 

Average

Debt

 

 

Interest

Expense

 

 

Interest

Rate

 

Working capital revolver

 

$

59,897

 

 

$

1,382

 

 

 

2.3

%

 

$

94,765

 

 

$

2,027

 

 

 

2.1

%

Notes payable

 

 

20

 

 

 

1

 

 

 

5.0

%

 

 

6,809

 

 

 

266

 

 

 

3.9

%

Interest Income

 

 

 

 

 

(7

)

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of debt issuance costs

 

 

 

 

 

250

 

 

 

 

 

 

 

 

 

291

 

 

 

 

Amortization of other deferred liabilities

 

 

 

 

 

37

 

 

 

 

 

 

 

 

 

135

 

 

 

 

Other interest expense

 

 

 

 

 

44

 

 

 

 

 

 

 

 

 

53

 

 

 

 

Subtotal

 

$

59,917

 

 

$

1,707

 

 

 

2.8

%

 

$

101,574

 

 

$

2,772

 

 

 

2.7

%

Capitalized interest

 

 

 

 

 

(84

)

 

 

 

 

 

 

 

 

(210

)

 

 

 

Total

 

$

59,917

 

 

$

1,623

 

 

 

2.7

%

 

$

101,574

 

 

$

2,562

 

 

 

2.5

%

The Company’s average overall debt for the year ended December 31, 2016 was $59,917 as compared to $101,574 for the comparable period of the previous year. As can be seen from the above table, on a gross basis, the effective interest rate on our working capital revolver decreased to 2.3%, as compared to 2.1% in 2015, due to lower interest rates on our new senior credit facility agreement and the absence of a fixed rate swap. After adjustments related to capitalized interest and including expenses related to the amortization of deferred liabilities, the overall effective rate was 2.7% for 2016 as compared to 2.5% in 2015. Reduction in deferred liabilities related to product line acquisitions contributed to the reduction in our effective interest rate in 2016.

Income tax expense for 2016 was $5,540, as compared to a tax expense of $2,009 for 2015. The effective tax rate for 2016 was 30%, as compared to 23% in 2015. The increase in the effective tax rate was driven by additional income generated in the U.S. as compared to the previous year. The ratio of domestic to foreign income has a material impact on the Company’s overall effective tax rate.

For the year ended December 31, 2016, the Company recorded losses on its equity investment of $353.  For the same period of 2015, the Company recorded losses on its equity investment of $629 and a loss on dilution in the amount of $7, for a total loss of $636 on its equity method investment.  In 2016, our net income was reduced by $236, representing the share of net income of our majority owned subsidiary that was allocated to the non-controlling interest.  In 2015, a net loss of $274 was allocated to the non-controlling interest share.  

Net income attributable to American Vanguard ended at $12,788 or $0.44 per diluted share in 2016 as compared to $6,591 or $.23 per diluted share in 2015.

Recently Issued Accounting Guidance

Please refer to NotesNote 3 of Consolidated Financial Statements – Description of Business, Basis of Consolidation, Basis of Presentation and Significant Accounting Policies in the accompanying Notes to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report for recently issued and adopted accounting standards.

Foreign Exchange

Management does not believe that the fluctuation in the value of the dollar in relationThe Company faces market risk to the currencies of its customersextent that changes in the last two fiscal years has adversely affected the Company’s ability to sell products at agreed upon prices denominated in U.S. dollars, where applicable. No assurance can be given, however, that adverseforeign currency exchange rate fluctuations willrates affect our non-U.S. dollar functional currency for some of our foreign subsidiaries’ revenues, expenses, assets and liabilities. We currently do not occurengage in the future.

28


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Should adverse currencyhedging activities with respect to such exchange rate fluctuations occurrisks.

Assets and liabilities outside the U.S. are located in geographiesregions where we have subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. Our investments in foreign subsidiaries and joint ventures with a functional currency other than the Company sells/exports its products, management isU.S. dollar are generally considered long-term. Accordingly, we do not certain such fluctuations will or will not materially impact the Company’s operating results.hedge these net investments.

Inflation

Management believes inflation has not had a significantminimal impact on the Company's operations during the past two years. The Company is working diligently with its critical raw material suppliers to control inflationary pressures, conducting contract negotiations with focus on two key market shifts: first, the relatively stable price of oil and natural gas, combined with higher global prices for basic feedstocks like phosphorus, caustic soda, methanol and sulfur have prompted some suppliers to announcefollowing: reducing or delaying price increases due to higher environmental costs from suppliers mainly in China and India, managing the Company,tariff impacts by sourcing and second, the Company monitors our international suppliers' forleveraging alternate geographies where possible, currency gains versusand lastly, monitoring strengths of the U.S. dollar vs other currencies in order to secure benefits and where appropriate uses this knowledge to forestall inflation in raw materials that are purchased in dollar terms.balance tariff effects. The Company recognizes there is long-term pressure on demand for raw materials in the developing world and is utilizing its expertise to minimize inflationary pressure. The Company has been able to push back on many of the proposed price increases for actives and intermediates that are shipped to our USU.S. factories, to either avoid, minimize or forestall them. In response to inflation and other factors that have increased the cost of goods and services, the Company has successfully implemented price increases on its products.

CRITICAL ACCOUNTING POLICIESESTIMATES

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

The Company’s critical accounting policies and estimates include:

Principles of Consolidation—The Company’s Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Less than wholly owned subsidiaries, including joint ventures, are consolidated when it is determined that the Company has a controlling financial interest, which is generally determined when the Company holds a majority voting interest. When protective rights, substantive rights or other factors exist, further analysis is performed in order to determine whether or not there is a controlling financial interest. The Consolidated Financial Statements reflect the assets, liabilities, revenues and expenses of consolidated subsidiaries and the non-controlling parties’ ownership share is presented as a non-controlling interest. All significant intercompany accounts and transactions are eliminated.

Revenue Recognition and Allowance for Doubtful AccountsRevenue Revenues from sales are recognized at the time title andcontrol is transferred to the risks of ownership pass.customer. This is typically the case when the customer has made the fixed commitment to purchase the goods, the products are shipped per the customer’s instructions, the sales price is fixed and determinable,can be identified, and collection is reasonably assured.probable. The Company has in placeadopted procedures to ensure that revenue isrevenues are recognized when earned. The procedures are subject to management’s review and from time to timetime-to-time certain salesrevenues are excluded until it is clear that the title has passed and there is no further recourse to the Company. We also have some arrangements whereby revenues are recognized over time for certain products that are deemed to have no alternative use accompanied by an enforceable right to payment for performance completed to date. From time to time,time-to-time, the Company may offer a program to eligible customers, in good standing, that provides extended payment terms on a portion of the sales on selected products. The Company analyzes these extended payment programs in connection with its revenue recognition policy to ensure all revenue recognition criteria are satisfied at the time of sale. AllowanceThe Company also earns royalty income from its licensing arrangements which qualify as functional licenses rather than symbolic licenses. Upon signing a new licensing agreement, we typically receive up-front fees, which are generally characterized as non-refundable royalties. These fees are recognized as revenue upon the execution of the license agreements. Minimum royalty fees are recognized once the Company has an enforceable right for doubtful accounts is establishedpayment. Sales-based royalty fees are typically

28


recognized when the sales occur. We calculate and accrue estimated royalties based on estimates of losses relatedthe agreement terms and correspondence with the licensees regarding actual sales.

Accrued Program Costs— The Company offers various discounts to customer receivable balances. Estimates are developed using either standard quantitative measurescustomers based on historical losses, adjusted for current economic conditions, or by evaluating specific customer accounts for risk of loss.

Accrued Program Costs—In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers asvolume purchased within a reduction of sales revenues. The Company describes these payments as “Programs”. Programs are a critical part of doing business in the U.S. agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include marketdefined period, other pricing adjustments, some grower volume take upincentives or other key performance indicator driven payments made to distributors, retailers or growers, predominantlyusually at the end of a growing season. The Company describes these payments as “Programs.” Programs are a critical part of doing business in both the U.S. crop and non-crop chemicals marketplaces. These discount Programs represent variable consideration. Revenues from sales are recorded at the net sales price, which is the transaction price, less an estimate of variable consideration. Variable consideration includes amounts expected to be paid to its customers using the expected value method. Each quarter management compares eachindividual sale transactiontransactions with program guidelinesPrograms to determine what, program liability hasif any, estimated Program liabilities have been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated programProgram balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in theagreed upon terms and conditions attached to each program. IfProgram. Following this assessment, management believes that customers are falling short of or exceeding their previously anticipated annual goals, then periodic adjustments will be madeadjust to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance

29


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

Allowance for Doubtful Accounts or Current Expected Credit LossesThe Company recorded accrued programsmaintains an allowance to cover its Current Expected Credit Losses ("CECL") on its trade receivables, other receivables and contract assets arising from the failure of $39,054 at December 31, 2017, as comparedcustomers to $42,930 at December 31, 2016.make contractual payments. The Company estimates credit losses expected over the life of its trade receivables, other receivables and contract assets based on historical information combined with current conditions that may affect a customer’s ability to pay and reasonable and supportable forecasts. In most instances, the Company’s policy is to write-off trade receivables when they are deemed uncollectible. The vast majority of the Company's trade receivables, other receivables and contract assets are less than 365 days. Under the CECL impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on multiple portfolios. The determination of portfolios is based primarily on geographical location, type of customer and aging.

Inventories — The Company values its inventories at lower of cost or net realizable value. Cost is determined by the first-in, first-out (“FIFO”) or average cost method, including, as appropriate, material,raw materials, labor, factory overhead and subcontracting services. The Company writes down and makes adjustmentsits inventory to its inventorythe net realizable value following assessments of slow moving and obsolete inventory and other annual adjustments to ensure that our standard costs continue to closely reflect actual manufacturing cost.

Leases The Company recorded an inventory reserve allowance of $3,137has operating leases for warehouses, manufacturing facilities, offices, cars, railcars and certain equipment. The Company recognizes operating lease right-of-use (ROU) assets and lease liabilities for all leases. The Company measures ROU assets throughout the lease term at December 31, 2017, as compared to $3,594 at December 31, 2016.

Long-lived Assets— Long-lived assets primarily consistthe carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. The lease liabilities are measured at the present value of the unpaid lease payments at the lease commencement date. Leases that include both lease and non-lease components are accounted for as a single lease component for each asset class, except for warehouses. The minimum payments under operating leases are recognized on a straight-line basis over the lease term in the consolidated statements of operations. Operating lease expenses related to variable lease payments are recognized in cost of sales or as operating expenses in a manner consistent with the nature of the underlying lease and as the events, activities, or circumstances in the lease agreement occur. Leases with a term of less than 12 months are not recognized on the consolidated balance sheets, and the related lease expenses are recognized in the consolidated statements of operations on a straight-line basis over the lease term. The accounting for leases requires management to exercise judgment and make estimates in determining the applicable discount rate, effective lease term and payments due under a lease. Most of our leases do not provide an implicit interest rate, nor is it available to us from our lessors. As an alternative, we use our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, including publicly available data, in determining the present value of lease payments. We also estimated the fair value of the lease and non-lease components for some of our warehouse leases based on market data and cost data. The lease term includes the non-cancellable period of the lease plus any additional periods covered by either an option to extend (or not terminate) that the Company is reasonably certain to exercise. The Company has leases with a lease term ranging from 1 year to 20 years. The operating leases of the Company do not contain major restrictions or covenants such as those relating to dividends or additional financial obligations. Finance leases are immaterial to the consolidated financial statements.

29


Intangible AssetsThe primary identifiable intangible assets of the Company relate to assets associated with its product and business acquisitions. All of proprietary returnable packagingthe Company’s intangible assets have finite lives and are amortized. The estimated useful life of an identifiable intangible asset is based upon a number of factors including Smartboxthe effects of demand, competition, and Lockexpected changes in the marketability of the Company’s products.

Business CombinationsThe Company uses its best estimates and Load containers.  assumptions to assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill or an adjustment to the gain from a bargain purchase. In addition, uncertain tax positions and tax-related valuation allowances are initially recorded in connection with a business combination as of the acquisition date. The Company continues to collect information and reevaluates these estimates and assumptions quarterly and records any adjustments to the Company’s preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statement of operations.

From time to time, certain of our acquisition agreements include contingent earn-out arrangements, which are generally based on the achievement of future income thresholds. The fair values of these earn-out arrangements are included as part of the purchase price of the acquired companies on their respective acquisition dates. For each transaction, we estimate the fair value of contingent earn-out payments as part of the initial purchase price and record the estimated fair value of contingent consideration as a liability on the consolidated balance sheets.

We review and re-assess the estimated fair value of contingent consideration on a quarterly basis until the contingent period ends, and the updated fair value could be materially different from the initial estimates or prior quarterly amounts. Changes in the estimated fair value of our contingent earn-out liabilities are reported in operating results.

Asset AcquisitionsIf an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The Company uses its best estimates and assumptions to assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The acquisitions costs are allocated to the assets acquired on a relative fair value basis. From time to time, certain of our acquisition agreements include contingent earn-out arrangements, which are recognized only when the contingency is resolved, and the consideration is paid or becomes payable.

ImpairmentThe carrying valuevalues of long-lived assets isother than goodwill are reviewed for impairment quarterlyannually and/or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. TheIn such circumstances, the Company evaluates recoverability of an asset group by comparing the carrying value to the future undiscounted cash flows that it expects to generate from the asset group. If the comparison indicates that the carrying value of an asset group is not recoverable, measurement of the impairment loss is based on the fair value of the asset. There were no circumstances that would indicate any impairment of the carrying value of these long-lived assets and no material impairment losses were recorded in 2017 or 2016.

Property, Plant and Equipment and Depreciation— Property, plant and equipment includes the cost of land, buildings, machinery and equipment, office furniture and fixtures, automobiles, construction projects and significant improvements to existing plant and equipment. Interest costs related to significant construction projects are capitalized at the Company’s current weighted average effective interest rate. Expenditures for minor repairs and maintenance are expensed as incurred. When property or equipment is sold or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the gain or loss realized on disposition is reflected in earnings. All plant and equipment is depreciated using the straight-line method, utilizing the estimated useful property lives. Once placed into service, building lives range from 10 to 30 years; machinery and equipment lives range from 3 to 15 years. During the years ended December 31, 2017, 2016 and 2015 the Company eliminated from assets and accumulated depreciation $6,317, $16,652, and $549, respectively, of fully depreciated assets.  

Foreign Currency Translation— Assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, have been translated at period end exchange rates, and profit and loss accounts have been translated using weighted average yearly exchange rates. Adjustments resulting from translation have been recorded in the equity section of the balance sheet as cumulative translation adjustments in other comprehensive income (loss). The effects of foreign currency exchange gains and losses on transactions that are denominated in currencies other than the Company’s functional currency, including transactions denominated in the local currencies of the Company’s international subsidiaries where the functional currency is the U.S. dollar, are remeasured to the functional currency using the end of the period exchange rates. The effects of remeasurement related to foreign currency transactions are included in the consolidated statements of operations.

Goodwill and Other Intangible Assets—The primary identifiable intangible assets of the Company relate to assets associated with its product and business acquisitions. The Company adopted the provisions of ASC 350, under which identifiable intangibles with finite lives are amortized and those with indefinite lives are not amortized. The estimated useful life of an identifiable intangible asset to the Company is based upon a number of factors including the effects of demand, competition, and expected changes in the marketability of the Company’s products. The Company re-evaluates whether these intangible assets are impaired on both a quarterly and an annual basis and anytime when there is a specific indicator for impairment, relying on a number of factors including operating results, business plans and future cash flows. Identifiable intangible assets that are subject to amortization are evaluated for impairment using a process similar to that used to evaluate long-lived assets. The impairment test for identifiable intangible assets not subject to amortization consists of either a qualitative assessment or a comparison of the fair value of the intangible asset with its carrying amount. An impairment loss, if any, is recognized for the amount by which the carrying value exceeds the fair value of the asset. Fair value is typically estimated using a discounted cash flow analysis. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. Estimating future cash flows requires significant judgment by the Company, in such areas as: future economic conditions, industry-specific conditions, product pricing and necessary capital expenditures. The use of different assumptions or estimates for future cash flows could produce different impairment amounts (or none at all) for long-lived assets, goodwill and identifiable intangible assets. The Company performed impairment reviews for the years ended December 31, 2017 and 2016 and recorded immaterial impairment losses.

30


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

The Company reviews goodwill for impairment utilizing either a qualitative assessment or a two-step process.quantitative assessment. If the Company decides that it is appropriate to perform a qualitative assessment and concludes that the fair value of a reporting unit more likely than not exceeds its carrying value, no further evaluation is necessary. If the Company performs a quantitative assessment, the two-step process, the first step of the goodwill impairment test is used to identify potential impairment by comparingCompany compares the fair value of a reporting unit with its carrying values and recognizes an impairment charge for the amount including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. Ifthat the carrying amount of aexceeds the reporting unit exceeds itsunit’s fair value, the second step is performed to measure the amount of impairment by comparing the carrying amount of the goodwill to a determination of the implied value of the goodwill. If the carrying amount of goodwill is greater than the implied value, an impairment charge is recognized for the difference.value. The Company annually tests goodwill for impairment inat the beginning of the fourth quarter.quarter, or earlier if triggering events occur.

30


Fair Value of Financial Instruments—The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard established a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:

Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The carrying amount of the Company’s financial instruments, which principally include cash and cash equivalents, short-term investments, accounts receivable, long-term investments, accounts payable and accrued expenses approximate fair value because of the relatively short maturity of such instruments. The carrying amount of the Company’s short-term and long-term borrowings, which are considered Level 2 liabilities, approximates fair value based upon current rates and terms available to the Company for similar debt.

We measure our contingent earn-out liabilities in connection with acquisitions at fair value on a recurring basis using significant unobservable inputs classified within Level 3 of the fair value hierarchy. We may use various valuation techniques depending on the terms and conditions of the contingent consideration including a Monte-Carlo simulation. This simulation uses probability distribution for each significant input to produce hundreds or thousands of possible outcomes and the results are analyzed to determine probabilities of different outcomes occurring.

Income taxesIncome tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United StatesU.S. and numerousseveral foreign jurisdictions. The Company assessed the realizability ofability to realize deferred tax assets and determined that based on the available evidence, including a history of taxable income and estimates of future taxable income, it is more likely than not that the net deferred tax assets relating to the Company’s operations in Brazil, Spain, and Ukraine will not be realized.realized and a full valuation allowance was recorded in those jurisdictions. Significant management judgment is required in determining the provision for income taxes and deferred tax assets and liabilities. In the event that actual results differ from these estimates, we will adjust these estimates in future periods, which may result in a change in the effective tax rate in a future period. Accounting for income taxes involves uncertainty and judgment on how to interpret and apply tax laws and regulations within the Company’s annual tax filings. Such uncertainties from time to time may result in a tax position that may be challenged and overturned by a tax authority in the future, which could result in additional tax liability, interest charges and possibly penalties. The Company classifies interest and penalties as a component of income tax expense.

31


AMERICAN VANGUARD CORPORATIONITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

ITEM 7A

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lendergroup of lenders is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate (LIBOR)(SOFR). An increase or decrease in interest rates by 25 bps would impact the Company’s net income by approximately $350 based on the Company’s historical average borrowing in 2022 and 2021. The Company may use derivative financial instruments for trading purposes to protect trading performance from exchange rate fluctuations on material contracts, though there are no such instruments in place during any periods presented in this Annual Report.

The Company conducts business in various foreign currencies, primarily when doing business in Europe, Mexico, Central and South America. Therefore, changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated, and will continue to mitigate, a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based.local-currency-based. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

31


As part of an on-going process of assessing business risk, management has identified risk factors which are disclosed in Item 1A. Risk Factors of this Report on Form 10-K.

ITEM 8

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Financial Statements and Supplementary Data required by this item are listed at Part IV, Item 15, Exhibits, and Financial Statement Schedules.Schedule.

ITEM 9

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A

CONTROLS AND PROCEDURES

ITEM 9A CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Management, under the supervision of the Company’s Chief Executive Officer and Chief Financial Officer, periodically evaluate the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon this evaluation, as of December 31, 2017,2022, the Chief Executive Officer and the Chief Financial Officer have concluded that these disclosure controls and procedures are effective in ensuring that the information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported on a timely basis, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934 for AVD and its subsidiaries (“the Company”).Company. The Company’s internal control system over financial reporting is designed to provide reasonable assurance to management and the Board of Directors as to the fair, reliable and timely preparation and presentation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America filed with the SEC.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even processes determined to be effective can provide only reasonable assurance with respect to the financial statement preparation and presentation.

Management conducted an evaluation of the Company’s internal controls over financial reporting based on a framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the effectiveness of controls and a conclusion on the evaluation. Based on this evaluation, management believes that as of December 31, 2017,2022, the Company’s internal control over financial reporting is effective.

32


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

(Dollars in thousands, except per share data)

Management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2017 excluded OHP and Agricenter which were acquired by the Company in the fourth quarter of 2017. Total assets constituted approximately 14% of consolidated total assets and total sales of these acquisitions constituted approximately 4% of consolidated sales and were included in the Company’s consolidated total assets and the Company’s consolidated sales, respectively, as of and for the year ended December 31, 2017. Companies are allowed to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company under guidelines established by the SEC.

BDO USA, LLP, the independent registered public accounting firm that audited the consolidated financial statements included in the Annual Report on Form 10-K, was engaged to attest to and report on the effectiveness of AVD’s internal control over financial reporting as of December 31, 2017. Its reports are2022. Their report is included herein.

Changes in Internal ControlsControl over Financial Reporting

There were no changes in internal controlscontrol over financial reporting during the fourth quarter of the year ended December 31, 20172022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

3332


Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors and Stockholders

American Vanguard Corporation

Newport Beach, California

Opinion on Internal Control over Financial Reporting

We have audited American Vanguard Corporation’s (the “Company’s”) internal control over financial reporting as of December 31, 2017,2022, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017,2022, based on the COSO criteria.criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company and subsidiaries as of December 31, 20172022 and 2016,2021, the related consolidated statements of operations and comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2017,2022, and the related notes and financial statement schedule listed in the accompanying index and our report dated March 14, 201816, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Item 9A, Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

As indicated in the accompanying Item 9A, Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of OHP, Inc. and Agricenter S.A. (collectively referred to as the “Acquisitions”), which were acquired on October 2, 2017 and October 27, 2017, respectively, and which are included in the consolidated balance sheet of the Company and subsidiaries as of December 31, 2017, and the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for the year then ended. The Acquisitions combined constituted approximately 14% of total assets as of December 31, 2017, and approximately 4% of revenues for the year then ended. Management did not assess the effectiveness of internal control over financial reporting of the Acquisitions because of the timing of the Acquisitions. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of the Acquisitions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ BDO USA, LLP

Costa Mesa, California

March 14, 201816, 2023

3433


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

ITEM 9B

OTHER INFORMATION

None.

ITEM 9B OTHER INFORMATION

None.

ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

34


AMERICAN VANGUARD CORPORATION

PART III

ITEM 10

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information set forth under the captions “Executive Officers of the Company,” “Election of Directors,” “Information about the Board of Directors and Committees of the Board” and “Transactions with Management and Others—Section 16(a) Beneficial Ownership Reporting Compliance” in our definitive proxy statement (the “Proxy Statement”) for our Annual Meeting of Stockholders to be held in 2018 (the “Proxy Statement”),on June 7, 2023, which will be filed with the SEC within 120 days of the end of our fiscal year ended December 31, 2017,2022, is incorporated herein by reference.

ITEM 11

EXECUTIVE COMPENSATION

ITEM 11 EXECUTIVE COMPENSATION

Except as specifically provided, the information set forth under the captions “Compensation of Executive Officers” and “Information about the Board of Directors and Committees of the Board—Compensation of Directors” in the Proxy Statement is incorporated herein by reference.

ITEM 12

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The disclosure contained in Part II, Item 5 under “Equity Compensation Plan Information” is incorporated herein by reference. Information regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth under the caption “Security Ownership of Certain Beneficial Owners and Management” in the Proxy Statement.

ITEM 13

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information set forth under the captions “Transactions with Management and Others” and “Information about the Board of Directors and Committees of the Board” in the Proxy Statement is incorporated herein by reference.

ITEM 14

PRINCIPAL ACCOUNTANT FEES AND SERVICES

ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information regarding principal accountant fees and services is incorporated herein by reference to the information set forth under the caption “Ratification of the Selection of Independent Registered Public Accounting Firm—Relationship of the Company with Independent Registered Public Accounting Firm” in the Proxy Statement.

35


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

PART IVEXHIBIT INDEX

ITEM 15

ITEM 15Exhibit

Number

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)

The following documents are filed as partDescription of this report:

Index to Consolidated Financial Statements and Supplementary Data:

Description

Page NoExhibit

Financial Statements:

Report of Independent Registered Public Accounting Firm  3.1

41

Consolidated Balance Sheets as of December 31, 2017 and 2016

42

Consolidated Statements of Operations for the Years Ended December 31, 2017, 2016, and 2015

43

Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2017, 2016, and 2015

44

Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2017, 2016 and 2015

45

Consolidated Statements of Cash Flows for the Years Ended December 31, 2017, 2016, and 2015

46

Summary of Significant Accounting Policies and Notes to Consolidated Financial Statements

47

(b) Exhibits Index

36


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

EXHIBIT INDEX

ITEM 15

Exhibit

Number

Description of Exhibit

  3.1

Amended and Restated Certificate of Incorporation of American Vanguard Corporation (filed as Exhibit 3.1 to the Company’s Form 10-K for the year ended December 31, 2003, which was filed on March 30, 2004, with the Securities Exchange Commission and incorporated herein by reference).

  3.2

Certificate of Amendment of Amended and Restated Certificate of Incorporation of American Vanguard Corporation (filed as Exhibit 3.2 to the Company’s Form 10-Q/A for the period ended June 30, 2004, which was filed with the Securities Exchange Commission on February 23, 2005, and incorporated herein by reference).

  3.3

Amended and Restated Bylaws of American Vanguard Corporation dated as of June 5, 2014 (filed as Exhibit 99.1 to the Company’s Form 8-K, which was filed with the Securities Exchange Commission on June 7, 2014, and incorporated herein by reference.)

  4

Form of Indenture (filed as Exhibit 4.4 to the Company’s Registration Statement on Form S-3 (File No. 333-122981) and incorporated herein by reference).

10.1

American Vanguard Corporation Employee Stock Purchase Plan (filed as Appendix BA to the Company’s Proxy Statement filed with the Securities and Exchange Commission on May 31, 2001April 23, 2018, and incorporated herein by reference).

10.2

American Vanguard Corporation Amended and Restated Stock Incentive Plan as of June 8, 2016 (filed as Appendix A to the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 25, 2016, and incorporated herein by reference).

10.3

Form of Incentive Stock Option Agreement under the American Vanguard Corporation Fourth Amended and Restated Stock Incentive Plan, , (filed as Exhibit 10.3 with the Company’s Annual Report on Form 10-K for the period ended December 31, 2004, which was filed with the Securities and Exchange Commission on March 16, 2005, and incorporated herein by reference).

10.4

Form of Non-Qualified Stock Option Agreement under the American Vanguard Corporation Fourth Amended and Restated Stock Incentive Plan, , (filed as Exhibit 10.4 with the Company’s Annual Report on Form 10-K for the period ended December 31, 2004, which was filed with the Securities and Exchange Commission on March 16, 2005, and incorporated herein by reference).

10.5

Employment Agreement between American Vanguard Corporation and Eric G. Wintemute dated January 15, 2008 (filed as Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities Exchange Commission on March 17, 2008, and incorporated herein by reference).

10.8

Form of Change of Control Severance Agreement, dated effective as of January 1, 2004, between American Vanguard Corporation and its executive and senior officers (filed as Exhibit 10.2 to the Company’s Form 10-Q for the period ended March 31, 2004, which was filed with the Securities Exchange Commission on May 17, 2004, and incorporated herein by reference.)

10.9

Form of Amendment of Change of Control Severance Agreement, dated effective as of July 11, 2008, between American Vanguard Corporation and named executive officers and senior officers (filed as Exhibit 99.1 to the Company’s Form 8-K, which was filed on July 11, 2008, with the Securities and Exchange Commission and incorporated herein by reference).

10.10

Form of Indemnification Agreement between American Vanguard Corporation and its Directors (as filed as Exhibit 10.7 to the Company’s Annual Report on Form 10-K for the period ended December 31, 2004, which was filed with the Securities and Exchange Commission on March 16, 2005, and incorporated herein by reference).

36


AMERICAN VANGUARD CORPORATION

Exhibit

Number

Description of Exhibit

10.11

10.11

Description of Compensatory Arrangements Applicable to Non-Employee Directors for 2005 (filed as Exhibit 10.1 to(as set forth on page 34 of the Company’s Form 8-K,Proxy Statement which was filed with the Securities and Exchange Commission on June 15, 2005April 22, 2019, and incorporated herein by reference).

37


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

Exhibit

Number

Description of Exhibit

10.12

10.12

American Vanguard Corporation Employee Stock Purchase Plan amended and restated as of June 30, 2011 (filed as Exhibit A to the Company’s Proxy Statement which was filed with the Securities Exchange Commission on April 2011

and is incorporated herein by reference).

10.13

Form of Restricted Stock Agreement between American Vanguard Corporation and named executive officers (fileddated as Exhibit 99.1of November 13, 2020. Filed as exhibit 10.12 to the Company’s Form 8-K, which was filed with10-K for the Securities Exchange Commission on July 24, 2008 and incorporated herein by reference).period ended December 31, 2020.

10.14

Form of AmendedPerformance-Based Restricted Stock Units Award Agreement between American Vanguard Corporation and Restated Change of Control Severance Agreement effectivenamed executive officer dated as of January 1, 2014 (filedNovember 13, 2020. Filed as Exhibitexhibit 10.14 to the Company’s Form 10-K which was filed withfor the Securities Exchange Commission on February 28, 2014 and incorporated herein by reference)period ended December 31, 2020.

10.15

Form of American Vanguard Corporation Amended and Restated Stock Incentive Plan TSR-Based Restricted Stock Units Award Agreement dated June 6, 2013 (filed as Exhibit 10.15 to the Company’s 10-K, which was filed with the Securities Exchange Commission on February 28, 2014, and incorporated herein by reference).

10.16

Form of American Vanguard Corporation Amended and Restated Stock Incentive Plan Performance-Based Restricted Stock Units Award Agreement dated June 6, 2013 (filed as Exhibit 10.16 to the Company’s 10-K, which was filed with the Securities Exchange Commission on February 28, 2014, and incorporated herein by reference).

10.17

Third Amendment to Second Amended and Restated Credit Agreement dated as of June 30, 2017 among AMVAC and certain affiliates on the other hand, and a group of commercial lenders led by Bank of the West as agent, swing line lender, and letter of credit issuer, on the other hand (filed as Exhibit 10.1 to the Company’s Form 8-K, which was filed with the Securities Exchange Commission on July 6, 2017 and is incorporated herein by reference).

10.18

EmploymentFourth Amendment to Second Amended and Restated Credit Agreement dated as of December 31, 2014November 27, 2019, among AMVAC and certain affiliates, on the one hand, and a group of commercial lenders led by Bank of the West as agent, swing line lender, and between AMVAC Chemical Corporation and Ulrich Trogeleletter of credit issuer, on the other hand (filed as Exhibit 10.18 towith the Company’s Annual Report on Form 10-K for the yearperiod ended December 31, 20162019). Third Amended and incorporated hereinRestated Loan and Security Agreement dated August 5, 2021 by reference).and among American Vanguard Corporation et al. and Bank of the West et al. a form of which was filed with the SEC as an exhibit to the Company’s Form 8-K on or about August 10, 2021.

21

List of Subsidiaries of the Company.*

23

Consent of BDO USA, LLP, Independent Registered Public Accounting Firm.*

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1

Certifications Pursuant to 18 U.S.C. Section 1350 as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101

The following materials from American Vanguard Corp’s Annual Report on Form 10-K for the year ended December 31, 2017,2022, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Statements of Stockholders’ Equity; (iv) Consolidated Statements of Comprehensive Income; (v) Consolidated Statements of Cash Flows; and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text.*

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

37


AMERICAN VANGUARD CORPORATION

*Exhibit

Number

Filed herewith.

Description of Exhibit

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

(c)
Valuation and Qualifying Accounts:

38


AMERICAN VANGUARD CORPORATION

(c)

Valuation and Qualifying Accounts:

Schedule II-A—Valuation and Qualifying Accounts

Allowance for Doubtful Accounts Receivable (in thousands)

 

 

Balance at

 

 

Additions

Charged to

 

 

 

 

 

 

Balance at

 

Fiscal Year Ended

 

Beginning of

Period

 

 

Costs and

Expenses

 

 

Deductions

 

 

End of

Period

 

December 31, 2017

 

$

42

 

 

$

31

 

 

$

(27

)

 

$

46

 

December 31, 2016

 

$

423

 

 

$

3

 

 

$

(384

)

 

$

42

 

December 31, 2015

 

$

166

 

 

$

332

 

 

$

(75

)

 

$

423

 

 

 

Balance at

 

 

Additions
Charged to

 

 

Foreign

 

 

Balance at

 

Fiscal Year Ended

 

Beginning of
Period

 

 

Costs and
Expenses

 

 

exchange
impact

 

 

End of
Period

 

December 31, 2022

 

$

3,938

 

 

 

1,171

 

 

 

27

 

 

$

5,136

 

December 31, 2021

 

$

3,297

 

 

 

649

 

 

 

(8

)

 

$

3,938

 

December 31, 2020

 

$

2,300

 

 

 

1,002

 

 

 

(5

)

 

$

3,297

 

38


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

Inventory Reserve (in thousands)

 

 

Balance at

 

 

 

 

 

 

 

Balance at

 

Fiscal Year Ended

 

Beginning of

Period

 

 

Additions

 

 

Deductions

 

 

End of

Period

 

December 31, 2017

 

$

3,594

 

 

 

 

 

$

(457

)

 

$

3,137

 

December 31, 2016

 

$

4,020

 

 

 

 

 

$

(426

)

 

$

3,594

 

December 31, 2015

 

$

2,995

 

 

$

1,025

 

 

 

 

 

$

4,020

 

 

 

Balance at

 

 

 

 

 

 

Balance at

 

Fiscal Year Ended

 

Beginning of
Period

 

 

Additions

 

 

Deductions

 

 

End of
Period

 

December 31, 2022

 

$

2,675

 

 

 

1,230

 

 

 

(890

)

 

$

3,015

 

December 31, 2021

 

$

2,868

 

 

 

948

 

 

 

(1,141

)

 

$

2,675

 

December 31, 2020

 

$

2,130

 

 

 

1,120

 

 

 

(382

)

 

$

2,868

 

Deferred Tax Assets Valuation Allowance (in thousands)

 

 

Balance at

 

 

Additions
Charged to

 

 

 

 

 

Balance at

 

Fiscal Year Ended

 

Beginning of
Period

 

 

Costs and
Expenses

 

 

Other Comprehensive (Gain) Loss

 

 

Deductions

 

 

End of
Period

 

December 31, 2022

 

$

4,262

 

 

$

628

 

 

$

(788

)

 

$

(249

)

 

$

3,853

 

December 31, 2021

 

$

 

 

$

3,304

 

 

$

958

 

 

$

 

 

$

4,262

 

See accompanying report of independent registered public accounting firm on page 4142 of this annual report.

ITEM 16

FORM 10-K SUMMARY

NoneITEM 16 FORM 10-K SUMMARY

None.

39


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

SIGNATURESSIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, American Vanguard Corporation has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMERICAN VANGUARD CORPORATION

(Registrant)

By:

/s/ ERIC G. WINTEMUTE

By:

/s/ DAVID T. JOHNSON

Eric G. Wintemute

Chief Executive Officer

and Chairman of the Board

David T. Johnson

Chief Financial Officer

and Principal Accounting Officer

March 14, 201816, 2023

March 14, 201816, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated.

By:

/s/ ERIC G. WINTEMUTE

By:

/s/ DAVID T. JOHNSON

Eric G. Wintemute

Principal Executive Officer

and Chairman of the Board

David T. Johnson

Principal Financial Officer

and Principal Accounting Officer

March 14, 201816, 2023

March 14, 201816, 2023

By:

/s/ DEBRA EDWARDS

By:

/s/ JOHN L. KILLMERMORTON D. ERLICH

Debra Edwards

Director

John L. KillmerMorton D. Erlich

Director

March 14, 201816, 2023

March 14, 201816, 2023

By:

/s/ LAWRENCE S. CLARKMARISOL ANGELINI

By:

/s/ SCOTT D. BASKIN

Lawrence S. ClarkMarisol Angelini

Director

Scott D. Baskin

Director

March 14, 201816, 2023

March 14, 201816, 2023

By:

/s/ MORTON D. ERLICHÉMER GUNTER

By:

/s/ ALFRED INGULLIPATRICK E. GOTTSCHALK

Morton D. ErlichÉmer Gunter

Director

Alfred IngulliPatrick E. Gottschalk

Director

March 14, 201816, 2023

March 14, 201816, 2023

By:

/s/ ESMAIL ZIRAKPARVAR

By:

Esmail Zirakparvar

Director/s/ MARK R. BASSETT

By:

/s/ KEITH M. ROSENBLOOM

Mark R. Bassett

Director

Keith M. Rosenbloom

Director

March 14, 2018

March 16, 2023

March 16, 2023

40


AMERICAN VANGUARD CORPORATION

PART IV

ITEM 15 EXHIBITS AND SUBSIDIARIESFINANCIAL STATEMENT SCHEDULE

(a)
The following documents are filed as part of this report:

Index to Consolidated Financial Statements and Supplementary Data:

Description

Page No

Financial Statement Schedule:

Schedule II—A Valuation and Qualifying Accounts

39

Financial Statements:

Report of Independent Registered Public Accounting Firm BDO USA, LLP; Costa Mesa, California, PCAOB ID#243

42

Consolidated Balance Sheets as of December 31, 2022 and 2021

44

Consolidated Statements of Operations for the Years Ended December 31, 2022, 2021 and 2020

45

Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2022, 2021 and 2020

46

Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2022, 2021 and 2020

47

Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020

48

Notes to Consolidated Financial Statements

49

(b)
Exhibits Index

41


AMERICAN VANGUARD CORPORATION

Report of Independent RegisteredRegistered Public Accounting Firm

Stockholders and Board of Directors and Stockholders

American Vanguard Corporation

Newport Beach, California

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of American Vanguard Corporation (the “Company”) and subsidiaries as of December 31, 20172022 and 2016,2021, the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2017,2022, and the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 20172022 and 2016,2021, and the results of theirits operations and theirits cash flows for each of the three years in the period ended December 31, 2017,2022, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company's internal control over financial reporting as of December 31, 2017,2022, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our report dated March 14, 201816, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Accrued Program Costs

As discussed in note 1 to the 2022 consolidated financial statements, the Company offers discounts to its customers based on various programs. As of December 31, 2022, the Company had accrued program costs of $60.7

42


AMERICAN VANGUARD CORPORATION

million and program costs recorded as a reduction of gross sales totaled $111.6 million in 2022. These discounts represent variable consideration. Revenues from sales are recorded at the net sales price, which is the transaction price, and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to customers using the expected value method. Each quarter management compares individual sale transactions with programs to determine what, if any, estimated program liabilities have been incurred.

We identified variable consideration related to program costs as a critical audit matter. The principal considerations were the recording of accrued program costs at the individual sale transaction level and the assessment that customers will meet the requirements set out in agreed upon terms and conditions attached to each program. Auditing these elements involved especially challenging auditor judgment due to the nature and extent of audit effort required to address this matter.

The primary procedures we performed to address the critical audit matter included:

Testing the design and operating effectiveness of certain internal controls related to management’s accounting for accrued program costs, specifically including controls over: (i) the calculation of significant components of the accrued program costs, and (ii) the completeness and accuracy of accrued program costs.

Assessing the completeness and reasonableness of the recorded accrued program costs at the individual sale transaction level through (i) comparing current year accrued program costs for certain product lines against historical program cost payments, and (ii) evaluating management’s ability to accurately accrue program costs by comparing the accruals made in prior periods to actual payment activity.

Testing the computation of the accrued program costs by (i) independently calculating portions of the accrued program costs at the individual sale transaction level, and (ii) validating management’s assessment that customers will meet the program requirements by comparing a sample of accrued program costs payments made to customers to the approved program rates and relevant source documents.

/s/ BDO USA, LLP

We have served as the Company's auditor since 1991.

Costa Mesa, California

March 14, 201816, 2023

4143


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

CONSOLIDATED BALANCEBALANCE SHEETS

December 31, 20172022 and 20162021

(In thousands, except share data)

 

2017

 

 

2016

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

11,337

 

 

$

7,869

 

 

$

20,328

 

 

$

16,285

 

Receivables:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade, net of allowance for doubtful accounts of $46 and $42, respectively

 

 

102,534

 

 

 

83,777

 

Trade, net of allowance for doubtful accounts of $5,136 and $3,938,
respectively

 

 

156,492

 

 

 

149,326

 

Other

 

 

7,071

 

 

 

3,429

 

 

 

9,816

 

 

 

9,595

 

 

 

109,605

 

 

 

87,206

 

Inventories

 

 

123,124

 

 

 

120,576

 

Total receivables, net

 

 

166,308

 

 

 

158,921

 

Inventories, net

 

 

184,190

 

 

 

154,306

 

Prepaid expenses

 

 

10,817

 

 

 

11,424

 

 

 

15,850

 

 

 

12,488

 

Income taxes receivable

 

 

1,891

 

 

 

 

Total current assets

 

 

254,883

 

 

 

227,075

 

 

 

388,567

 

 

 

342,000

 

Property, plant and equipment, net

 

 

49,321

 

 

 

50,295

 

 

 

70,912

 

 

 

66,111

 

Intangible assets, net of applicable amortization

 

 

180,950

 

 

 

121,433

 

Operating lease right-of-use assets

 

 

24,250

 

 

 

25,386

 

Intangible assets, net of amortization

 

 

184,664

 

 

 

197,841

 

Goodwill

 

 

22,184

 

 

 

 

 

 

47,010

 

 

 

46,260

 

Other assets

 

 

28,254

 

 

 

31,153

 

 

 

10,769

 

 

 

16,292

 

Deferred income tax assets, net

 

 

141

 

 

 

270

 

Total assets

 

$

535,592

 

 

$

429,956

 

 

$

726,313

 

 

$

694,160

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current installments of other liabilities

 

$

5,395

 

 

$

26

 

 

$

 

 

$

802

 

Accounts payable

 

 

53,748

 

 

 

24,358

 

 

 

69,000

 

 

 

67,140

 

Deferred revenue

 

 

14,574

 

 

 

3,848

 

Customer prepayments

 

 

110,597

 

 

 

63,064

 

Accrued program costs

 

 

39,054

 

 

 

42,930

 

 

 

60,743

 

 

 

63,245

 

Accrued expenses and other payables

 

 

12,061

 

 

 

12,072

 

 

 

20,982

 

 

 

20,745

 

Income taxes payable

 

 

1,370

 

 

 

13,840

 

 

 

 

 

 

3,006

 

Operating lease liabilities, current

 

 

5,279

 

 

 

5,059

 

Total current liabilities

 

 

126,202

 

 

 

97,074

 

 

 

266,601

 

 

 

223,061

 

Long-term debt, excluding current installments

 

 

77,486

 

 

 

40,951

 

Long-term debt, net of deferred loan fees

 

 

51,477

 

 

 

52,240

 

Other liabilities, excluding current installments

 

 

10,306

 

 

 

2,868

 

 

 

4,167

 

 

 

5,335

 

Operating lease liabilities, long-term

 

 

19,492

 

 

 

20,780

 

Deferred income tax liabilities, net

 

 

16,284

 

 

 

6,706

 

 

 

14,597

 

 

 

20,006

 

Total liabilities

 

 

230,278

 

 

 

147,599

 

 

 

356,334

 

 

 

321,422

 

Commitments and contingent liabilities

 

 

 

 

 

 

 

 

Commitments and contingent liabilities (Notes 5 and 11)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued

 

 

 

 

 

 

Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 32,241,866 shares in 2017 and 31,819,695 shares in 2016

 

 

3,225

 

 

 

3,183

 

Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued

 

 

 

 

 

 

Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,446,194 shares in 2022 and 34,248,218 shares in 2021

 

 

3,444

 

 

 

3,426

 

Additional paid-in capital

 

 

75,658

 

 

 

71,699

 

 

 

105,634

 

 

 

101,450

 

Accumulated other comprehensive loss

 

 

(4,507

)

 

 

(4,851

)

 

 

(12,182

)

 

 

(13,784

)

Retained earnings

 

 

238,953

 

 

 

220,428

 

 

 

328,745

 

 

 

304,385

 

 

 

313,329

 

 

 

290,459

 

 

 

425,641

 

 

 

395,477

 

Less treasury stock at cost, 2,450,634 shares in 2017 and in 2016

 

 

(8,269

)

 

 

(8,269

)

American Vanguard Corporation stockholders’ equity

 

 

305,060

 

 

 

282,190

 

Non-controlling interest

 

 

254

 

 

 

167

 

Less treasury stock at cost, 5,029,892 shares in 2022 and 3,361,040 in 2021

 

 

(55,662

)

 

 

(22,739

)

Total stockholders’ equity

 

 

305,314

 

 

 

282,357

 

 

 

369,979

 

 

 

372,738

 

Total liabilities and stockholders’ equity

 

$

535,592

 

 

$

429,956

 

 

$

726,313

 

 

$

694,160

 

See summary of significant accounting policies and notes to consolidated financial statements.

4244


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

CONSOLIDATED STATEMENTSSTATEMENTS OF OPERATIONS

Years ended December 31, 2017, 20162022, 2021 and 20152020

(In thousands, except per share data)

 

2017

 

 

2016

 

 

2015

 

 

2022

 

 

2021

 

 

2020

 

Net sales

 

$

355,047

 

 

$

312,113

 

 

$

289,382

 

 

$

609,615

 

 

$

557,676

 

 

$

458,704

 

Cost of sales

 

 

207,655

 

 

 

183,825

 

 

 

177,480

 

 

 

(368,263

)

 

 

(343,629

)

 

 

(286,114

)

Gross profit

 

 

147,392

 

 

 

128,288

 

 

 

111,902

 

 

 

241,352

 

 

 

214,047

 

 

 

172,590

 

Operating expenses

 

 

120,598

 

 

 

107,748

 

 

 

100,378

 

 

 

(200,701

)

 

 

(183,272

)

 

 

(154,339

)

Bargain purchase gain on business acquisition

 

 

 

 

 

171

 

 

 

4,657

 

Operating income

 

 

26,794

 

 

 

20,540

 

 

 

11,524

 

 

 

40,651

 

 

 

30,946

 

 

 

22,908

 

Change in fair value of equity investments, net

 

 

(732

)

 

 

(790

)

 

 

717

 

Other income

 

 

 

 

 

672

 

 

 

 

Interest expense, net

 

 

1,941

 

 

 

1,623

 

 

 

2,562

 

 

 

(3,954

)

 

 

(3,687

)

 

 

(5,178

)

Income before provision for income taxes and loss on equity investments

 

 

24,853

 

 

 

18,917

 

 

 

8,962

 

Income before provision for income taxes and loss on equity method investment

 

 

35,965

 

 

 

27,141

 

 

 

18,447

 

Provision for income taxes

 

 

4,443

 

 

 

5,540

 

 

 

2,009

 

 

 

(8,561

)

 

 

(8,166

)

 

 

(3,080

)

Income before loss on equity investments

 

 

20,410

 

 

 

13,377

 

 

 

6,953

 

Less net loss from equity method investments

 

 

(49

)

 

 

(353

)

 

 

(636

)

Income before loss on equity method investment

 

 

27,404

 

 

 

18,975

 

 

 

15,367

 

Loss from equity method investment

 

 

 

 

 

(388

)

 

 

(125

)

Net income

 

 

20,361

 

 

 

13,024

 

 

 

6,317

 

 

$

27,404

 

 

$

18,587

 

 

$

15,242

 

Net (income) loss attributable to non-controlling interest

 

 

(87

)

 

 

(236

)

 

 

274

 

Net income attributable to American Vanguard

 

$

20,274

 

 

$

12,788

 

 

$

6,591

 

Earnings per common share—basic

 

$

0.70

 

 

$

0.44

 

 

$

0.23

 

 

$

0.94

 

 

$

0.62

 

 

$

0.52

 

Earnings per common share—assuming dilution

 

$

0.68

 

 

$

0.44

 

 

$

0.23

 

 

$

0.92

 

 

$

0.61

 

 

$

0.51

 

Weighted average shares outstanding—basic

 

 

29,100

 

 

 

28,859

 

 

 

28,673

 

 

 

29,234

 

 

 

29,811

 

 

 

29,450

 

Weighted average shares outstanding—assuming dilution

 

 

29,703

 

 

 

29,394

 

 

 

29,237

 

 

 

29,872

 

 

 

30,410

 

 

 

29,993

 

See summary of significant accounting policies and notes to consolidated financial statements.

4345


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Years ended December 31, 2017, 20162022, 2021 and 20152020

(In thousands)

 

 

2017

 

 

2016

 

 

2015

 

Net income

 

$

20,361

 

 

$

13,024

 

 

$

6,317

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

344

 

 

 

(1,310

)

 

 

(1,571

)

Comprehensive income

 

 

20,705

 

 

 

11,714

 

 

 

4,746

 

Less: Comprehensive income (loss) attributable to non-controlling interest

 

 

87

 

 

 

236

 

 

 

(274

)

Comprehensive income attributable to American Vanguard

 

$

20,618

 

 

$

11,478

 

 

$

5,020

 

 

 

2022

 

 

2021

 

 

2020

 

Net income

 

$

27,404

 

 

$

18,587

 

 

$

15,242

 

Other comprehensive gain (loss)

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment, net of tax effects

 

 

1,602

 

 

 

(4,462

)

 

 

(3,624

)

Comprehensive income

 

$

29,006

 

 

$

14,125

 

 

$

11,618

 

See summary of significant accounting policies and notes to consolidated financial statementsstatements.

4446


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Years ended December 31, 2017, 20162022, 2021 and 20152020

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-

 

 

 

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

AVD

 

 

Controlling

 

 

 

 

 

 

 

Shares

 

 

 

 

Amount

 

 

Capital

 

 

Income/(loss)

 

 

Earnings

 

 

Shares

 

 

Amount

 

 

Total

 

 

Interest

 

 

Total

 

Balance, December 31, 2014

 

 

31,550,477

 

 

 

 

$

3,156

 

 

$

66,232

 

 

$

(1,970

)

 

$

202,488

 

 

 

2,450,634

 

 

$

(8,269

)

 

$

261,637

 

 

$

(634

)

 

$

261,003

 

Stocks issued under ESPP

 

 

50,452

 

 

 

 

 

5

 

 

 

568

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

573

 

 

 

 

 

 

573

 

Cash dividends on common stock ($0.02

   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(572

)

 

 

 

 

 

 

 

 

(572

)

 

 

 

 

 

(572

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,571

)

 

 

 

 

 

 

 

 

 

 

 

(1,571

)

 

 

 

 

 

(1,571

)

Stock based compensation

 

 

 

 

 

 

 

 

 

 

3,881

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,881

 

 

 

 

 

 

3,881

 

Stock options exercised; grants, termination,

   and vesting of restricted stock units (net of

   shares in lieu of taxes)

 

 

37,296

 

 

 

 

 

3

 

 

 

(259

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(256

)

 

 

 

 

 

(256

)

Tax effect from share based compensation

 

 

 

 

 

 

 

 

 

 

(924

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(924

)

 

 

 

 

 

(924

)

Adjustment and purchase of non-controlling

   interest

 

 

 

 

 

 

 

 

 

 

(964

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(964

)

 

 

839

 

 

 

(125

)

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,591

 

 

 

 

 

 

 

 

 

6,591

 

 

 

(274

)

 

 

6,317

 

Balance, December 31, 2015

 

 

31,638,225

 

 

 

 

 

3,164

 

 

 

68,534

 

 

 

(3,541

)

 

 

208,507

 

 

 

2,450,634

 

 

 

(8,269

)

 

 

268,395

 

 

 

(69

)

 

 

268,326

 

Stocks issued under ESPP

 

 

42,730

 

 

 

 

 

4

 

 

 

558

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

562

 

 

 

 

 

 

562

 

Cash dividends on common stock ($0.03

   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(867

)

 

 

 

 

 

 

 

 

(867

)

 

 

 

 

 

(867

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,310

)

 

 

 

 

 

 

 

 

 

 

 

(1,310

)

 

 

 

 

 

(1,310

)

Stock based compensation

 

 

 

 

 

 

 

 

 

 

3,167

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,167

 

 

 

 

 

 

3,167

 

Stock options exercised; grants, termination,

   and vesting of restricted stock units (net of

   shares in lieu of taxes)

 

 

138,740

 

 

 

 

 

15

 

 

 

(336

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(321

)

 

 

 

 

 

(321

)

Tax effect from share based compensation

 

 

 

 

 

 

 

 

 

 

(224

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(224

)

 

 

 

 

 

(224

)

Net income

 

 

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

12,788

 

 

 

 

 

 

 

 

 

12,788

 

 

 

236

 

 

 

13,024

 

Balance, December 31, 2016

 

 

31,819,695

 

 

 

 

 

3,183

 

 

 

71,699

 

 

 

(4,851

)

 

 

220,428

 

 

 

2,450,634

 

 

 

(8,269

)

 

 

282,190

 

 

 

167

 

 

 

282,357

 

Stocks issued under ESPP

 

 

34,016

 

 

 

 

 

4

 

 

 

551

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

555

 

 

 

 

 

 

555

 

Cash dividends on common stock ($0.06

   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,749

)

 

 

 

 

 

 

 

 

(1,749

)

 

 

 

 

 

(1,749

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

 

 

344

 

 

 

 

 

 

 

 

 

 

 

 

344

 

 

 

 

 

 

344

 

Stock based compensation

 

 

 

 

 

 

 

 

 

 

4,714

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,714

 

 

 

 

 

 

4,714

 

Stock options exercised; grants, termination,

   and vesting of restricted stock units (net of

   shares in lieu of taxes)

 

 

388,155

 

 

 

 

 

38

 

 

 

(1,306

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,268

)

 

 

 

 

 

(1,268

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

20,274

 

 

 

 

 

 

 

 

 

20,274

 

 

 

87

 

 

 

20,361

 

Balance, December 31, 2017

 

 

32,241,866

 

 

 

 

$

3,225

 

 

$

75,658

 

 

$

(4,507

)

 

$

238,953

 

 

 

2,450,634

 

 

$

(8,269

)

 

$

305,060

 

 

$

254

 

 

$

305,314

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Retained

 

 

Treasury Stock

 

 

AVD

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

loss

 

 

Earnings

 

 

Shares

 

 

Amount

 

 

Total

 

Balance, December 31, 2019

 

 

33,233,614

 

 

$

3,324

 

 

$

90,572

 

 

$

(5,698

)

 

$

274,118

 

 

 

3,061,040

 

 

$

(18,160

)

 

$

344,156

 

Stocks issued under ESPP

 

 

49,668

 

 

 

5

 

 

 

716

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

721

 

Cash dividends on common stock ($0.04
   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,178

)

 

 

 

 

 

 

 

 

(1,178

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

(3,624

)

 

 

 

 

 

 

 

 

 

 

 

(3,624

)

Stock based compensation

 

 

 

 

 

 

 

 

6,561

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,561

 

Stock options exercised, grants, termination,
   and vesting of restricted stock units (net of
   shares in lieu of taxes)

 

 

639,151

 

 

 

65

 

 

 

(1,207

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,142

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,242

 

 

 

 

 

 

 

 

 

15,242

 

Balance, December 31, 2020

 

 

33,922,433

 

 

 

3,394

 

 

 

96,642

 

 

 

(9,322

)

 

 

288,182

 

 

 

3,061,040

 

 

 

(18,160

)

 

 

360,736

 

Stocks issued under ESPP

 

 

50,782

 

 

 

4

 

 

 

739

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

743

 

Cash dividends on common stock ($0.08
   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,384

)

 

 

 

 

 

 

 

 

(2,384

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

(4,462

)

 

 

 

 

 

 

 

 

 

 

 

(4,462

)

Stock based compensation

 

 

 

 

 

 

 

 

6,880

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,880

 

Stock options exercised, grants, termination,
   and vesting of restricted stock units (net of
   shares in lieu of taxes)

 

 

275,003

 

 

 

28

 

 

 

(2,811

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,783

)

Shares repurchased

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

300,000

 

 

 

(4,579

)

 

 

(4,579

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

18,587

 

 

 

 

 

 

 

 

 

18,587

 

Balance, December 31, 2021

 

 

34,248,218

 

 

 

3,426

 

 

 

101,450

 

 

 

(13,784

)

 

 

304,385

 

 

 

3,361,040

 

 

 

(22,739

)

 

 

372,738

 

Stocks issued under ESPP

 

 

51,240

 

 

 

4

 

 

 

833

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

837

 

Cash dividends on common stock ($0.10
   per share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,044

)

 

 

 

 

 

 

 

 

(3,044

)

Foreign currency translation adjustment, net

 

 

 

 

 

 

 

 

 

 

 

1,602

 

 

 

 

 

 

 

 

 

 

 

 

1,602

 

Stock based compensation

 

 

 

 

 

 

 

 

5,684

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,684

 

Stock options exercised, grants, termination,
   and vesting of restricted stock units (net of
   shares in lieu of taxes)

 

 

146,736

 

 

 

14

 

 

 

(1,254

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,240

)

Shares repurchased

 

 

 

 

 

 

 

 

(1,079

)

 

 

 

 

 

 

 

 

1,668,852

 

 

 

(32,923

)

 

 

(34,002

)

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

27,404

 

 

 

 

 

 

 

 

 

27,404

 

Balance, December 31, 2022

 

 

34,446,194

 

 

$

3,444

 

 

$

105,634

 

 

$

(12,182

)

 

$

328,745

 

 

 

5,029,892

 

 

$

(55,662

)

 

$

369,979

 

See summary of significant accounting policies and notes to consolidated financial statementsstatements.

45

47


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

CONSOLIDATED STATEMENTSSTATEMENTS OF CASH FLOWS

Years ended December 31, 2017, 20162022, 2021 and 20152020

(In thousands)

 

 

2022

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net income

 

$

27,404

 

 

$

18,587

 

 

$

15,242

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization of property, plant and equipment and intangible assets

 

 

22,138

 

 

 

22,229

 

 

 

19,902

 

Loss on disposal of property, plant and equipment

 

 

268

 

 

 

194

 

 

 

119

 

Amortization of other long-term assets

 

 

3,573

 

 

 

3,943

 

 

 

3,947

 

Amortization and accretion of deferred loan fees and discounted liabilities

 

 

289

 

 

 

359

 

 

 

309

 

Provision for bad debts

 

 

1,171

 

 

 

649

 

 

 

1,002

 

Provision for inventory obsolescence

 

 

340

 

 

 

1,034

 

 

 

738

 

Loan principal and interest forgiveness

 

 

 

 

 

(672

)

 

 

 

Fair value adjustment of contingent consideration

 

 

610

 

 

 

758

 

 

 

250

 

Decrease in environmental liability

 

 

 

 

 

(167

)

 

 

(1,155

)

Stock-based compensation

 

 

5,684

 

 

 

6,880

 

 

 

6,561

 

Deferred income taxes

 

 

(5,278

)

 

 

(2,090

)

 

 

969

 

Changes in liabilities for uncertain tax positions or unrecognized tax benefits

 

 

(1,441

)

 

 

(1,783

)

 

 

(2,092

)

Change in equity investment fair value

 

 

732

 

 

 

790

 

 

 

(717

)

Loss from equity method investment

 

 

 

 

 

388

 

 

 

125

 

Bargain purchase gain

 

 

 

 

 

(171

)

 

 

(4,657

)

Non-cash lease expense

 

 

68

 

 

 

286

 

 

 

18

 

Foreign currency transaction (gains) losses

 

 

(29

)

 

 

(225

)

 

 

126

 

Changes in assets and liabilities associated with operations, net of business combinations:

 

 

 

 

 

 

 

 

 

(Increase) decrease in net receivables

 

 

(6,447

)

 

 

(24,347

)

 

 

15,407

 

(Increase) decrease in inventories

 

 

(29,560

)

 

 

8,323

 

 

 

6,683

 

(Increase) decrease in income tax receivable, net

 

 

(4,910

)

 

 

6,051

 

 

 

(287

)

(Increase) decrease in prepaid expenses and other assets

 

 

(3,082

)

 

 

(4,581

)

 

 

140

 

Increase (decrease) in accounts payable

 

 

1,704

 

 

 

8,783

 

 

 

(8,199

)

Increase in deferred revenue

 

 

47,551

 

 

 

19,280

 

 

 

36,803

 

(Decrease) increase in accrued program costs

 

 

(2,449

)

 

 

17,877

 

 

 

(2,517

)

Increase in other payables and accrued expenses

 

 

90

 

 

 

3,986

 

 

 

1,607

 

Payment of contingent consideration

 

 

(1,321

)

 

 

 

 

 

 

Net cash provided by operating activities

 

 

57,105

 

 

 

86,361

 

 

 

90,324

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(13,261

)

 

 

(9,518

)

 

 

(11,249

)

Proceeds from disposal of property, plant and equipment

 

 

84

 

 

 

 

 

 

 

Acquisitions of businesses and product lines

 

 

 

 

 

(10,000

)

 

 

(19,342

)

Intangible assets

 

 

(1,293

)

 

 

(524

)

 

 

(4,014

)

Investment

 

 

 

 

 

 

 

 

(1,190

)

Net cash used in investing activities

 

 

(14,470

)

 

 

(20,042

)

 

 

(35,795

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Payments under line of credit agreement

 

 

(254,000

)

 

 

(186,569

)

 

 

(168,400

)

Borrowings under line of credit agreement

 

 

253,000

 

 

 

131,000

 

 

 

126,776

 

Payment of contingent consideration

 

 

(68

)

 

 

(1,301

)

 

 

(1,227

)

Net receipt from the issuance of common stock under ESPP

 

 

837

 

 

 

743

 

 

 

721

 

Net receipt from the exercise of stock options

 

 

827

 

 

 

172

 

 

 

1,603

 

Net payment from common stock purchased for tax withholding

 

 

(2,067

)

 

 

(2,955

)

 

 

(2,745

)

Repurchase of common stock

 

 

(34,002

)

 

 

(4,579

)

 

 

 

Payment of cash dividends

 

 

(2,787

)

 

 

(2,382

)

 

 

(1,168

)

Net cash used in financing activities

 

 

(38,260

)

 

 

(65,871

)

 

 

(44,440

)

Net increase in cash and cash equivalents

 

 

4,375

 

 

 

448

 

 

 

10,089

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(332

)

 

 

(86

)

 

 

(747

)

Cash and cash equivalents at beginning of year

 

 

16,285

 

 

 

15,923

 

 

 

6,581

 

Cash and cash equivalents at end of year

 

$

20,328

 

 

$

16,285

 

 

$

15,923

 

 

 

2017

 

 

2016

 

 

2015

 

Increase cash

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

20,361

 

 

$

13,024

 

 

$

6,317

 

Adjustments to reconcile net income to net cash provided by (used in)

   operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization of fixed and intangible assets

 

 

16,959

 

 

 

16,327

 

 

 

16,474

 

Amortization of other long term assets and debt issuance costs

 

 

5,221

 

 

 

5,203

 

 

 

5,275

 

Amortization of discounted liabilities

 

 

110

 

 

 

16

 

 

 

140

 

Stock-based compensation

 

 

4,714

 

 

 

3,167

 

 

 

3,881

 

Excess tax benefit from share based compensation

 

 

 

 

 

(96

)

 

 

(23

)

Increase (decrease) in deferred income taxes

 

 

398

 

 

 

(151

)

 

 

27

 

Operating loss from equity method investment

 

 

49

 

 

 

353

 

 

 

629

 

Loss from dilution of equity method investment

 

 

 

 

 

 

 

 

7

 

Changes in assets and liabilities associated with operations, net of business

   combinations:

 

 

 

 

 

 

 

 

 

 

 

 

Decrease (increase) in net receivables

 

 

754

 

 

 

(11,817

)

 

 

13,034

 

Decrease in inventories

 

 

16,183

 

 

 

15,901

 

 

 

29,154

 

(Increase) decrease in income tax receivable/payable, net

 

 

(12,073

)

 

 

1,186

 

 

 

4,872

 

Decrease (increase) in prepaid expenses and other assets

 

 

647

 

 

 

(3,872

)

 

 

2,082

 

Increase (decrease) in accounts payable

 

 

3,322

 

 

 

9,015

 

 

 

(5,068

)

Increase (decrease) in deferred revenue

 

 

10,726

 

 

 

(5,040

)

 

 

7,990

 

Decrease in accrued program costs

 

 

(4,529

)

 

 

(1,441

)

 

 

(8,175

)

(Decrease) increase in other payables

 

 

(3,841

)

 

 

4,631

 

 

 

1,952

 

Net cash provided by operating activities

 

 

59,001

 

 

 

46,406

 

 

 

78,568

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(6,666

)

 

 

(10,630

)

 

 

(6,899

)

Investment

 

 

(950

)

 

 

(3,283

)

 

 

(125

)

Acquisitions of businesses and intangible assets

 

 

(81,896

)

 

 

(224

)

 

 

(36,667

)

Net cash used in investing activities

 

 

(89,512

)

 

 

(14,137

)

 

 

(43,691

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Payments under line of credit agreement

 

 

(103,975

)

 

 

(107,600

)

 

 

(121,400

)

Borrowings under line of credit agreement

 

 

141,000

 

 

 

80,000

 

 

 

90,880

 

Debt issuance cost

 

 

(751

)

 

 

 

 

 

 

Payment on other long-term liabilities

 

 

(26

)

 

 

(704

)

 

 

(1,543

)

Excess tax benefit from share based compensation

 

 

 

 

 

96

 

 

 

23

 

Net payment from the issuance of common stock (sale of stock under ESPP,

   exercise of stock options and shares purchased for tax withholding)

 

 

(713

)

 

 

241

 

 

 

317

 

Payment of cash dividends

 

 

(1,600

)

 

 

(578

)

 

 

(1,141

)

Net cash provided by (used in) financing activities

 

 

33,935

 

 

 

(28,545

)

 

 

(32,864

)

Net increase in cash and cash equivalents

 

 

3,424

 

 

 

3,724

 

 

 

2,013

 

Effect of exchange rate changes on cash and cash equivalents

 

 

44

 

 

 

(1,379

)

 

 

(1,374

)

Cash and cash equivalents at beginning of year

 

 

7,869

 

 

 

5,524

 

 

 

4,885

 

Cash and cash equivalents at end of year

 

$

11,337

 

 

$

7,869

 

 

$

5,524

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid (received) during the year for:

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

$

1,500

 

 

$

1,748

 

 

$

2,750

 

Income taxes, net

 

$

17,841

 

 

$

4,947

 

 

$

(3,697

)

See summary of significant accounting policies and notes to the consolidated financial statementsstatements.

4648


AMERICAN VANGUARD CORPORATION

AND SUBSIDIARIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years Ended December 31, 2017, 20162022, 2021 and 20152020

(Dollars in thousands, except per share data)

(1)
Description of Business Basisand Summary of Consolidation, Basis of Presentation and Significant Accounting Policies

American Vanguard Corporation (the “Company” or “AVD”) is primarily a specialty chemical manufacturer that develops and markets safe and effective products for agricultural, commercial and consumer uses. The Company manufactures and formulates chemicals for crops, human and animal protection. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and Envance, its majority owned subsidiary.subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company operates within a single operating category.segment.

All U.S. Dollar amounts reflected in the notes to the consolidated financial statements are presented in thousands, except per share data.

The Company believes that the combination of its cash flows from future operations, current cash on hand and the availability under the Company’s credit facility will be sufficient to meet its working capital and capital expenditure requirements and will provide the Company with adequate liquidity to meet its anticipated operating needs for at least the next 12 months from the issuance of these consolidated financial statements. Although operating activities are expected to provide cash, to the extent of growth in the future, its operating and investing activities will use cash and, consequently, this growth may require the Company to access some or all of the availability under the credit facility. It is also possible that additional sources of finance may be necessary to support additional growth.

Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable category. Selective enterprise information is as follows:

 

 

2022

 

 

2021

 

 

2020

 

Net sales:

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

288,624

 

 

$

263,632

 

 

$

211,357

 

U.S. non-crop

 

 

76,709

 

 

 

78,605

 

 

 

60,367

 

Total U.S.

 

 

365,333

 

 

 

342,237

 

 

 

271,724

 

International

 

 

244,282

 

 

 

215,439

 

 

 

186,980

 

Total net sales

 

$

609,615

 

 

$

557,676

 

 

$

458,704

 

Gross profit:

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

132,509

 

 

$

109,568

 

 

$

92,723

 

U.S. non-crop

 

 

35,257

 

 

 

37,443

 

 

 

27,842

 

Total U.S.

 

 

167,766

 

 

 

147,011

 

 

 

120,565

 

International

 

 

73,586

 

 

 

67,036

 

 

 

52,025

 

Total gross profit

 

$

241,352

 

 

$

214,047

 

 

$

172,590

 

 

 

2017

 

 

2016

 

 

2015

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

Insecticides

 

$

132,137

 

 

$

119,226

 

 

$

117,180

 

Herbicides/soil fumigants/fungicides

 

 

121,581

 

 

 

123,540

 

 

 

111,897

 

Other, including plant growth regulators

 

 

47,691

 

 

 

29,438

 

 

 

29,013

 

Total crop

 

 

301,409

 

 

 

272,204

 

 

 

258,090

 

Non-crop

 

 

53,638

 

 

 

39,909

 

 

 

31,292

 

 

 

$

355,047

 

 

$

312,113

 

 

$

289,382

 

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

Crop

 

$

117,892

 

 

$

107,821

 

 

$

97,198

 

Non-crop

 

 

29,500

 

 

 

20,467

 

 

 

14,704

 

 

 

$

147,392

 

 

$

128,288

 

 

$

111,902

 

Due to elements inherent to the Company’s business, such as differing and unpredictable weather patterns, crop growing cycles, changes in product mix of sales and ordering patterns that may vary in timing, measuring the Company’s performance on a quarterly basis (for example, gross profit margins on a quarterly basis may vary significantly) even when such comparisons are favorable, is not as good an indicator as full-year comparisons.

Out-of-period adjustment to 2021 consolidated statements of operations—In Australia, the Company sells its products to distribution companies as well as directly to growers via third-party agents. The Company identified errors related to the classification of third-party agent’s commission amounts. The Company evaluated these errors and the impact to previously issued financial statements and concluded that the adjustments and impact of this classification error is not material to any previously issued quarterly or annual financial statements. However, to improve the consistency and comparability of the financial statements, management has recorded an out-of-period adjustment to previously reported financial statement line items and related disclosures in this report. The third-party agents’ commission in the amount of $804 was reclassified from net sales to operating expenses. The impact was an increase in net sales and gross profit in the amount of $804 and an offsetting increase in operating expenses in the same amount. This adjustment to the 2021 consolidated statements of operations did not have any impact on operating income, net income, and earnings per common share.

Reclassifications — 49


Reclassifications—Certain prior years’ amounts have been reclassified to conform to the current year’s presentation.

Cost of Sales—In addition to normal Cost of sales is the Company’s capitalized cost centers (i.e.,of inventory procurement and production that is sold in the respective periods. These costs include direct labor, raw materials),materials, and manufacturing overhead, Additionally the Company also includes such cost centers as Health and Safety, Environmental, Maintenance and Quality Control in cost of sales.

Operating Expenses—Operating expenses include cost centers for Selling, General and Administrative, Research, Product Development, and Regulatory, and outbound Freight, Delivery and Warehousing.

 

 

2017

 

 

2016

 

 

2015

 

Selling

 

$

29,112

 

 

$

27,442

 

 

$

27,052

 

General and administrative

 

 

37,660

 

 

 

32,128

 

 

 

28,516

 

Research, product development and regulatory

 

 

26,076

 

 

 

21,298

 

 

 

19,116

 

Freight, delivery and warehousing

 

 

27,750

 

 

 

26,880

 

 

 

25,694

 

 

 

$

120,598

 

 

$

107,748

 

 

$

100,378

 

 

 

2022

 

 

2021

 

 

2020

 

Selling

 

$

52,512

 

 

$

49,409

 

 

$

42,389

 

General and administrative:

 

 

 

 

 

 

 

 

 

Other

 

 

51,671

 

 

 

47,971

 

 

 

36,084

 

Proxy contest activities

 

 

1,785

 

 

 

 

 

 

 

Amortization

 

 

13,953

 

 

 

13,713

 

 

 

12,744

 

Research, product development and regulatory

 

 

31,816

 

 

 

28,855

 

 

 

26,310

 

Freight, delivery and warehousing

 

 

48,964

 

 

 

43,324

 

 

 

36,812

 

Total operating expenses

 

$

200,701

 

 

$

183,272

 

 

$

154,339

 

Advertising Expense—The Company expenses advertising costs in the period incurred. Advertising expenses, which include promotional costs, are recognized in operating costs (specifically inas selling expenses)expenses in the consolidated statements of operations and were $3,020$5,836, $5,201 and $4,833 in 2017, $2,271 in 20162022, 2021 and $3,535 in 2015.2020, respectively.


Cash and Cash Equivalents—Cash and cash equivalents—The Company’s cash and cash equivalents consist primarily of certificates of deposit with an initial term of less than three months. For purposes of the consolidated statements of cash flows, the Company considers allinclude short-term investments, which are highly liquid debt instrumentsinvestments with original maturities of three months or less when purchased. The Company maintains cash and cash equivalent balances that exceed federally insured limits with a number of financial institutions. When evaluating cash and cash equivalents for current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term and macroeconomic trends, including current conditions and forecasts to be cash equivalents.the extent they are reasonable and supportable.

Inventories —Inventories—The Company values its inventories at lower of cost or net realizable value. Cost is determined by the first-in, first-out (“FIFO”) or average cost method, including material, labor, factory overhead and subcontracting services. The Company writes down and makes adjustments to its inventory carrying values as a result of net realizable value assessments of slow moving and obsolete inventory and other annual adjustments to ensure that ourits standard costs continue to closely reflect manufacturingactual cost. The Company recorded an inventory reserve allowance of $3,137$3,015 and $2,675 at December 31, 2017, as compared to $3,594 at December 31, 2016.  2022 and 2021, respectively.

The components of inventories, net of reserve allowance, consist of the following:

 

 

2022

 

 

2021

 

Finished products

 

$

155,128

 

 

$

138,159

 

Raw materials

 

 

29,062

 

 

 

16,147

 

Total inventories, net

 

$

184,190

 

 

$

154,306

 

 

 

2017

 

 

2016

 

Finished products

 

$

107,595

 

 

$

103,832

 

Raw materials

 

 

15,529

 

 

 

16,744

 

 

 

$

123,124

 

 

$

120,576

 

Revenue Recognition and Allowance for Doubtful Accounts—Revenue from sales is recognized at the time title and the risks of ownership pass. This is when the customer has made the fixed commitment to purchase the goods, the products are shipped per the customer’s instructions, the sales price is fixed and determinable, and collection is reasonably assured.Leases The Company has operating leases for warehouses, manufacturing facilities, offices, cars, railcars and certain equipment for which operating lease right-of-use (“ROU”) assets and corresponding lease liabilities are recorded. The Company measures ROU assets throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. The lease liabilities are measured at the present value of the unpaid lease payments at the lease commencement date. Leases that include both lease and non-lease components are accounted for as a single lease component for each asset class, except for warehouse leases.

50


The minimum payments under operating leases are recognized on a straight-line basis over the lease term in place proceduresthe consolidated statements of operations. Operating lease expenses related to ensure that revenuevariable lease payments are recognized in cost of sales or as operating expenses in a manner consistent with the nature of the underlying lease and as the events, activities, or circumstances in the lease agreement occur. Leases with a term of less than 12 months are not recognized on the consolidated balance sheets, and the related lease expenses are recognized in the consolidated statements of operations on a straight-line basis over the lease term.

The accounting for leases requires management to exercise judgment and make estimates in determining the applicable discount rate, lease term and payments due under a lease. Most of our leases do not provide an implicit interest rate, nor is recognized when earned.it available to us from our lessors. As an alternative, the Company uses our estimated incremental borrowing rate, which is derived from information available at the lease commencement date, including publicly available data, in determining the present value of lease payments. The procedures are subjectCompany also estimated the fair value of the lease and non-lease components for some of our warehouse leases based on market data and cost data.

The lease term includes the non-cancellable period of the lease plus any additional periods covered by either an option to management’s review and from time to time certain sales are excluded until it is clearextend (or not terminate) that the titleCompany is reasonably certain to exercise. The Company has passed and there is no further recourseleases with a lease term ranging from 1 year to 20 years.

The operating leases of the Company do not contain major restrictions or covenants such as those relating to dividends or additional financial obligations. Finance leases are immaterial to the Company. From timeconsolidated financial statements. There were no lease transactions with related parties during 2022, 2021 and 2020.

The operating lease expense for the years ended December 31, 2022, 2021 and 2020 was $6,531, $6,053 and $5,662, respectively. Lease expenses related to time,variable lease payments and short-term leases were immaterial. Additional information related to operating leases are as follows:

 

 

Year Ended
December 31, 2022

 

 

Year Ended
December 31, 2021

 

 

Year Ended
December 31, 2020

 

Cash paid for amounts included in the measurement of lease liabilities

 

$

6,450

 

 

$

5,750

 

 

$

5,657

 

ROU assets obtained in exchange for new liabilities

 

$

4,468

 

 

$

18,521

 

 

$

6,309

 

The weighted-average remaining lease term and discount rate related to the operating leases as of December 31, 2022 and 2021 were as follows:

 

 

December 31, 2022

 

 

December 31, 2021

 

Weighted-average remaining lease term (in years)

 

 

5.93

 

 

 

6.72

 

Weighted-average discount rate

 

 

4.00

%

 

 

4.02

%

Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 were as follows:

2023

 

$

6,073

 

2024

 

 

5,204

 

2025

 

 

4,688

 

2026

 

 

3,464

 

2027

 

 

2,387

 

Thereafter

 

 

6,194

 

Total lease payments

 

$

28,010

 

Less: imputed interest

 

 

(3,239

)

Total

 

$

24,771

 

 

 

 

 

Amounts recognized in the consolidated balance sheets:

 

 

 

Operating lease liabilities, current

 

$

5,279

 

Operating lease liabilities, long term

 

$

19,492

 

51


Revenue Recognition— The Company may offer a program to eligible customers, in good standing, that provides extended payment terms on a portionrecognizes revenue when control of the sales on selected products. The Company analyzes these extended payment programs in connection with its revenue recognition policy to ensure all revenue recognition criteriaordered goods or services are satisfied at the time of sale. Allowance for doubtful accounts is established based on estimates of losses related to customer receivable balances. Estimates are developed using either standard quantitative measures based on historical losses, adjusted for current economic conditions or by evaluating specific customer accounts for risk of loss.

Accrued Program Costs— In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain paymentstransferred to its customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company sells its products mainly to distributors and retailers. The products include insecticides, herbicides, soil fumigants, fungicides and biologicals. In addition, the Company recognizes royalty income related to licensing arrangements which qualify as functional licenses rather than symbolic licenses. Upon signing a reductionnew licensing agreement, the Company typically receives up-front fees, which are generally characterized as non-refundable royalties. These fees are recognized as revenue upon the execution of the license agreements. Minimum royalty fees are recognized once the Company has an enforceable right for payment. Sales-based royalty fees are typically recognized when the sales occur. The Company calculates and accrues estimated royalties based on the contractual terms and correspondence with the licensees regarding actual sales. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information of sales revenues.disaggregated by category and geographic region is as follows:

 

 

2022

 

 

2021

 

 

2020

 

Net sales:

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

288,624

 

 

$

263,632

 

 

$

211,357

 

U.S. non-crop

 

 

76,709

 

 

 

78,605

 

 

 

60,367

 

Total U.S.

 

 

365,333

 

 

 

342,237

 

 

 

271,724

 

International

 

 

244,282

 

 

 

215,439

 

 

 

186,980

 

Total net sales

 

$

609,615

 

 

$

557,676

 

 

$

458,704

 

Timing of revenue recognition:

 

 

 

 

 

 

 

 

 

Goods and services transferred at a point in time

 

$

609,409

 

 

$

557,176

 

 

$

455,726

 

Goods and services transferred over time

 

 

206

 

 

 

500

 

 

 

2,978

 

Total net sales

 

$

609,615

 

 

$

557,676

 

 

$

458,704

 

Contract Assets— Contract assets relate to royalties earned on certain functional licenses granted for the use of the Company’s intellectual property and amounted to $3,100 and $3,900 at December 31, 2022 and 2021, respectively. The short-term and long-term contract assets of $2,098 and $1,002 are included in other receivables and other assets, respectively, on the consolidated balance sheets as of December 31, 2022. As of December 31, 2021, the short-term and long-term assets amounted to $1,825 and $2,075, respectively.

Accrued Program Costs— The Company offers various discounts to customers based on the volume purchased within a defined period, other pricing adjustments, some grower volume incentives or other key performance indicator driven payments, which are usually made at the end of a growing season, to distributors, retailers or growers. The Company describes these payments as “Programs”.“Programs.” Programs are a critical part of doing business in both the U.S. agriculturalcrop and non-crop chemicals business market place. For accounting purposes, programsmarketplaces. These discount Programs represent variable consideration. Revenues from sales are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator driven payments made to distributors, retailers or growers predominantly at the endnet sales price, which is the transaction price net of a growing season.the impact of Programs and includes estimates of variable consideration. Variable consideration includes amounts expected to be paid to its customers, estimated using the expected value method. Each quarter management compares eachindividual sale transactiontransactions with program guidelinesPrograms to determine what, if any, estimated program liability hasliabilities have been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management, along with executive and financial management, review the accumulated programProgram balance and, for volume driven payments, make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in theagreed upon terms and conditions attached to each program. IfProgram. Following this assessment, management believes that customers are falling short of or exceeding their previously anticipated annual goals, then periodicwill make adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

Customer Prepayments— From time to time, the Company receives prepayments from customers which are recorded as customer prepayments on the Company’s consolidated balance sheets. The Company recorded accrued program costs of $39,054 atdoes not recognize revenue on any such payments unless and until the customer places binding purchase orders, the goods are shipped, and control is transferred to the customer. Revenue recognized for the years ended December 31, 2017, as compared2022, 2021, and 2020 that were included in the customer prepayments balance at the beginning of 2022, 2021, and 2020 was $63,064, $37,779, and $5,652, respectively.

52


Allowance for Doubtful Accounts or Current Expected Credit Losses—The Company maintains an allowance to $42,930 at December 31, 2016.

Long-lived Assets— Long-livedcover its Current Expected Credit Losses ("CECL") on its trade receivables, other receivables and contract assets primarily consistarising from the possible failure of customers to make contractual payments. The Company estimates credit losses expected over the life of its trade receivables, other receivables and contract assets based on historical information combined with current conditions that may affect a customer’s ability to pay and reasonable and supportable forecasts. In most instances, the Company’s policy is to write-off trade receivables when they are deemed uncollectible. The vast majority of the Company's trade receivables, other receivables and contract assets are less than 365 days. Under the CECL impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on multiple portfolios. The determination of portfolios is based primarily on geographical location, type of customer and aging.

Debt Issuance Costs— The Company capitalizes costs incurred with borrowing and records debt issuance costs as a reduction to the debt amount. These costs in connection with the Company’s revolving line of credit are amortized on a straight-line basis over the life of the borrowing and included in interest expense.

Property, Plant and Equipment and Depreciation— Property, plant and equipment includes the cost of land, buildings, machinery and equipment, office furniture and fixtures, automobiles, construction projects and significant improvements to existing plant and equipment. Interest costs related to significant construction projects are capitalized at the Company’s current weighted average effective interest rate. Expenditures for minor repairs and maintenance are expensed as incurred. When property or equipment is sold or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the gain or loss realized on disposition is reflected in operations. All plant and equipment are depreciated using the straight-line method, utilizing the estimated useful property lives.

Intangible AssetsThe primary identifiable intangible assets of the Company relate to assets associated with its product and business acquisitions. All the Company’s intangible assets are amortizing assets with finite lives. The estimated useful life of proprietary returnable packagingan identifiable intangible asset is based upon several factors including the effects of demand, competition, and expected changes in the marketability of the Company’s products.

Business CombinationsThe Company uses its best estimates and assumptions to assign fair value to the tangible and intangible assets including Smartboxacquired and Lockliabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and Load containers.subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill or an adjustment to the gain from a bargain purchase. In addition, when appropriate uncertain tax positions and tax-related valuation allowances are initially recorded in connection with a business combination as of the acquisition date. The Company continues to collect information and reevaluates these estimates and assumptions quarterly and records any adjustments to the Company’s preliminary estimates to goodwill or an adjustment to the gain from a bargain purchase, provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statement of operations.

From time to time, certain of our acquisition agreements include contingent earn-out arrangements, which are generally based on the achievement of future income thresholds. The fair values of these earn-out arrangements are included as part of the purchase price of the acquired companies on their respective acquisition dates. For each transaction, the Company engages third-party valuation specialists to assist it in making estimates of the fair value of contingent earn-out payments, both as part of the initial purchase price and at each subsequent financial statement date until the end of the related performance period. The Company records the estimated fair value of contingent consideration as a liability on the consolidated balance sheets.

We review and re-assess the estimated fair value of contingent consideration on a quarterly basis, and the updated fair value could be materially different from the initial estimates or prior quarterly amounts. Changes in the estimated fair value of our contingent earn-out liabilities are reported in operating results.

Asset AcquisitionsIf an acquisition of an asset or group of assets does not meet the definition of a business, the transaction is accounted for as an asset acquisition rather than a business combination. An asset acquisition does not result in the recognition of goodwill and transaction costs are capitalized as part of the cost of the asset or group of assets acquired. The Company uses its best estimates and assumptions to assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The acquisitions costs are allocated to the assets acquired on a relative fair value basis.

53


Impairment The carrying valuevalues of long-lived assets isother than goodwill are reviewed for impairment quarterlyannually and/or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. The Company evaluates recoverability of an asset group by comparing the carrying value to the future undiscounted cash flows that it expects to generate from the asset group. If the comparison indicates that the carrying value of an asset group is not recoverable, measurement of the impairment loss is based on the fair value of the asset. There were no circumstances that would indicate any impairment of the carrying value of these long-lived assets and no material impairment losses were recorded in 20172022, 2021, or 2016.


Property, Plant and Equipment and Depreciation— Property, plant and equipment includes the cost of land, buildings, machinery and equipment, office furniture and fixtures, automobiles, construction projects and significant improvements to existing plant and equipment. Interest costs related to significant construction projects are capitalized at the Company’s current weighted average effective interest rate. Expenditures for minor repairs and maintenance are expensed as incurred. When property or equipment is sold or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the gain or loss realized on disposition is reflected in earnings. All plant and equipment is depreciated using the straight-line method, utilizing the estimated useful property lives. See note 1 for useful lives.  2020.

Foreign Currency Translation— Assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, have been translated at period end exchange rates, and profit and loss accounts have been translated using weighted average yearly exchange rates. Adjustments resulting from translation have been recorded in the equity section of the balance sheet as cumulative translation adjustments in other comprehensive income (loss). The effects of foreign currency exchange gains and losses on transactions that are denominated in currencies other than the Company’s functional currency, including transactions denominated in the local currencies of the Company’s international subsidiaries where the functional currency is the U.S. dollar, are remeasured to the functional currency using the end of the period exchange rates. The effects of remeasurement related to foreign currency transactions are included in the consolidated statements of operations.

Goodwill and Other Intangible Assets— The primary identifiable intangible assets of the Company relate to assets associated with its product and business acquisitions. The Company adopted the provisions of ASC 350, under which identifiable intangibles with finite lives are amortized and those with indefinite lives are not amortized. The estimated useful life of an identifiable intangible asset to the Company is based upon a number of factors including the effects of demand, competition, and expected changes in the marketability of the Company’s products. The Company re-evaluates whether these intangible assets are impaired on both a quarterly and an annual basis and anytime when there is a specific indicator for impairment, relying on a number of factors including operating results, business plans and future cash flows. Identifiable intangible assets that are subject to amortization are evaluated for impairment using a process similar to that used to evaluate long-lived assets. The impairment test for identifiable intangible assets not subject to amortization consists of either a qualitative assessment or a comparison of the fair value of the intangible asset with its carrying amount. An impairment loss, if any, is recognized for the amount by which the carrying value exceeds the fair value of the asset. Fair value is typically estimated using a discounted cash flow analysis. When determining future cash flow estimates, the Company considers historical results adjusted to reflect current and anticipated operating conditions. Estimating future cash flows requires significant judgment by the Company, in such areas as: future economic conditions, industry-specific conditions, product pricing and necessary capital expenditures. The use of different assumptions or estimates for future cash flows could produce different impairment amounts (or none at all) for long-lived assets, goodwill and identifiable intangible assets. The Company performed impairment reviews for the years ended December 31, 2017 and 2016 and recorded immaterial impairment losses.

The Company reviews goodwill for impairment utilizing either a qualitative assessment or a two-step process.quantitative assessment. If the Company decides that it is appropriate to perform a qualitative assessment and concludes that the fair value of a reporting unit more likely than not exceeds its carrying value, no further evaluation is necessary. If the Company performs a quantitative assessment, the two-step process, the first step of the goodwill impairment test is used to identify potential impairment by comparingCompany compares the fair value of a reporting unit with its carrying amounts and recognizes an impairment charge for the amount including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. Ifthat the carrying amount of aexceeds the reporting unit exceeds itsunit’s fair value, the second step is performed to measure the amount of impairment by comparing the carrying amount of the goodwill to a determination of the implied value of the goodwill. If the carrying amount of goodwill is greater than the implied value, an impairment charge is recognized for the difference.value. The Company annually tests goodwill for impairment in the beginning of the fourth quarter.quarter, or earlier if triggering events occur. The Company did not record any impairment losses in 2022, 2021, or 2020.

Fair Value of Financial Instruments— The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. This accounting standard established a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required:

Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The Company did not have any significant Level 1 investments as of December 31, 2022 and 2021, except for its equity investment in Clean Seed Capital Group Ltd. (see Note 16 – Equity Investments).

The carrying amount of receivables, payables and other amounts arising out of the normal course of business approximates fair value because of the relatively short maturity of such instruments. The carrying amount of the Company’s short-term and long-term borrowings, which are considered Level 2 liabilities, approximates fair value based on current rates and terms available to the Company for similar debt.

The Company's contingent earn-out liabilities in connection with its acquisitions are measured at fair value on a recurring basis using significant unobservable inputs classified within Level 3. The Company may use various valuation techniques depending on the terms and conditions of the contingent consideration including a Monte-Carlo simulation. This simulation uses probability distribution for each significant input to produce hundreds or thousands of possible outcomes and the results are analyzed to determine probabilities of different outcomes occurring. Refer to Note 10 for a reconciliation of the Company’s contingent consideration.

Foreign Currency Translation— Certain international operations use the respective local currencies as their functional currency, while other international operations use the U.S. Dollar as their functional currency. The Company considers the U.S. Dollar as its reporting currency. Translation adjustments for subsidiaries where the functional currency is its local currency are included in other comprehensive gain (loss). Foreign currency transaction gains (losses) resulting from exchange rate fluctuation on transactions denominated in a currency other than the functional currency are reported in earnings. Assets and liabilities of the foreign operations denominated in local currencies are translated at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the weighted average rate of exchange during the period. Translations of intercompany loans of a long-term investment nature are included as a component of translation adjustment in other comprehensive gain (loss).

54


Income Taxes—The Company utilizes the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. In determining the need for valuation allowances, the Company considers projected future taxable income and the availability of tax planning strategies. If in the future the Company determines that it would not be able to realize its recorded deferred tax assets, an increase in the valuation allowance would be recorded, decreasing earnings in the period in which such determination is made.

The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon the Company’s evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, the Company has recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been


recognized in the consolidated financial statements. At December 31, 2017 and 2016, the Company recorded unrecognized tax benefits of $2,118 and $1,893, respectively.

Per Share Information—FASB ASC 260 requires dual presentation of basicBasic earnings per share (“EPS”) and diluted EPS on the face of all consolidated statements of operations. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution to EPS that could occur if securities or other contracts, which, for the Company, consists of restricted stock grants and options to purchase shares of the Company’s common stock, are exercised as calculated using the treasury stock method.

The components of basic and diluted earnings per share were as follows:

 

2017

 

 

2016

 

 

2015

 

 

2022

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income attributable to American Vanguard

 

$

20,274

 

 

$

12,788

 

 

$

6,591

 

Net income

 

$

27,404

 

 

$

18,587

 

 

$

15,242

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding—basic

 

 

29,100

 

 

 

28,859

 

 

 

28,673

 

 

 

29,234

 

 

 

29,811

 

 

 

29,450

 

Dilutive effect of stock options and grants

 

 

603

 

 

 

535

 

 

 

564

 

 

 

638

 

 

 

599

 

 

 

543

 

 

 

29,703

 

 

 

29,394

 

 

 

29,237

 

Weighted average shares outstanding—diluted

 

 

29,872

 

 

 

30,410

 

 

 

29,993

 

For the years ended December 31, 2017, 2016,2022, 2021, and 2015 2020, no options or grants were excluded from the computation.

AccountingUse of Estimates—The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities revenues,(including those related to litigation), and expensesrevenues, at the date that the consolidated financial statements are prepared. Significant estimates relate to the allowance for doubtful accounts, inventory reserves, impairment of long-lived assets, investments and goodwill, assets acquired, and liabilities assumed in connections with business combinations and asset acquisitions, accrued program costs, stock-based compensation and stock based compensation.income taxes. Actual results could materially differ from those estimates.

Total comprehensive income—In addition to net income, total comprehensive income includes changes in equity that are excluded from the consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the consolidated balance sheets. For the years ended December 31, 2017, 2016,2022, 2021, and 20152020, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock-Based Compensation—The Company accounts for stock-based awards to employees and directors pursuant to ASC 718. When applying the provisions of ASC 718, the Company also applies the provisions of Staff Accounting Bulletin (“SAB”) No. 107 and SAB No. 110.

ASC 718 requires companies to estimateestimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statementsconsolidated statements of Operations.operations.

55


Stock-based compensation expense recognized during the period is based on the fair value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized is reduced for estimated forfeitures pursuant to ASC 718.forfeitures. Estimated forfeitures recognized in the Company’s Consolidated Statementsconsolidated statements of Operationsoperations reduced compensation expense by $177, $118,$370, $320, and $144$222 for the years ended December 31, 2017, 2016,2022, 2021, and 2015,2020, respectively. The Company estimates that 15.1%18% of allboth restricted stock grants 15.1% of the performance basedand performance-based restricted shares and 4.5% of all stock option grants that are currently subject to vesting will be forfeited. These estimates are reviewed quarterly and revised as necessary.


The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the years ended December 31, 2017, 2016 and 2015. This projected expense will change if any stock options and restricted stock are granted or cancelled prior to the respective reporting periods, or if there are any changes required to be made for estimated forfeitures.

 

 

Stock-Based

Compensation

 

 

Unamortized

Stock-Based

Compensation

 

 

Remaining

Weighted

Average

Period (years)

 

December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

Incentive Stock Options

 

$

345

 

 

$

 

 

 

 

Performance Based Options

 

 

416

 

 

 

 

 

 

 

Restricted Stock

 

 

2,705

 

 

 

3,788

 

 

 

1.0

 

Performance Based Restricted Stock

 

 

1,248

 

 

 

1,642

 

 

 

1.8

 

Total

 

$

4,714

 

 

$

5,430

 

 

 

 

 

December 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

Incentive Stock Options

 

$

354

 

 

$

397

 

 

 

1.0

 

Performance Based Options

 

 

188

 

 

 

178

 

 

 

1.0

 

Restricted Stock

 

 

1,630

 

 

 

2,153

 

 

 

1.6

 

Performance Based Restricted Stock

 

 

995

 

 

 

796

 

 

 

1.7

 

Total

 

$

3,167

 

 

$

3,524

 

 

 

 

 

December 31, 2015

 

 

 

 

 

 

 

 

 

 

 

 

Incentive Stock Options

 

$

431

 

 

$

887

 

 

 

2.0

 

Performance Based Options

 

 

149

 

 

 

331

 

 

 

2.0

 

Restricted Stock

 

 

2,972

 

 

 

2,153

 

 

 

1.3

 

Performance Based Restricted Stock

 

 

329

 

 

 

583

 

 

 

1.5

 

Total

 

$

3,881

 

 

$

3,954

 

 

 

 

 

The Company uses the Black-Scholes option-pricing model (“Black-Scholes model”) to value option grants using the following weighted average assumptions (i.e. risk freerisk-free interest rate, dividend yield, volatility and average lives). There were no option shares stock options granted during 2017, 20162022, 2021 or 2015. 2020.

The expected volatility and expected life assumptions are highly complex and use subjective variables. The variables take into consideration, among other things, actual and projected employee stock option exercise behavior. The Company estimates the expected term or vesting period using the “safe harbor” provisions of SABStaff Accounting Bulletin (“SAB”) 107 and SAB 110. The Company used historical volatility as a proxy for estimating expected volatility.

The Company values restricted stock grants using the Company’s traded stock price at closing on the date of grant. The weighted average grant-date fair values of restricted stock grants during 2017, 2016,2022, 2021, and 20152020 were $16.24, $15.22,$23.53, $20.00, and $12.68,$14.39, respectively.

Recently Issued Accounting Guidance—Guidance:

Accounting Standards Adopted

In February 2018,November 2021, the Financial Accounting Standards Board (“FASB”(the “FASB”) issued Accounting Standards Update (“ASU”) 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220).  On December 22, 2017,ASU No. 2021-10, “Disclosures by Business Entities about Government Assistance.” This ASU codifies new requirements to disclose information about the U.S federalnature of certain government signed into lawassistance received, the Tax Cuts and Jobs Act, (the “Tax Reform Act”).  The current generally accepted accounting principles (“GAAP”) requires deferred tax liabilities and assetspolicy used to be adjustedaccount for the effect of a change in tax laws or rates withtransactions, the effect included in income from continuing operationslocation in the reporting period that includes the enactment date.  That guidance is applicable even in situations where the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in income from continuing operations).  The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Reform Act, eliminating the stranded tax effects.  The update does not affect the requirement on the effect of a change in tax laws or rates be included in income from continuing operations.  The update is effective for fiscal years beginning after December 15, 2018.  The Company will evaluate the impact of this update for its adoption.  

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other (Topic 350).  The FASB eliminated the Step 2 from the goodwill impairment test.  In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination.  Under this update, an entity should perform its goodwill impairment test by comparing the fair value of a


reporting unit with its carrying amount.  An entity should recognize an impairment charge for the amount the carrying amount exceeds the reporting unit’s fair value.  This update is effective for fiscal years beginning after December 15, 2019 with early adoption permitted after January 1, 2017.  The Company will evaluate the impact of this update and expects to adopt ASU 2017-04 in its financial statements for fiscal year 2018.

In January 2017, the FASB issued ASU 2017-01, Business Combination (Topic 805).  where such transactions were recorded, and significant terms and conditions associated with such transactions. The FASB issued this update to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisition (or disposals) of assets or businesses.  The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation.  The Company adopted this update and has evaluated its current year acquisitions under this standard.  

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230).  The new standard requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows.  The new standard is effective for fiscal years beginning after December 15, 2017.  Based on the composition of the Company’s cash and cash equivalent, adoption of the new standard is not expected to have a material impact on our consolidated cash flows statements and will adopt the standard for the year beginning January 1, 2018.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230).  The new standard addresses eight specific classification issues within the current practice regarding the manner in which certain cash receipts and cash payments are presented.  The new standard is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The Company has reviewed the eight specific issues addressed and does not believe that the adoption of ASU 2016-15 will have a material impact on its statement of cash flows and will adopt the revised standard for the year beginning January 1, 2018.

In October 2016, FASB issued ASU 2016-16, Income Taxes (Topic 740).  Current US GAAP prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party.  Under the new standard, an entity is to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs.  The new standard does not include new disclosure requirements; however, existing disclosure requirements might be applicable when accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory.  The new standard is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual periods.2021. Effective January 1, 2022, the Company adopted ASU No. 2021-10 on a prospective basis. The adoption of this standard was not material to the Company’s consolidated financial statements.

Accounting Standards Not Yet Adopted

In March 2020, the FASB issued ASU 2020-04 Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,as amended and supplemented by subsequent ASUs (collectively, “ASU 2020-04” and “ASU 2022-06”), which provides practical expedients for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. This guidance is applicable for borrowing instruments, which use LIBOR as a reference rate, and is available through December 31, 2024. The Company has considered its activities with regard to such intra-entity transfers,evaluated this ASU and does not expect theits adoption of ASU 2016-16 to have a material impact on ourits consolidated financial statements and will adopt the standard for the year beginning January 1, 2018.statements.

In February 2016, FASB issued ASU 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available.  We will evaluate our operating lease arrangements to determine the impact of this amendment on the consolidated financial statements. The evaluation will include an extensive review of our leases, which are primarily related to our manufacturing sites, regional sales offices, lease vehicles, and office equipment. The ultimate impact will depend on the Company’s lease portfolio at the time the new standard is adopted.  The Company expects to adopt ASU 2016-02 for the year beginning on January 1, 2019.56


In May 2014, FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. In March 2016, FASB issued an amendment to the standard, ASU 2016-08, to clarify the implementation guidance on principal versus agent considerations. Under the amendment, an entity is required to determine whether the nature of its promise is to provide the specified good or service itself (that is, the entity is a principal) or to arrange for that good or service to be provided by the other party (that is, the entity is an agent). In April 2016, FASB issued another amendment to the standard, ASU 2016-10, to clarify identifying performance obligations and the licensing implementation guidance, which retaining the related principles for those areas. The standard and the amendments are effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the


cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures).  These amendments will be effective upon adoption of Topic 606.  This standard also requires enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue and cash flows.

The Company will adopt the new revenue standard as of January 1, 2018 using the modified retrospective method.  The Company has substantially completed its analysis of the effect of the adoption of Topic 606 on its revenue streams, which included a detailed contract review to evaluate whether the adoption will result in a change in the timing or amount of revenue recognition.  As a result of the analysis performed thus far, the Company determined that for certain products that are deemed to have no alternative use accompanied by an enforceable right to payment for performance completed to date, recognition will change from point in time, to over time.  These sales were previously recognized upon delivery, and will now be recognized over time utilizing an output method.  In addition, the Company earns royalties on certain licenses granted for the use of its intellectual property, which was previously recognized over time.  For certain licenses that are considered functional intellectual property, the Company will change to a point in time recognition. The Company currently estimates that gross revenues of approximately $3,000, that would have otherwise been reflected in the consolidated statement of operations in future years, will be recorded in equity as part of a cumulative effect adjustment, and will increase retained earnings by approximately $2,370, net of taxes, when we adopt Topic 606 as of January 1, 2018.  The new standard also requires enhanced disclosures related to the disaggregation of revenue, information about contract balances, and other disclosures about contracts with customers, including revenue recognition policies to identify performance obligations and significant judgments in measurement and recognition. The estimated impact of adopting Topic 606 is based on the Company’s best estimates at the time of the preparation of this Annual Report Form 10-K. The actual impact is subject to change and completion of the analysis prior to the first quarter 2018 Form 10-Q filing.

(1)(2) Property, Plant and Equipment

Property, plant and equipment at December 31, 20172022 and 20162021 consist of the following:

 

2017

 

 

2016

 

 

Estimated

useful lives

 

2022

 

 

2021

 

 

Estimated
useful lives

Land

 

$

2,458

 

 

$

2,458

 

 

 

 

$

2,757

 

 

$

2,756

 

 

 

Buildings and improvements

 

 

16,678

 

 

 

15,515

 

 

10 to 30 years

 

 

20,794

 

 

 

19,844

 

 

10 to 30 years

Machinery and equipment

 

 

107,722

 

 

 

102,146

 

 

3 to 15 years

 

 

142,980

 

 

 

132,159

 

 

3 to 15 years

Office furniture, fixtures and equipment

 

 

4,925

 

 

 

5,016

 

 

3 to 10 years

 

 

13,231

 

 

 

10,094

 

 

3 to 10 years

Automotive equipment

 

 

735

 

 

 

387

 

 

3 to 6 years

 

 

1,584

 

 

 

1,832

 

 

3 to 6 years

Construction in progress

 

 

1,917

 

 

 

8,047

 

 

 

 

 

5,897

 

 

 

8,199

 

 

 

Total gross value

 

 

134,435

 

 

 

133,569

 

 

 

 

 

187,243

 

 

 

174,884

 

 

 

Less accumulated depreciation

 

 

(85,114

)

 

 

(83,274

)

 

 

 

 

(116,331

)

 

 

(108,773

)

 

 

Total net value

 

$

49,321

 

 

$

50,295

 

 

 

 

$

70,912

 

 

$

66,111

 

 

 

 

 

 

 

 

 

 

 

Domestic

 

 

66,268

 

 

 

61,533

 

 

 

International

 

 

4,644

 

 

 

4,578

 

 

 

Total net value

 

$

70,912

 

 

$

66,111

 

 

 

For the years ended December 31, 2017, 2016,2022, 2021, and 2015,2020, the Company’s aggregate depreciation expense related to property, plant and equipment was $8,154, $8,307,$7,974, $8,530, and $8,953,$7,466, respectively. For the years ended December 31, 2017, 2016,2022, 2021, and 2015,2020, the Company eliminated from assets and accumulated depreciation $6,317, $16,652$416, $658 and $549$1,400 of fully depreciated assets, respectively.

(2)(3) Long-Term Debt

Long-term debt of the Company at December 31, 20172022 and 20162021 is summarized as follows:

 

2017

 

 

2016

 

Revolving line of credit(a)

 

$

78,425

 

 

$

41,400

 

 

2022

 

 

2021

 

Revolving line of credit

 

$

52,300

 

 

$

53,300

 

Less debt issuance costs

 

 

(939

)

 

 

(449

)

 

 

(823

)

 

 

(1,060

)

 

$

77,486

 

 

$

40,951

 

 

$

51,477

 

 

$

52,240

 

Principal payments on long-term debt at December 31, 20172022 of $78,425$52,300 are due in 2022.August 2026.

The Company’s main bank is Bank of the West, a wholly owned subsidiary of BMO Financial Group. Bank of the West has been the Company’s bank for more than 30 years and is the syndication manager for the Company’s loans.

The Company and certain of its affiliates are parties to a revolving line of credit agreement entitled the “Third Amended and Restated Loan and Security Agreement” dated as of August 5, 2021 (the “Credit Agreement”), which is a senior secured lending facility among AMVAC, the Company’s principal operating subsidiary, as Borrower Agent (including the Company and AMVAC BV), as Borrowers, on the one hand, and a group of commercial lenders led by Bank of the West as administrative agent, documentation agent, syndication agent, collateral agent, sole lead arranger and book runner, on the other hand. The Credit Agreement consists of a line of credit of up to $275,000, an accordion feature of up to $150,000, a letter of credit and swingline sub-facility (each having limits of $25,000) and has a maturity date of August 5, 2026. The Credit Agreement amends and restates the previous credit facility, which had a maturity date of June 30, 2022. With respect to key financial covenants, the Credit Agreement contains two: namely, borrowers are required to maintain a Total Leverage (“TL”) Ratio of no more than 3.5-to-1, during the first three years, stepping down to 3.25-to-1 as of September 30, 2024, and a Fixed Charge Coverage Ratio of at least 1.25-to-1. In addition, to the extent that it completes acquisitions totaling $15 million or more in any 90-day period, AMVAC may step-up the TL Ratio by 0.5-to-1, not to exceed 4.00-to-1, for the next three full consecutive quarters. Acquisitions below $50 million no longer require Agent consent. Distributions to the Company’s stockholders are limited to net income for the four fiscal quarter period ending on the fiscal quarter immediately prior to the fiscal quarter in which the current distribution was declared.

a)

As of June 30, 2017, AMVAC, the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer.  The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a


maturity date of June 30, 2022.  The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1.   The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period.  Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

57


The Company’s borrowing capacity varies with its financial performance, measured in terms of Consolidated EBITDA as defined in the Credit Agreement, for the trailing twelve-month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Margin” which is based upon the Total Leverage (“TL”) Ratio (“LIBOR Revolver Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Margin (“Adjusted Base Rate Revolver Loan”). Interest payments for LIBOR Revolver Loans are payable on the last day of each interest period (either one-, three- or six- months, as selected by the borrower) and the maturity date, while interest payments for Adjusted Base Rate Revolver Loans are payable on the last business day of each month and the maturity date. The interest rate on December 31, 2022, was 5.67%.

At December 31, 2017,2022, according to the terms of the Credit Agreement, as amended, and based on our performance against the most restrictive covenantscovenant listed above, the Company had the capacityavailability to increase its borrowings by up to $139,241.$200,372. This compares to an available borrowing capacityavailability of $104,853$178,705 as of December 31, 2016.2021. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve monthtwelve-month period, which has improved, (2) the inclusion of proforma EBITDA related to acquisitions completed during 2017the preceding twelve months and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

The Company and the Lenders entered into an amendment to the Credit Agreement (“Amendment”), effective March 9, 2023, whereby LIBOR was replaced by SOFR with a credit spread adjustment of 10.0 bps for all SOFR periods. The revolving loans now bear interest at a variable rate based at borrower’s election with proper notice, on either (i) SOFR plus 0.1% per annum and the “Applicable Margin” or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month SOFR Rate plus 1.10%, plus, in the case of (x), (y) or (z) the Applicable Margin (“Adjusted Base Rate Revolver Loan”). In addition, the Amendment waived the minimum fixed charge coverage ratio (“FCCR”) requirement for the year ended December 31, 2022, and adjusted the terms of the FCCR for the periods ending March 31, 2023 and June 30, 2023. The Company was in compliance with all other debt covenants as of December 31, 2022.

Substantially all of the Company’s assets are pledged as collateral under the Credit Agreement.  The Company was in compliance with all its debt covenantsAgreement, as of December 31, 2017.

The Company has various loans in place that together constitute the loan balances shown in the consolidated balance sheets at December 31, 2017 and December 31, 2016.  The average amount outstanding on the senior secured revolving line of credit during the years ended December 31, 2017 and 2016 was $51,103 and $59,897, respectively. The weighted average interest rate on the revolving credit line during the years ended December 31, 2017, 2016, and 2015 was 3.0%,  2.3%, and 2.1% respectively.amended.


(3)(4) Income Taxes

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Reform Act”) was signed into law.  The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rate, implementing a territorial tax system and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries.  The Tax Reform Act reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. The SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. A company may select between one of three scenarios to determine a reasonable estimate arising from the Tax Reform Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate as the law is still being analyzed. The Company was able to provide a reasonable estimate for the revaluation of deferred taxes and the effects of the repatriation undistributed foreign subsidiary earnings and profits. As a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its net deferred tax liabilities at December 31, 2017, resulting in a $4,683 benefit included in the provision for income taxes for the year ended December 31, 2017. The Tax Reform Act also provided for a one-time deemed mandatory repatriation of Post-1986 E&P through the year ended December 31, 2017.  As a result, the Company recognized a provisional $1,250 charge in the provision for income taxes for the year ended December 31, 2017 related to the deemed mandatory repatriation. The Company continues to evaluate the various provisions of Tax Reform Act, including, the global intangible low-taxed income (“GILTI”) and the foreign derived intangible income (“FDII”) provisions. The ultimate impact of the Tax Reform Act may differ from these amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and any related actions the Company may take. The measurement period begins in the reporting period that includes the enactment date and ends when an entity has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC Topic 740.

The provisions for income taxes are:

 

 

2022

 

 

2021

 

 

2020

 

Current:

 

 

 

 

 

 

 

 

 

Federal

 

$

7,439

 

 

$

6,684

 

 

$

(1,197

)

State

 

 

2,173

 

 

 

2,149

 

 

 

(3

)

Foreign

 

 

3,943

 

 

 

1,106

 

 

 

2,831

 

Deferred:

 

 

 

 

 

 

 

 

 

Federal

 

 

(2,763

)

 

 

(2,369

)

 

 

2,177

 

State

 

 

(1,243

)

 

 

(1,039

)

 

 

403

 

Foreign

 

 

(988

)

 

 

1,635

 

 

 

(1,131

)

Total

 

$

8,561

 

 

$

8,166

 

 

$

3,080

 

58


 

 

2017

 

 

2016

 

 

2015

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

2,124

 

 

$

5,136

 

 

$

573

 

State

 

 

1,347

 

 

 

(122

)

 

 

417

 

Foreign

 

 

570

 

 

 

655

 

 

 

991

 

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

160

 

 

 

(1,345

)

 

 

(319

)

State

 

 

242

 

 

 

1,216

 

 

 

347

 

 

 

$

4,443

 

 

$

5,540

 

 

$

2,009

 

Total income tax expense differed from the amounts computed by applying the U.S. Federal income tax rate of 35.0%21.0% to income before income tax expense, as a result of the following:

 

 

2022

 

 

2021

 

 

2020

 

Computed tax expense at statutory federal rates

 

$

7,553

 

 

$

5,619

 

 

$

3,874

 

Increase (decrease) in taxes resulting from:

 

 

 

 

 

 

 

 

 

State taxes, net of federal income tax benefit

 

 

1,493

 

 

 

1,485

 

 

 

559

 

Unrecognized tax benefits

 

 

(1,441

)

 

 

(1,783

)

 

 

(2,092

)

Bargain purchase gain on business acquisition

 

 

 

 

 

(35

)

 

 

(978

)

Income tax credits

 

 

(1,342

)

 

 

(1,206

)

 

 

(812

)

Foreign tax rate differential

 

 

785

 

 

 

262

 

 

 

2,145

 

Stock based compensation

 

 

55

 

 

 

208

 

 

 

377

 

Global intangible low-taxed income

 

 

 

 

 

162

 

 

 

 

Change in valuation allowance

 

 

379

 

 

 

3,304

 

 

 

 

Return to provision

 

 

(693

)

 

 

(651

)

 

 

71

 

Nondeductible / (deductible) expenses

 

 

989

 

 

 

(103

)

 

 

(111

)

Gross receipts taxes

 

 

602

 

 

 

567

 

 

 

 

Other

 

 

181

 

 

 

337

 

 

 

48

 

Total

 

$

8,561

 

 

$

8,166

 

 

$

3,080

 

 

 

2017

 

 

2016

 

 

2015

 

Computed tax expense at statutory federal rates

 

$

8,651

 

 

$

6,415

 

 

$

3,010

 

Increase (decrease) in taxes resulting from:

 

 

 

 

 

 

 

 

 

 

 

 

State taxes, net of federal income tax benefit

 

 

988

 

 

 

820

 

 

 

639

 

Domestic production deduction

 

 

(150

)

 

 

(1,272

)

 

 

(179

)

Impact of the enactment of the Tax Cuts and Jobs Act (net)

 

 

(3,433

)

 

 

 

 

 

 

Income tax credits

 

 

(431

)

 

 

(335

)

 

 

(662

)

Foreign tax rate differential

 

 

(1,503

)

 

 

(1,587

)

 

 

(1,590

)

Subpart F income

 

 

3

 

 

 

14

 

 

 

9

 

Loss on equity investment

 

 

62

 

 

 

123

 

 

 

223

 

Stock based compensation

 

 

262

 

 

 

208

 

 

 

244

 

Tax interest

 

 

(22

)

 

 

920

 

 

 

 

Other

 

 

16

 

 

 

234

 

 

 

315

 

 

 

$

4,443

 

 

$

5,540

 

 

$

2,009

 


Income before provision for income taxes and losses on equity investmentinvestments are:

 

 

2022

 

 

2021

 

 

2020

 

Domestic

 

$

28,739

 

 

$

21,212

 

 

$

11,858

 

International

 

 

7,226

 

 

 

5,929

 

 

 

6,589

 

Total

 

$

35,965

 

 

$

27,141

 

 

$

18,447

 

59


 

 

2017

 

 

2016

 

 

2015

 

Domestic

 

$

18,931

 

 

$

12,513

 

 

$

1,589

 

Foreign

 

 

5,922

 

 

 

6,404

 

 

 

7,373

 

 

 

$

24,853

 

 

$

18,917

 

 

$

8,962

 

Temporary differences between the consolidated financial statementstatements’ carrying amounts and tax bases of assets and liabilities that give rise to significant portions of the net deferred tax liability at December 31, 20172022 and 20162021 relate to the following:

 

 

2022

 

 

2021

 

Deferred tax assets

 

 

 

 

 

 

Inventories

 

$

2,401

 

 

$

1,777

 

Program accrual

 

 

8,277

 

 

 

9,098

 

Vacation pay accrual

 

 

772

 

 

 

792

 

Accrued bonuses

 

 

1,707

 

 

 

1,250

 

Bad debt expense

 

 

1,450

 

 

 

1,361

 

Stock compensation

 

 

1,414

 

 

 

1,532

 

Domestic NOL carryforward

 

 

609

 

 

 

675

 

Foreign NOL carryforward

 

 

2,554

 

 

 

1,718

 

Tax credits

 

 

842

 

 

 

807

 

Lease liability

 

 

6,209

 

 

 

6,718

 

Accrued expenses

 

 

570

 

 

 

723

 

Unrealized foreign exchange loss

 

 

3,220

 

 

 

3,847

 

Section 174 capitalized costs

 

 

4,600

 

 

 

 

Other

 

 

 

 

 

744

 

Deferred tax assets

 

$

34,625

 

 

$

31,042

 

Less valuation allowance

 

 

(3,853

)

 

 

(4,262

)

Deferred tax assets, net

 

$

30,772

 

 

$

26,780

 

Deferred tax liabilities

 

 

 

 

 

 

Plant and equipment, principally due to differences in depreciation and capitalized interest

 

$

36,158

 

 

$

37,113

 

Lease assets

 

 

6,079

 

 

 

6,600

 

Prepaid expenses

 

 

1,685

 

 

 

1,666

 

Deferred revenue

 

 

777

 

 

 

1,014

 

Other

 

 

529

 

 

 

123

 

Deferred tax liabilities

 

$

45,228

 

 

$

46,516

 

 

 

 

 

 

 

 

Total net deferred tax liabilities

 

$

14,456

 

 

$

19,736

 

As of December 31, 2022, the Company maintained a full valuation allowance against its net deferred income tax assets related to the Company’s operations in Brazil, Spain, and Ukraine totaling $3,853. The valuation allowance decreased by $409 for the year ended December 31, 2022, of which $788 relates to unrealized foreign exchange losses and foreign currency translation included in other comprehensive income for 2022, partially offset by $379 included in the provision for income taxes for 2022. As of December 31, 2021, the Company recorded a full valuation allowance against the net deferred income tax assets related to the Company’s operations in Brazil totaling $4,262, of which $3,304 is included in the provision for income taxes for 2021 and $958 related to unrealized foreign exchange losses included in other comprehensive income for 2021.

Gross foreign NOLs related to the Company's foreign operations were $8,342 and $5,491 for the years ended December 31, 2022 and 2021, respectively. Substantially all of the Company’s foreign NOLs can be carried forward indefinitely.

Gross domestic federal and state NOLs available across all jurisdictions in which we operate were $3,622 and $3,733 as of December 31, 2022 and 2021, respectively. The Company’s federal and state NOLs expire over varying intervals in the future and are subject to annual limitation in accordance with IRC Section 382.

60


 

 

2017

 

 

2016

 

Deferred tax asset

 

 

 

 

 

 

 

 

Inventories

 

$

3,213

 

 

$

5,359

 

State income taxes

 

 

330

 

 

 

213

 

Program accrual

 

 

7,381

 

 

 

12,318

 

Vacation pay accrual

 

 

600

 

 

 

818

 

Accrued bonuses

 

 

1,073

 

 

 

2,072

 

Bad debt expense

 

 

12

 

 

 

6

 

Stock compensation

 

 

822

 

 

 

1,614

 

NOL carryforward

 

 

54

 

 

 

351

 

Tax credit

 

 

778

 

 

 

14

 

Other

 

 

381

 

 

 

2,707

 

Deferred tax asset

 

$

14,644

 

 

$

25,472

 

Deferred tax liability

 

 

 

 

 

 

 

 

Plant and equipment, principally due to differences in

   depreciation and capitalized interest

 

$

29,986

 

 

$

30,636

 

Prepaid expenses

 

 

942

 

 

 

1,542

 

Deferred tax liability

 

 

30,928

 

 

 

32,178

 

Total net deferred tax liability

 

$

16,284

 

 

$

6,706

 

The following is a roll-forward of the Company’s total gross unrecognized tax liabilities,benefits, not including interest and penalties, for the years ended December 31, 20172022 and 2016:2021 included in other liabilities, excluding current installments on the Company’s consolidated balance sheets:

 

2017

 

 

2016

 

 

2022

 

 

2021

 

Balance at beginning of year

 

$

1,893

 

 

$

2,007

 

 

$

2,426

 

 

$

3,222

 

Additions for tax positions related to the current year

 

 

77

 

 

 

65

 

 

 

225

 

 

 

223

 

Additions for tax positions related to the prior year

 

 

 

 

 

86

 

Additions for tax positions related to new acquired businesses

 

 

1,766

 

 

 

 

Reduction for tax positions related to the prior year

 

 

(1,618

)

 

 

(265

)

Additions for tax positions related to the prior years

 

 

5

 

 

 

56

 

Reduction for tax positions related to the prior years

 

 

(745

)

 

 

(971

)

Effect of exchange rate changes

 

 

95

 

 

 

(104

)

Balance at end of year

 

$

2,118

 

 

$

1,893

 

 

$

2,006

 

 

$

2,426

 

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the Company’s consolidated financial statements. For the years endedAs of December 31, 2017, 2016,2022, 2021, and 20152020 the Company had recognized approximately $2,257, $408,$2,161, $2,909, and $335$4,195, respectively in interest and penalties related to unrecognized tax benefits accrued.on its consolidated balance sheets.

It is expected that the amount of unrecognized tax benefits will change and $1,680 of unrecognized tax benefits is expected to be released within the next 12 months; however we do not expect the changetwelve months due to have a significant impact on our consolidated financial statements. At this time, an estimateexpiration of the rangestatute of the reasonable possible outcomes cannot be made.limitations.

The Company believes it is more likely than not that the deferred tax assets detailed in the table above, exclusive of those in Brazil, Spain and Ukraine with the previously mentioned full valuation allowances, will be realized in the normal course of business. It is the intent of the Company that undistributed earnings of foreign subsidiaries are permanently reinvested and, accordingly, no deferred liability for federal and state income taxes has been recorded.reinvested. The amount of undistributed earnings was $35,084$17,012 as of December 31, 2017.2022. Upon distribution of earnings in the form of dividends or otherwise, the Company may still be subject to state income taxes and withholding taxes payable to the various foreign countries. Determination of the unrecognized deferred tax liability is not practical due to the complexities of a hypothetical calculation.


The Company has effectively settled its examination withis subject to U.S. federal income tax as well as to income tax in multiple state jurisdictions. Federal income tax returns of the Company are subject to Internal Revenue Service (“IRS”) examination for the 2019 through 2021 tax years ended December 31, 2012 through 2014.  The Company’s 2015 and 2016 federalyears. State income tax returns are still subject to IRS examination.examination for the 2018 through 2021 tax years. The Company has other state and foreign income tax returns that are subject to examination.

(4)Beginning in 2022, The Tax Cuts and Jobs Act of 2017 ("TCJA"), requires taxpayers to capitalize and amortize research and development expenditures pursuant to Internal Revenue Code, or IRC, Section 174, which resulted in increases in the Company’s deferred tax asset balance and cash tax payments in the amount of $4,600 and $6,180 for the year ended December 31, 2022, respectively.

(5) Litigation and Environmental

A. The Company records a liability on its consolidated financial statements for loss contingencies when a loss is known or considered probable, and the amount can be reasonably estimated. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded. The Company recognizes legal expense in connection with loss contingencies as incurred.

DBCP Cases

Over the course of the past 30 years, AMVAC and/or the Company have been named or otherwise implicated in a number of lawsuits concerning injuries allegedly arising from either contamination of water supplies or personal exposure to 1, 2-dibromo-3-chloropropane (“DBCP®”DBCP”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC (which ceased manufacture in about 1980) and was approved by the USEPA to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. That suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product.

At present, there are three domestic lawsuits and approximately 85 61


Nicaraguan lawsuits filed by former banana workers in which AMVAC has been named as a party. Only two of the Nicaraguan actions have actually been served on AMVAC.  With respectDBCP Matters

According to Nicaraguan matters, there was no change in status during 2017. As described more fully below, activity in domestic cases during 2017 is as follows.  The one case remaining in Delaware includes 57 plaintiffs who have appealed a lower court finding that the matter was barred by the statute of limitations; this matter has been stayed pending a ruling by the Delaware Supreme Court on the question of when or if the statute of limitations has run out.  In Hawaii, in the matter of Patrickson, et. al. v. Dole Food Company, following the appellate court’s remand to the trial court for adjudication in 2016, there has been no activity; while in Adams, there has been no activity since 2014, when the court granted dismissal of co-defendant Dole on the basis of a worker’s compensation bar and gave plaintiffs leave to amend their complaint in light of that ruling.

Nicaraguan Matters

A review of court filings in Chinandega, Nicaragua, has found 85 suits alleging personal injury allegedly due to exposure to DBCP and involving approximately 3,592 plaintiffs have been filed against AMVAC and other parties. Of these cases, only two – Flavio Apolinar Castillo et al. v. AMVAC et al., No. 535/04 and Luis Cristobal Martinez Suazo et al. v. AMVAC et al., No. 679/04 (which were filed in 2004 and involve 15 banana workers) – have been served on AMVAC. All but one of the suits in Nicaragua have been filed pursuant to Special Law 364, an October 2000 Nicaraguan statute that contains substantive and procedural provisions that Nicaragua’s Attorney General previously expressed as unconstitutional. Each of the Nicaraguan plaintiffs’ claims $1 million in compensatory damages and $5 million in punitive damages. In all of these cases, AMVAC is a joint defendant with Dow Chemical Company and Dole Food Company, Inc. AMVAC contends that the Nicaragua courts do not have jurisdiction over it and that Public Law 364 violates international due process of law. AMVAC hasThe company objected to personal jurisdiction and due process in those matters and demanded under Law 364 that the claims be litigated in the United States. In 2007, theThe local court denied these objections andin 2007, AMVAC appealed the denial. It is not presently known asdenial, and, to how many ofthe company’s knowledge, there has been no activity in these plaintiffs actually claim exposure to DBCP at the time AMVAC’s product was allegedly used nor is there any verification of the claimed injuries. Further, tomatters since that time. To date, plaintiffs have not had success in enforcing Nicaraguan judgments against domestic companies before U.S. courts. With respect to these Nicaraguan matters,Nevertheless, AMVAC intends to defend any claimthese claims vigorously. Furthermore, the Company does not believe that a loss is either probable or reasonably estimable and has not recorded a loss contingency for these matters.

Delaware DBCP Cases

Abad Castillo and Marquinez.  On or about May 31, 2012, twoChavez & Marquinez. Two cases (captioned Abad Castillo and Marquinez) were filed withindependently in 2012 by the same law firm (HendlerLaw, P.C.) in Louisiana and Delaware involving claims on behalf of banana workers for personal injury allegedly arising from exposure to DBCP. Through several years of law and motion practice, the number of plaintiffs in the actions has been reduced from about 2,750 to 290 banana workers from Costa Rica, Ecuador, Guatemala and Panama, and both cases have been consolidated before the United States District Court for the District of Delaware (USDC DE No. 1:12-CV-00695-LPS) involving claims for physical injury arising12-CV-00695 & 00697). Discovery commenced in 2018 and has consisted largely of seeking medical examinations from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala, and Panama.  Defendant Dole broughtremaining plaintiffs. In December 2022, defendants in this matter filed a motion to dismiss 22for summary judgment against the Ecuadorian plaintiffs from Abad Castillo onunder the groundtheory that they were parties in cases that had been filed by HendlerLaw, P.C. in Louisiana.  On September 19, 2013, the appeals court granted, in part, and denied, in part, the motion to dismiss, holding that 14 of the 22 plaintiffs should be dismissed.  On May 27, 2014, the district court granted Dole’s motion to dismiss the matter without prejudice on the ground that the applicable statute of limitations had expiredfor negligence barred the action. Briefing on the motion is set to conclude in 1995.  Then, on August 5, 2014, the parties stipulated to summary judgment in favor of defendants (on the same ground as the earlier motion) and the court entered judgmentMarch 2023. At this stage in the matter.  Plaintiffs were given an opportunity to appeal; however, only 57 of the 2,700 actually entered an appeal.  Thus, at this stage, only 57 plaintiffs remain in the action.  On or about June 18, 2017, the Third Circuit Court submitted a certified question of law to the Delaware Supreme Court on the question of when the tolling period ended. The Delaware Supreme Court heard oral argument on January 17, 2018 and is expected


to issue a ruling within 90 days. During the pendency of this question, these matters will be effectively stayed.  At any rate,proceedings, the Company believesdoes not believe that a loss is neither probable noror reasonably estimable in these matters and has not recorded a loss contingency.  contingency for these matters.

Hawaiian DBCP Matters

Patrickson, et. al. v. Dole Food Company, et al.al. In October 1997, AMVAC was served with two complaints in which it was named as a defendant, filed in the Circuit Court, First Circuit, State of Hawai’i and in the Circuit Court of the Second Circuit, State of Hawai’i (two identical suits) entitled Patrickson, et. al. v. Dole Food Company, et. al (“Patrickson Case”) alleging damages sustained from injuries (including sterility) to banana workers caused by plaintiffs’ exposure to DBCP while applying the product in their native countries. Other named defendants include: Dole Food Company, Shell Oil Company and Dow Chemical Company. After several years of law and motion activity the court granted judgmentparties stipulated that, because it was not named as a defendant in favoran earlier class action matter that gave rise to the tolling of the defendants based upon the statute of limitations, on July 28, 2010. On August 24, 2010, the plaintiffs filed a notice of appeal. On October 21, 2015, the Hawai’i Supreme Court granted the appeal and overturned the lower court decision, rulingAMVAC should be dismissed from this matter. Thus, we expect that the State of Hawai’i now recognizes cross-jurisdictional tolling, that plaintiffs filed their complaint withinCompany will be dismissed with prejudice from this action as soon as the applicable statute of limitations and that the matter is to be remanded to the lower court for further adjudication. No discoveryissues an order. There has taken placebeen no activity in this matter and, at this stage in the proceedings,since November 2018. Further, the Company does not believe that a loss is either probable or reasonably estimable and accordingly, has not recorded a loss contingency for this matter.

Adams v. Dole Food Company et al. On approximately November 23, 2007, AMVAC was served with a suit filed by two former Hawaiian pineapple workers (and their spouses), alleging that they had testicular cancer due to DBCP exposure; the action is captioned Adams v. Dole Food Company et al in the First Circuit for the State of Hawaii. Plaintiff alleges that they were exposed to DBCP between 1971 and 1975. AMVAC denies that any of its product could have been used at the times and locations alleged by these plaintiffs. Following the dismissal of Dole Food Company on the basis of the exclusive remedy of worker’s compensation benefits, plaintiffs appealed the dismissal. The court of appeals subsequently remanded the matter to the lower court in February 2014, effectively permitting plaintiffs to amend their complaint to circumvent the workers’ compensation bar. There has been no activity in the case since that time.time, and there is no estimated date of determination. The Company does not believe that a loss is either probable or reasonably estimable and has not recorded a loss contingency for this matter.

B.

62


Other Matters

EPA FIFRA/RCRA Matter.Department of Justice ("DOJ") and Environmental Protection Agency Investigation. On November 10, 2016, the CompanyAMVAC was served with a grand jury subpoena out offrom the U.S. District CourtUnited States Attorney’s Office for the Southern District of Alabama, seeking documents regarding the importation, transportation, and management of a specific pesticide. The Company retained defense counsel to assist in whichresponding to the U.S. Departmentsubpoena and otherwise in defending the Company’s interests. AMVAC is cooperating in the investigation. After interviewing multiple witnesses (including three employees before a grand jury in February 2022) and making multiple document requests, the DOJ identified the Company and a manager-level employee as targets of Justicethe government’s investigation. DOJ’s investigation focused on potential violations of two environmental statutes, the Federal Insecticide, Fungicide, and Rodenticide Act (“DoJ”FIFRA”) sought productionand the Resource Conservation and Recovery Act (“RCRA”), as well as obstruction of documentsan agency proceeding and false statement statutes. In March 2022, the individual target entered into a plea agreement relating to provision of false information in a government proceeding. In July 2022, the DOJ sent correspondence to the Company’s counsel to the effect that it was focusing on potential RCRA violations relating to the Company’s reimportation of depleted ThimetAustralian containers from Canada and Australia.  The Company has retainedin 2015. Our defense counsel spoke with DOJ on the subject in early October, and has substantially completed the productionDOJ, which expressed an interest in resolving the matter, stated that it would get back to the Company with its position.

The governmental agencies involved in this investigation have a range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of FIFRA, RCRA and other federal statutes including, but not limited to, injunctive relief, fines, penalties and modifications to business practices and compliance programs, including the appointment of a monitor. If violations are established, the amount of any fines or monetary penalties which could be assessed and the scope of possible non-monetary relief would depend on, among other factors, findings regarding the amount, timing, nature and scope of the violations, and the level of cooperation provided to the governmental authorities during the course of which it incurred approximately $2,350 in legal costs and fees responding to this subpoena.  During the third quarter of 2017,investigation. As a result, the Company receivedcannot yet anticipate the timing or predict the ultimate resolution of this investigation, financial or otherwise or whether it could have a request from DoJ to interview several individuals who may be knowledgeable of the matter.  Those interviews are likely to take place during the second quarter of 2018. At this stage, DoJ has not made clear its intentions with regard to either its theory of the case or potential criminal or civil enforcement.  Thus, it is too early to tell whether a loss is probable or reasonably estimable. Accordingly, the Company hasmaterial adverse effect on our business prospects, operations, financial condition and cash flow; accordingly, we have not recorded a loss contingency onfor this matter.

WalkerPitre etc. v. AMVAC.Agrocentre Ladauniere et al. On February 11, 2022, a strawberry grower named Les Enterprises Pitre, Inc. filed a complaint in the Superior Court, District of Labelle, Province of Quebec, Canada, entitled Pitre, etc. v. Agrocentre Ladauniere, Inc. etal, including Amvac Chemical Corporation, seeking damages in the amount of approximately $5 million arising from stunted growth of, and reduced yield from, its strawberry crop allegedly from the application of Amvac’s soil fumigant, Vapam, in spring of 2021. Examinations of plaintiff were held in mid-August 2022, during which plaintiff in effect confirmed that he had planted his seedlings before expiration of the full time interval following product application (as per the product label), that he had failed to follow the practice of planting a few test seedlings before planting an entire farm, and that he had placed his blind trust in his application adviser on all manner of timing and rate. The company believes that the claims have no merit and intends to defend the matter. At this stage in the proceedings, there is not sufficient information to form a judgment as to either the probability or about April 10, 2017,amount of loss; thus, the Companycompany has not set aside a reserve in connection with this matter.

Catalano v. AMVAC Chemical Corp. On June 6, 2022, AMVAC was served with a summons and complaint that had been filed with the United State District Court for the Eastern District of Tennessee under the caption Larry L. Walkera matter entitled Andrew Catalano and Ruth Catalano v. AMVAC (as No. 4:17-cv-00017).  Plaintiffin the Superior Court of the State of California, County of Orange (30-2022-01263987-CU-PL-CXC) in which plaintiff, who worked as a professional applicator of pesticides, including Orthene (for which AMVAC is registrant) seeks contract damages correction of inventorship, accounting and injunctive relieffor an injury (specifically, cardiomyopathy) allegedly arising from his exposure to this product. AMVAC is unaware of any link between cardiovascular disease and Orthene (which has been commercially available for the Company’s alleged misuse of his confidential information to support a patent application (which was subsequently issued) for a post-harvest corn herbicide that the Company has not commercialized.  Plaintiff claims further that he, not the Company, should be identified as the inventor in such application.  The Companyover 30 years) and believes that these claims are withoutthis case has no merit and intends to defend it vigorously. On May 24, 2017, theThe Company filed an answer in early July, including multiple affirmative defenses. Further, the parties are exchanging document requests, and plaintiffs have been unable to supply any data establishing a motion to dismisscausal link between use of this action, or inproduct and the alternative, for transfer of venue, on the groundheart condition that (i) the complaint fails to state claim upon which relief can be granted, (ii) the contracts cited by plaintiff in his complaint include a forum selection clause requiring that disputes are to be adjudicated in the U.S. District Court for the Central District of California, and (iii) the doctrine of forum non conveniens applies.  The District Court in Tennessee has yet to rule on the motion.alleges. At this stage, there is not sufficient information to form a judgment as to either the probability or amount of any loss; thus, the company has not set aside a reserve in connection with this matter.

63


Notice of Intention to Suspend DCPA. On April 28, 2022, the proceedings, it is too earlyUSEPA published a notice of intent to determine whether a loss is probable or reasonably estimable; accordingly,suspend (“NOITS”) DCPA, the active ingredient of an herbicide marketed by the Company has not recorded a loss contingency.  

Harold Reed v. AMVAC et al.  During January 2017,under the name Dacthal. The agency cited as the basis for the suspension that the Company was served with two Statementsdid not take appropriate steps to provide data studies requested in support of Claim thatthe registration review. In fact, over the course of several years, the Company cooperated in performing the vast majority of the nearly 90 studies requested by USEPA and had been filed on March 29, 2016 withworking in good faith to meet the Courtagency’s schedule. After an appeals court (the Environmental Appeals Board) clarified the proper standard for use at the hearing (namely, whether registrant took appropriate steps to respond to the data call-in), a hearing was held in January 2023 before the ALJ, by which time USEPA had narrowed the scope of Queen’s Benchits claim to nine outstanding studies, all of Alberta, Canada (as case numbers 160600211 and 160600237) in which plaintiffs Harold Reed (an applicator) and 819596 Alberta Ltd. dba Jem Holdings (an application equipment rental company) allege physical injury and damage to equipment, respectively, arising from a fire that occurred during an application of the Company’s potato sprout inhibitor, SmartBlock, at a potato storage facility in Coaldale, Alberta on April 2, 2014.  Plaintiffs allege, among other things, that AMVAC was negligent and failed to warn them of the risks of such application.  Reed seeks damages of $250 for pain and suffering, while Jem Holdings seeks $60 in lost equipment; both plaintiffs also seek unspecified damages as well.  Also during


January 2017,have been started by the Company received notice that four related actions relatingand none of which are necessary for USEPA to commence its risk assessment. The parties are now preparing post-hearing briefs, after the same incident were filed withsubmission of which the same court: (i) Van Giessen Growers, Inc. v Harold Reed et al (No. 160303906)(in which grower seeks $400 for loss of potatoes); (ii) James Houweling et al. v. Harold Reed et al. (No. 160104421)(in which equipment owner seeks damages for lost equipment); (iii) Chin Coulee Farms, etc. v. Harold Reed et al. (No. 150600545)(in which owner of potatoes and truck seeks $530 for loss thereof); and (iv) Houweling Farms v. Harold Reed et al. (No. 15060881)(in which owner of several Quonset huts seeks damages for lost improvements, equipment and business income equal to $4,300).  The Company was subsequently named as cross-defendant in those actions by Reed.ALJ will render a decision. During the third quartercourse of 2017, counsel forthese proceedings, AMVAC has been free to make, sell and distribute both the Company filed a Statement of Defence (the Canadian equivalent of an answer), alleging that Reed was negligent in his application of thetechnical grade material and end-use product and thatmay continue to do so unless and until there is an adverse ruling at both the other cross-defendants were negligent for using highly flammable insulationtrial and failing to maintain sparking electrical fixtures in the storage units affected by the fire.  The Company believes that the claims against it in these matters are without merit and intends to defend them vigorously.  At this stage in the proceedings, however, it is too early to determine whether a loss is probable or reasonably estimable; accordingly, the Company has not recorded a loss contingency.

Galvan v. AMVAC In an action entitled Graciela Galvan v. AMVAC filed on April 7, 2014 with the Superior Court for the State of California for the County of Orange (No. 00716103CXC), plaintiff, a former employee, alleges violations of wages and hours requirements under the California Labor Code. The Company completed the deposition of putative class representative and participated in mediation on the matter. In February 2016, the court granted plaintiff’s motion for class certification with respect to only one of the seven original claims (namely, that allegedly discretionary bonus payments made to class members during the subject period should have been taken into account when calculating overtime)appellate level (if any). The Company believes that such bonus payments were discretionary and, as such, were properly excluded from overtime calculations.  Nevertheless, in the interest of saving defense costs, the Company engaged in settlement discussions with plaintiff’s counsel over the course of several months.  During the third quarter of 2016, the Company recorded a loss contingency to cover the estimated amount of settlement.  During December 2016, the parties reached agreement on terms of settlement,is neither probable nor estimable and, on February 9, 2018, the court gave its final approval to the terms of the class settlement. The settlement wasconsequently, has not material to the Company’s consolidated financial statements and the Company is to provide the courtset aside a reserve in connection with a report of administration of the settlement proceeds to the class in August 2018, after which the Company expects that the matter will be dismissed with prejudice.this matter.

(5)(6) Employee Deferred Compensation Plan and Employee Stock Purchase Plan

The Company maintains a deferred compensation plan (“the Plan”) for all eligible employees. The Plan calls for each eligible employee, at the employee’s election, to participate in an income deferral arrangement under Internal Revenue Code Section 401(k). The plan allows eligible employees to make contributions, which cannot exceed 100%100% of compensation, or the annual dollar limit set by the Internal Revenue Code. The Company matches the first 5%5% of employee contributions. The Company’s contributions to the Plan amounted to $1,550, $1,258$2,409, $2,273 and $1,261$2,172 in 2017, 20162022, 2021 and 2015,2020, respectively.

During 2001, the Company’s Board of Directors adopted the AVD Employee Stock Purchase Plan (the “ESPP Plan”). The Plan allows eligible employees to purchase shares of common stock through payroll deductions at a discounted price. An original aggregate number of approximately 1,000,000 shares of the Company’s Common Stock, par value $0.10$0.10 per share (subject to adjustment for any stock dividend, stock split or other relevant changes in the Company’s capitalization) were allowed to be sold pursuant to the Plan, which is intended to qualify under Section 423 of the Internal Revenue Code. The Plan allows for purchases in a series of offering periods, each six months in duration, with new offering periods (other than the initial offering period) commencing on January 1 and July 1 of each year.year. The initial offering period commenced on July 1, 2001. Pursuant to action taken by the Company’s Board of Directors inon December 10, 2010, the expiration of the Plan was extended to December 31, 2013. The Plan was amended and restated on June 30, 2011, following stockholders’ ratification of the extended expiration date. In December 2013, the BoardThe Plan was amended as of Directors resolvedJune 6, 2018, following stockholders’ ratification of a ten-year extension to extend the expiration date of the Plan five years, that is, until (which now stands at December 31, 2018.2028). Under the Plan, as amended as of June 30, 2011, 6, 2018, 995,000 shares of the Company’s common stock were authorized. As of December 31, 2017, 2016,2022, 2021, and 2015, 726,809, 760,825,2020, 491,940, 543,180, and 803,555593,962 shares, respectively, remained available under the plan. The expense recognized under the Plan was immaterial during the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.

Shares of common stock purchased through the Plan in 2017, 20162022, 2021 and 20152020 were 34,016, 42,73051,240, 50,782 and 50,452,49,668, respectively.

(6)(7) Major Customers and International Sales

In 2017,2022, there were three companiesdomestic customers that accounted for 13%18%, 10%13% and 10%8%, respectively, of the Company’s consolidated sales. In 2016,2021, there were three companiesdomestic customers that accounted for 15%17%, 11%14%, and 8%8% of the Company’s consolidated sales. In 2015,2020, there were three companiesdomestic customers that accounted for 14%17%, 11%12% and 10%10% of the Company’s consolidated sales.

The Company primarily sells its products to large distributors, buying cooperatives, other co-operative groups and, groupsin certain territories, end users, and extends credit based on an evaluation of the customer’s financial condition. The Company had three significant domestic customers who each accounted for approximately


10%15%, 9%3% and 8%3% of the Company’s receivables as of December 31, 2017.2022. The Company had three significant domestic customers who each accounted for approximately 15%11%, 11%4% and 8%4% of the Company’s receivables as of December 31, 2016.2021. The Company has long-standing relationships with its customers and the Company considers its overall credit risk for accounts receivables to be low.minimal.

64


The Company’s receivables, excluding allowances for doubtful accounts, by geography as of December 31, 2022 and 2021 are summarized as follows:

 

 

2022

 

 

2021

 

Domestic receivables

 

$

65,825

 

 

$

66,987

 

International receivables

 

 

105,619

 

 

 

95,872

 

Total receivables

 

$

171,444

 

 

$

162,859

 

International sales for 2017, 20162022, 2021 and 20152020 were as follows:

 

 

2022

 

 

2021

 

 

2020

 

South and Central America

 

$

124,525

 

 

$

108,975

 

 

$

102,281

 

Mexico

 

 

45,995

 

 

 

40,724

 

 

 

33,517

 

Asia

 

 

26,588

 

 

 

26,234

 

 

 

19,290

 

Australia

 

 

19,674

 

 

 

21,061

 

 

 

9,902

 

Canada

 

 

14,860

 

 

 

10,377

 

 

 

10,572

 

Africa

 

 

8,840

 

 

 

3,468

 

 

 

6,072

 

Middle East

 

 

1,836

 

 

 

2,357

 

 

 

3,054

 

Europe

 

 

1,964

 

 

 

2,243

 

 

 

2,292

 

Total international net sales

 

$

244,282

 

 

$

215,439

 

 

$

186,980

 

 

 

2017

 

 

2016

 

 

2015

 

Asia

 

$

28,880

 

 

$

17,138

 

 

$

13,847

 

South and Central America

 

 

25,748

 

 

 

16,234

 

 

 

15,970

 

Mexico

 

 

16,030

 

 

 

16,690

 

 

 

17,096

 

Europe

 

 

10,700

 

 

 

14,519

 

 

 

12,350

 

Africa

 

 

7,893

 

 

 

7,111

 

 

 

8,622

 

Australia

 

 

4,334

 

 

 

3,735

 

 

 

4,158

 

Canada

 

 

4,083

 

 

 

3,690

 

 

 

1,585

 

Middle East

 

 

1,237

 

 

 

4,041

 

 

 

3,230

 

Other

 

 

 

 

 

101

 

 

 

437

 

 

 

$

98,905

 

 

$

83,259

 

 

$

77,295

 

(8) Product and Business Acquisitions

(7) RoyaltiesDuring the year ended December 31, 2022, the Company did not complete any acquisitions.

The Company has two licensing agreements that require minimum annual royalty payments. Those agreements related tocompleted one product acquisition during the year ended December 31, 2021. The acquisition of certain products.was completed on July 1, 2021, for $10,000 in cash consideration. The Company also has two other licensing arrangementsacquisition was accounted for as an asset acquisition and the $10,000 in which royalty are paid based on percentage of annual sales. Certain royalty agreements contain confidentiality covenants. Royalty expenses were $81, $83 and $111 for 2017, 2016 and 2015, respectively.

(8) Business and Product Acquisitions

During 2017, the Company completed acquisitions with a total combined purchase consideration net of cash acquired of $92,888 including cash paid at closing in the amount of $81,896 and deferred consideration of $10,992. At closing the Company recorded $12,814 related to tax matters associated with the acquisitions. The purchase price has beenwas allocated as follows: product registrations and product rights $55,127,$8,225, trade names and trademarks $9,500, customer relationships$1,650, and customer lists $3,700, goodwill $22,184, working capital $14,679 and property, plant and equipment $512.  Includedprepaid assets $125.

During the year ended December 31, 2020, the Company completed two acquisitions:

On October 2, 2020, the Company completed the acquisition of all outstanding stock of the Agrinos Group Companies ("Agrinos"), except for Agrinos AS. Agrinos has operating entities in the detail above,U.S., Mexico, India, Brazil, China, Ukraine, and Spain. Agrinos is a fully integrated biological input supplier with proprietary technology, manufacturing capacity, and global distribution capabilities. At closing, the amountsCompany paid cash consideration of $3,125, which was net of cash acquired of $1,813. The acquisition was accounted for as a business combination and resulted in a bargain gain. The purchase consideration was allocated as follows:

Trade receivables

 

$

2,277

 

Inventory and other current assets

 

 

5,371

 

Property, plant, and equipment

 

 

5,141

 

Product registrations and product rights

 

 

50

 

Liabilities assumed

 

 

(4,886

)

Bargain

 

 

(4,828

)

Total

 

$

3,125

 

Agrinos was acquired out of bankruptcy. This provided the Company with an opportunity to acquire Agrinos at an advantageous purchase price which was below the fair value of Agrinos’ net assets acquired, resulting in the bargain purchase gain. The liabilities assumed include liabilities of $407 related to the products acquired from The Andersons, Adama and Syngenta are completed as at December 31, 2017. During 2017,income tax matters.

65


On October 8, 2020, the Company incurred approximately $937completed the acquisition of professional fees in connection with these transactions, which were expensed. all outstanding stock of AgNova Technologies Pty Ltd (“AgNova”). AgNova is an Australian entity that sources, develops, and distributes specialty crop protection and production solutions for agricultural and horticultural producers, and for selected non-crop users. The purchase price consideration was as follows:

Cash

 

$

16,997

 

Less cash acquired

 

 

(157

)

Contingent consideration

 

 

1,052

 

Total consideration

 

$

17,892

 

The fair value of the contingent consideration was estimated using a Monte Carlo Simulation. The acquisition was accounted for as a business combination and the purchase consideration was allocated as follows:

Trade receivables

 

$

1,508

 

Inventory and other current assets

 

 

5,698

 

Property, plant, and equipment

 

 

73

 

Product registrations and product rights

 

 

8,327

 

Trade names and trademarks

 

 

351

 

Distribution agreements

 

 

3,584

 

Customer relationships and customer lists

 

 

386

 

Goodwill

 

 

4,618

 

Liabilities assumed

 

 

(6,653

)

Total consideration

 

$

17,892

 

The liabilities assumed include liabilities of $3,857 related to income tax matters.

Cash paid at closing for the asset acquisitions and business combinations was funded through our revolving line of credit.

The assessment of purchase price allocation related to OHP and AgriCenter are preliminary as at December 31, 2017 and will be completed during 2018. The purchase price allocations are based on information available to management at the time the consolidated financial statements were prepared and reflect the best estimate of fair value. The fair value allocations are subject to change, which may be significant. The goodwill consists largely of acquired workforce, tax related matters and expected synergies arising from the acquisition. With regard to goodwill, $5,088 is expected to be deductible for income tax purposes, the balance is not expected to be deductible for income tax purposes.  

The Company considers that the acquisitions completed during 2017 are immaterial to the accompanying consolidated financial statements individually and material in aggregate.

On January 13, 2017, the Company acquired from The Andersons, Inc. certain assets relating to proprietary formulations containing PCNB, chlorothalonil and propiconazole which are marketed under the name FFII and FFIII. The acquired assets included end use registrations. The acquired products were included in the Company’s consolidated statement of operations from the date of acquisition.    

On June 6, 2017, Amvac completed an acquisition of certain assets relating to the abamectin, chlorothalonil and paraquat product lines from a group of companies, including Adama Agricultural Solutions, Ltd.  The consideration for the acquired assets was paid in cash and has been allocated to intangible assets and inventory.  The acquired products were included in the Company’s consolidated statement of operations from the date of acquisition.

On August 22, 2017, AMVAC BV, completed the acquisition of certain selective herbicides and contact fungicides including chlorothanonil, ametryn, and isopyrazam, sold in the Mexican agricultural market. The assets were purchased from Syngenta AG.  


The consideration for the acquired assets was paid in cash and has been allocated to intangible assets and inventory.  The acquired products were included in the Company’s consolidated statement of operations from the date of acquisition.

On October 2, 2017, the Company acquired substantially all of the assets of OHP, resulting in OHP becoming a wholly owned subsidiary of the Company whereby the Company gained greater access to distribution in the U.S. ornamental market. OHP is a leading provider of technology based pesticide solutions for greenhouse and nursery production applications throughout the United States and Puerto Rico. The consideration for the acquired assets was paid in cash and has been preliminarily allocated to working capital, property, plant and equipment, intangible assets, inventory and goodwill. The acquired business was included in the Company’s consolidated statement of operations from the date of acquisition.

On October 27, 2017, AMVAC BV acquired 100% ownership in AgriCenter whereby the Company gained significant access and distribution to the Central American market. AgriCenter is centralized in Costa Rica with offices in six other Central American and Caribbean countries. AgriCenter is an agrochemical distribution company providing a range of services including bringing generic produced product as well as its own branded products to growers. The consideration for the acquired assets was paid in cash and has been preliminarily allocated to working capital, property, plant and equipment, intangible assets, inventory and goodwill. The acquired business was included in the Company’s consolidated statement of operations from the date of acquisition.

The following unaudited pro forma information presents a summary of the Company’s combined results of operations for the years ended December 31, 2017 and 2016, as if the business acquisitions had occurred on January 1, 2016. The following pro forma Pro-forma financial information is not necessarily indicativeincluded herein as the pro-forma impact of the results of operations as they would have been had the transaction been effected on the assumed date, noracquisitions is it necessarily an indication of trends in future results for a number of reasons. Consequently, actual results will differ from the unaudited pro forma financial information.not material.

66


 

 

Year ended December 31

 

 

 

2017

 

 

2016

 

Pro forma net sales

 

$

458,793

 

 

$

433,756

 

Pro forma net income

 

 

24,540

 

 

 

17,614

 

Pro forma earnings per common share – basic

 

 

0.84

 

 

 

0.61

 

Pro forma earnings per common share – assuming dilution

 

 

0.83

 

 

 

0.60

 


(9) Intangible Assets and Goodwill

The following schedule represents intangible assets recognized in connection with product acquisitions (See description of Business, Basis of Consolidation and Significant Accounting PoliciesNote 1 for the Company’s accounting policy regarding intangible assets):

 

 

Amount

 

Intangible assets at December 31, 2014

 

$

100,211

 

Additions during fiscal 2015

 

 

36,667

 

Write offs during fiscal 2015

 

 

(33

)

Impact of movement in exchange rates

 

 

(197

)

Amortization expense

 

 

(7,488

)

Intangible assets at December 31, 2015

 

 

129,160

 

Additions during fiscal 2016

 

 

224

 

Write offs during fiscal 2016

 

 

(78

)

Impact of movement in exchange rates

 

 

69

 

Amortization expense

 

 

(7,942

)

Intangible assets at December 31, 2016

 

 

121,433

 

Additions during fiscal 2017

 

 

68,327

 

Impact of movement in exchange rates

 

 

(6

)

Amortization expense

 

 

(8,804

)

Intangible assets at December 31, 2017

 

$

180,950

 

 

 

 

 

 

Goodwill at December 31, 2016

 

 

 

Additions during fiscal 2017

 

 

22,184

 

Goodwill at December 31, 2017

 

$

22,184

 

 

 

 

 

 

Intangible assets and goodwill at December 31, 2017

 

$

203,134

 

 

 

Amount

 

Intangible assets at December 31, 2019

 

$

198,261

 

Additions during fiscal 2020

 

 

12,675

 

Write offs

 

 

(41

)

Impact of movement in exchange rates

 

 

(637

)

Amortization expense

 

 

(12,744

)

Intangible assets at December 31, 2020

 

 

197,514

 

Additions during fiscal 2021

 

 

10,524

 

Measurement period adjustment

 

 

4,226

 

Impact of movement in exchange rates

 

 

(710

)

Amortization expense

 

 

(13,713

)

Intangible assets at December 31, 2021

 

 

197,841

 

Additions during fiscal 2022

 

 

1,292

 

Impact of movement in exchange rates

 

 

(516

)

Amortization expense

 

 

(13,953

)

Intangible assets at December 31, 2022

 

$

184,664

 

 

 

 

 

Goodwill at December 31, 2019

 

$

46,673

 

Additions during fiscal 2020

 

 

8,830

 

Other

 

 

617

 

Impact of movement in exchange rates

 

 

(4,012

)

Goodwill at December 31, 2020

 

 

52,108

 

Measurement period adjustment

 

 

(4,054

)

Impact of movement in exchange rates

 

 

(1,794

)

Goodwill at December 31, 2021

 

 

46,260

 

Impact of movement in exchange rates

 

 

750

 

Goodwill at December 31, 2022

 

$

47,010

 

 

 

 

 

Intangible assets and goodwill at December 31, 2022

 

$

231,674

 

The following schedule represents the gross carrying amount and accumulated amortization of intangible assets and goodwill. Product rights and trademarks are amortized over their expected useful lives of 25 years. Customer lists are amortized over their expected useful lives of nine to ten years.years. The amortization expense is included in operating expenses on the consolidated statements of operations.

 

 

2022

 

 

2021

 

 

 

Gross

 

 

Accumulated
Amortization

 

 

Net Book
Value

 

 

Gross

 

 

Accumulated
Amortization

 

 

Net Book
Value

 

Product Rights

 

$

272,339

 

 

$

121,209

 

 

$

151,130

 

 

$

271,632

 

 

$

110,090

 

 

$

161,542

 

Trademarks

 

 

40,459

 

 

 

11,615

 

 

 

28,844

 

 

 

40,578

 

 

 

9,870

 

 

 

30,708

 

Customer Lists

 

 

11,204

 

 

 

6,514

 

 

 

4,690

 

 

 

10,966

 

 

 

5,375

 

 

 

5,591

 

Total intangibles assets

 

 

324,002

 

 

 

139,338

 

 

 

184,664

 

 

 

323,176

 

 

 

125,335

 

 

 

197,841

 

Goodwill

 

 

47,010

 

 

 

 

 

 

47,010

 

 

 

46,260

 

 

 

 

 

 

46,260

 

Total intangibles and goodwill

 

$

371,012

 

 

$

139,338

 

 

$

231,674

 

 

$

369,436

 

 

$

125,335

 

 

$

244,101

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Domestic

 

 

194,395

 

 

 

92,352

 

 

 

102,043

 

 

 

193,091

 

 

 

84,477

 

 

 

108,614

 

International

 

 

176,617

 

 

 

46,986

 

 

 

129,631

 

 

 

176,345

 

 

 

40,858

 

 

 

135,487

 

Total intangibles and goodwill

 

$

371,012

 

 

$

139,338

 

 

$

231,674

 

 

$

369,436

 

 

$

125,335

 

 

$

244,101

 

67


 

 

2017

 

 

2016

 

$000’s

 

Gross

 

 

Accumulated

Amortization

 

 

Net Book

Value

 

 

Gross

 

 

Accumulated

Amortization

 

 

Net Book

Value

 

Product Rights

 

$

223,022

 

 

$

70,701

 

 

$

152,321

 

 

$

167,906

 

 

$

63,141

 

 

$

104,765

 

Trademarks

 

 

27,541

 

 

 

4,233

 

 

 

23,308

 

 

 

18,041

 

 

 

3,411

 

 

 

14,630

 

Customer Lists

 

 

6,791

 

 

 

1,470

 

 

 

5,321

 

 

 

3,091

 

 

 

1,053

 

 

 

2,038

 

Goodwill

 

 

22,184

 

 

 

 

 

 

22,184

 

 

 

 

 

 

 

 

 

 

Total intangibles and goodwill

 

$

279,538

 

 

$

76,404

 

 

$

203,134

 

 

$

189,038

 

 

$

67,605

 

 

$

121,433

 

The following schedule represents future amortization charges related to intangible assets:

Year ending December 31,

 

Amount

 

2023

 

$

13,299

 

2024

 

 

13,001

 

2025

 

 

12,819

 

2026

 

 

12,713

 

2027

 

 

12,476

 

Thereafter

 

 

120,356

 

 

 

$

184,664

 

(10) Contingent Consideration

Year ending December 31,

 

 

 

 

2018

 

$

10,732

 

2019

 

 

10,732

 

2020

 

 

10,784

 

2021

 

 

10,675

 

2022

 

 

10,554

 

Thereafter

 

 

127,473

 

 

 

$

180,950

 


The following schedule represents the Company’s obligationscontingent consideration liability under acquisitions agreements:

 

 

Amount

 

Obligations under acquisition agreements at December 31, 2019

 

$

1,244

 

Additional obligations acquired

 

 

2,044

 

Fair value adjustment

 

 

250

 

Accretion of discounted liabilities

 

 

16

 

Payments on existing obligations

 

 

(1,227

)

Foreign exchange effect

 

 

141

 

Obligations under acquisition agreements at December 31, 2020

 

 

2,468

 

Purchase price adjustment

 

 

(955

)

Fair value adjustment

 

 

758

 

Accretion of discounted liabilities

 

 

(8

)

Payments on existing obligations

 

 

(1,301

)

Foreign exchange effect

 

 

(176

)

Obligations under acquisition agreements at December 31, 2021

 

 

786

 

Fair value adjustment

 

 

610

 

Accretion of discounted liabilities

 

 

27

 

Payments on existing obligations

 

 

(1,389

)

Foreign exchange effect

 

 

(34

)

Obligations under acquisition agreements at December 31, 2022

 

$

 

(11) Commitments

We enter into various obligations in the ordinary course of business, generally of a short-term nature. They primarily relate to purchase commitments for inventory and licensing agreements:

 

 

Amount

 

Obligations under acquisition agreements at December 31, 2014

 

$

2,492

 

Additional obligations acquired

 

 

1,367

 

Adjustment to deferred liabilities

 

 

65

 

Amortization of discounted liabilities

 

 

135

 

Payments on existing obligations

 

 

(2,524

)

Obligations under acquisition agreements at December 31, 2015

 

 

1,535

 

Additional obligations acquired

 

 

224

 

Adjustment to deferred liabilities

 

 

(22

)

Amortization of discounted liabilities

 

 

38

 

Payments on existing obligations

 

 

(960

)

Obligations under acquisition agreements at December 31, 2016

 

 

815

 

Additional obligations acquired

 

 

10,992

 

Adjustment to deferred liabilities

 

 

(223

)

Amortization of discounted liabilities

 

 

109

 

Payments on existing obligations

 

 

(26

)

Obligations under acquisition agreements at December 31, 2017

 

$

11,667

 

As of December 31, 2017, the $11,667 in remaining obligations under product acquisitions and licensing agreements is included in other liabilities.

(10) Commitments

The Company has various lease agreementsorders submitted for officesequipment for our production plants as well as long-term ground leases for its facilities at Axis, AL, Hannibal, MO and Marsing, ID. The office leases contain provisions to pass through to the Company its pro-rata share of certain of the building’s operating expenses. The long-term ground lease at Axis, AL is for twenty years (commencing May 2001) with up to five automatic renewals of three years each for a total of thirty-five years. The long-term ground lease at Hannibal, MO is for a period of 20 years (commencing December 2007) with automatic one year extensions thereafter, subject to termination with a twelve-month notice. At its Marsing facility, the Company owns 15 acres and holds a long-term ground lease on two acres for a period of 25 years (commencing in March 2008). Rent expense for the years ended December 31, 2017, 2016 and 2015 was $1,102, $946 and $947. In addition, the Company has various vehicle lease agreements for its sales force. Vehicle lease expense for the years ended December 31, 2017, 2016 and 2015 was $529, $555, and $435 respectively.service agreements.

Future minimum lease payments under the terms of the leases are as follows:

Year ending December 31,

 

 

 

 

2018

 

$

2,250

 

2019

 

 

1,938

 

2020

 

 

1,660

 

2021

 

 

1,103

 

2022

 

 

521

 

Thereafter

 

 

650

 

 

 

$

8,122

 

(11)(12) Research and Development

Research and development expenses which are included in operating expenses were $8,455, $6,998$10,829, $10,354 and $6,337$8,757 for the years ended December 31, 2017, 20162022, 2021 and 2015,2020, respectively.

68



(12)(13) Equity Plan Awards

Under the Company’s Equity Incentive Plan of 1993, as amended (“the Plan”), all employees are eligible to receive non-assignable and non-transferable restricted stock, options to purchase common stock, and other forms of equity. As of December 31, 2017,2022, the number of securities remaining available for future issuance under the Plan is 2,000,579.1,524,567.

Incentive Stock Option Plans (“ISOP”)

Under the terms ofThe below tables illustrate the Company’s ISOP, under which options to purchase common stock can be issued, all employees are eligible to receive non-assignable and non-transferable options to purchase shares. The exercise price of any option may not be less than the fair market value of the shares on the date of grant; provided, however, that the exercise price of any option granted to an eligible employee owning more than 10% of the outstanding common stock may not be less than 110% of the fair market value of the shares underlying such option on the date of grant. No options granted may be exercisable more than ten years after the date of grant.

In 2017, 2016 and 2015, no options were granted.

Option activity within each plan is as follows:

 

 

Incentive

Stock Option

Plans

 

 

Weighted

Average

Price Per

Share

 

 

Exercisable

Weighted

Average

Price

Per Share

 

Balance outstanding, December 31, 2014

 

 

724,904

 

 

$

9.22

 

 

$

7.82

 

Options exercised,

 

 

(63,950

)

 

$

7.50

 

 

 

 

 

Options forfeited,

 

 

(34,109

)

 

 

12.00

 

 

 

 

 

Balance outstanding, December 31, 2015

 

 

626,845

 

 

$

9.25

 

 

$

7.73

 

Options exercised,

 

 

(58,900

)

 

$

7.50

 

 

 

 

 

Options forfeited,

 

 

(26,040

)

 

 

11.49

 

 

 

 

 

Balance outstanding, December 31, 2016

 

 

541,905

 

 

$

9.33

 

 

$

7.97

 

Options exercised,

 

 

(55,979

)

 

$

8.37

 

 

 

 

 

Options forfeited,

 

 

(13,143

)

 

 

11.49

 

 

 

 

 

Balance outstanding, December 31, 2017

 

 

472,783

 

 

$

9.38

 

 

$

9.38

 

Information relating to stock options at December 31, 2017 summarized by exercise price is as follows:

 

 

Outstanding Weighted Average

 

 

Exercisable Weighted Average

 

Exercise Price Per Share

 

Shares

 

 

Remaining

Life

(Months)

 

 

Exercise

Price

 

 

Shares

 

 

Exercise

Price

 

Incentive Stock Option Plan:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$7.50

 

 

249,050

 

 

 

35

 

 

$

7.50

 

 

 

249,050

 

 

$

7.50

 

$11.32-$14.75

 

 

223,733

 

 

 

82

 

 

$

11.48

 

 

 

223,733

 

 

$

11.48

 

 

 

 

472,783

 

 

 

57

 

 

$

9.38

 

 

 

472,783

 

 

$

9.38

 

During 2017, 2016 and 2015, the Company recognized stock-based compensation, expense related to incentive stock options of $345, $354,unamortized stock-based compensation, and $431, respectively.


Theremaining weighted average exercise pricesperiod for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of December 31, 2017 and 2016 was as follows:

 

 

Number

of

Shares

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Life

(Months)

 

 

Intrinsic

Value

(thousands)

 

As of December 31, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Incentive Stock Option Plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding

 

 

472,783

 

 

$

9.38

 

 

 

57

 

 

$

4,853

 

Vested

 

 

472,783

 

 

$

9.38

 

 

 

57

 

 

$

4,853

 

Exercisable

 

 

472,783

 

 

$

9.38

 

 

 

57

 

 

$

4,853

 

As of December 31, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Incentive Stock Option Plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding

 

 

541,905

 

 

$

9.33

 

 

 

67

 

 

$

5,321

 

Expected to Vest

 

 

536,531

 

 

$

9.31

 

 

 

67

 

 

$

5,280

 

Exercisable

 

 

332,684

 

 

$

7.97

 

 

 

49

 

 

$

3,719

 

The total intrinsic value of options exercised during 2017, 2016 and 2015 was $545, $493, and $361, respectively. Cash received from stock options exercised during 2017, 2016, and 2015 was $468, $442, and $480, respectively.

Nonstatutory Stock Options (“NSSO”)

The Company did not grant any non-statutory stock options during the three years ended December 31, 2017.  There2022, 2021 and 2020. This projected expense will change if any stock options and restricted stock are 16,333 sharesgranted or cancelled prior to the respective reporting periods, or if there are any changes required to be made for estimated forfeitures.

 

 

Stock-Based
Compensation

 

 

Unamortized
Stock-Based
Compensation

 

 

Remaining
Weighted
Average
Period (years)

 

December 31, 2022

 

 

 

 

 

 

 

 

 

Restricted Stock

 

$

4,407

 

 

$

6,585

 

 

 

1.8

 

Unrestricted Stock

 

 

499

 

 

 

217

 

 

 

0.4

 

Performance-Based Restricted Stock

 

 

778

 

 

 

2,441

 

 

 

1.8

 

Total

 

$

5,684

 

 

$

9,243

 

 

 

 

December 31, 2021

 

 

 

 

 

 

 

 

 

Restricted Stock

 

$

5,682

 

 

$

6,804

 

 

 

1.8

 

Unrestricted Stock

 

 

421

 

 

 

187

 

 

 

0.4

 

Performance-Based Restricted Stock

 

 

777

 

 

 

2,888

 

 

 

1.8

 

Total

 

$

6,880

 

 

$

9,879

 

 

 

 

December 31, 2020

 

 

 

 

 

 

 

 

 

Restricted Stock

 

$

3,166

 

 

$

6,954

 

 

 

1.9

 

Unrestricted Stock

 

 

461

 

 

 

183

 

 

 

0.4

 

Performance-Based Restricted Stock

 

 

2,934

 

 

 

3,352

 

 

 

1.9

 

Total

 

$

6,561

 

 

$

10,489

 

 

 

 

The Company also granted stock options in past periods. All outstanding stock options are fully vested and exercisable and no expense was recorded during the years ended December 31, 2022, 2021 and 2020.

Restricted and Unrestricted Stock

A summary of options outstanding fornonvested restricted and unrestricted stock is presented below:

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

Number
of Shares

 

 

Weighted
Average
Grant
Date Fair
Value

 

 

Number
of Shares

 

 

Weighted
Average
Grant
Date Fair
Value

 

Nonvested shares at January 1st

 

 

817,290

 

 

$

17.04

 

 

 

820,624

 

 

$

16.64

 

Granted

 

 

256,417

 

 

 

23.53

 

 

 

295,619

 

 

 

20.00

 

Vested

 

 

(262,521

)

 

 

17.84

 

 

 

(244,651

)

 

 

19.23

 

Forfeited

 

 

(69,136

)

 

 

18.58

 

 

 

(54,302

)

 

 

17.11

 

Nonvested shares at December 31st

 

 

742,050

 

 

$

18.86

 

 

 

817,290

 

 

$

17.04

 

69


Performance-Based Restricted Stock

A summary of nonvested performance-based stock is presented below:

 

 

December 31, 2022

 

 

December 31, 2021

 

 

 

Number
of Shares

 

 

Weighted
Average
Grant
Date Fair
Value

 

 

Number
of Shares

 

 

Weighted
Average
Grant
Date Fair
Value

 

Nonvested shares at January 1st

 

 

379,061

 

 

$

16.43

 

 

 

391,771

 

 

$

16.26

 

Granted

 

 

83,190

 

 

 

23.63

 

 

 

102,043

 

 

 

20.03

 

Additional granted based on performance achievement

 

 

(68,484

)

 

 

16.87

 

 

 

71,180

 

 

 

20.53

 

Vested

 

 

(51,308

)

 

 

17.09

 

 

 

(175,087

)

 

 

19.78

 

Forfeited

 

 

(23,760

)

 

 

17.21

 

 

 

(10,846

)

 

 

16.89

 

Nonvested shares at December 31st

 

 

318,699

 

 

$

18.05

 

 

 

379,061

 

 

$

16.43

 

Performance Based Restricted Stock Granted in 2022During the year ended December 31, 2017.

Common Stock Grants

During 2017,2022, the Company issued a total of 290,977 shares of common stock to certain employees and non-executive board members. Of these, 26,820 shares vest immediately, 1,300 shares will vest one-half each year on the anniversaries of the employee’s employment date, 1,782 shares will vest two years from the employee’s employment date, and the balance will cliff vest after three years of service. The fair values of the grants range from $14.92 to $19.90 per share based on the publicly traded share prices at the date of grants. The total fair value of $4,726 is being recognized over the vesting period, which is representative of the related service periods. During 2017, 20,815 shares of common stock granted to employees were forfeited.

During 2016, the Company issued a total of 150,009 shares of common stock to certain employees and non-executive board members. Of these, 21,139 shares vest immediately, 2,600 shares will vest one-half each year on the anniversaries of the employee’s employment date, 3,000 shares will vest two years from the employee’s employment date, and the balance will cliff vest after three years of service. The fair values of the grants range from $15.08 to $17.35 per share based on the publicly traded share prices at the date of grants. The total fair value of $2,283 is being recognized over the vesting period, which is representative of the related service periods. During 2016, 35,615 shares of common stock granted to employees were forfeited.

A status summary of non-vested shares as of December 31, 2017 and 2016, are presented below:

 

 

December 31, 2017

 

 

December 31, 2016

 

 

 

Number

of Shares

 

 

Weighted

Average

Grant

Date Fair

Value

 

 

Number

of Shares

 

 

Weighted

Average

Grant

Date Fair

Value

 

Nonvested shares at January 1st

 

 

324,756

 

 

$

14.75

 

 

 

362,841

 

 

$

20.43

 

Granted

 

 

290,977

 

 

 

16.24

 

 

 

150,009

 

 

 

15.22

 

Vested

 

 

(203,165

)

 

 

15.14

 

 

 

(152,479

)

 

 

15.19

 

Forfeited

 

 

(20,815

)

 

 

15.29

 

 

 

(35,615

)

 

 

18.89

 

Nonvested shares at December 31st

 

 

391,753

 

 

$

15.63

 

 

 

324,756

 

 

$

14.75

 


During 2017, 2016 and 2015, the Company recognized stock-based compensation expense related to restricted shares of $2,705, $1,630, and $2,972, respectively.

Performance Based Stock Grants

During the year ended December 31, 2017, the Company issued a total of 128,594 performance based83,190 performance-based shares to employees. The shares granted during 20172022 have an average fair value of $15.43.$23.63. The fair value was determined by using the publicly traded share price as of the market close on the date of grant.grant and Monte Carlo valuation method. The Company will recognize as expense the value of the performance basedperformance-based shares over the required service period from grant date. The shares will cliff vest on February 8, 2020April 20, 2025, with a measurement period commencing January 1, 20172022, and ending December 31, 2019.  2024. Eighty percent of these performance basedperformance-based shares are based upon the financial performance of the Company, specifically, an earnings before income taxesinterest and tax (“EBIT”) goal weighted at 50%50% and a net sales goal weighted at 30% 30%. The remaining 20%20% of performance basedperformance-based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 20162021 Proxy Statement. All parts of these awards vest in three years but are subject to reduction to a minimum (or even zero) for recording less than the targeted performance and to increase to a maximum of 200%200% for achieving in excess of the targeted performance.

On January 6, 2016,Performance Based Restricted Stock Granted in 2021During the year ended December 31, 2021, the Company grantedissued a total of 52,170 performance based102,043 performance-based shares thatto employees. The shares granted during 2021 have an average fair value of $20.03. The fair value was determined by using the publicly traded share price as of the market close on the date of grant and Monte Carlo valuation method. The Company will recognize as expense the value of the performance-based shares over the required service period from grant date. The shares will cliff vest on January 6, 2019April 16, 2024, with a measurement period commencing January 1, 2016 through2021, and ending December 31, 2018, provided that the participating employees are continuously employed by the Company during the vesting period. 2023. Eighty percent of these performance basedperformance-based shares are based upon the financial performance of the Company, specifically, an earnings before income tax (“EBIT”)EBIT goal weighted at 50%50% and a net sales goal weighted at 30%30%. The remaining 20%20% of performance basedperformance-based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 20162020 Proxy Statement. All parts of these awards vest in three years but are subject to reduction to a minimum (or even zero) for meetingrecording less than the targeted performance and to increase to a maximum of 200%200% for meetingachieving in excess of the targeted performance.

70


Performance Based Restricted Stock Granted in 2020During 2015,the year ended December 31, 2020, the Company grantedissued a total of 10,696 performance based shares. Of these, 7,500160,706 performance-based shares to employees. The shares granted during 2020 have an average fair value of $14.29. The fair value was determined by using the publicly traded share price as of the market close on the date of grant and Monte Carlo valuation method. The Company will recognize as expense the value of the performance-based shares over the required service period from grant date. The shares will cliff vest on January 5, 2018May 13, 2023, with a measurement period commencing JanuaryOctober 1, 20152020, and ending DecemberMarch 31, 2017 and 3,196 shares will cliff vest on August 1, 2018 with a measurement period commencing July 1, 2015 and ending June 30, 2018, provided that the participating employees are continuously employed by the Company during the vesting period. 2023. Eighty percent of these performance basedperformance-based shares are based upon the financial performance of the Company, specifically, an earnings before income tax (“EBIT”)EBIT goal weighted at 50%50% and a net sales goal weighted at 30%30%. The remaining 20%20% of performance basedperformance-based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 20152020 Proxy Statement. All parts of these awards vest in three years but are subject to reduction to a minimum (or even zero) for meetingrecording less than the targeted performance and to increase to a maximum of 200%200% for meetingachieving in excess of the targeted performance.

As of December 31, 2017, the performance based shares related to EBIT and net sales have an average fair value of $16.10 per share. The fair value was determined by using the publicly traded share price as of the date of grant.  The performance based shares related to the Company’s stock price have an average fair value of $12.60 per share. The fair value was determined by using the Monte Carlo valuation method.  For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period.

As of December 31, 2016, the performance based shares related to EBIT and net sales have an average fair value of $15.08 per share. The fair value was determined by using the publicly traded share price as of the date of grant.  The performance based shares related to the Company’s stock price have an average fair value of $11.63 per share.  The fair value was determined by using the Monte Carlo valuation method.  For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period.  


As of December 31, 2015, performance based shares related to EBIT and net sales have an average fair value of $11.86 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $9.48 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period.

During 2017, 2016 and 2015, the Company recognized stock-based compensation expense related to performance based shares of $1,248, $995, and $329, respectively. In 2017,2022, the Company assessed the likelihood of achieving the performance measures based on peer group information currently available for the performance basedperformance-based shares granted in 2015 and 2014.2020. Based on the performance thus far, the Company has concluded that it is likely that the performance measure based on EBIT will not be met and net sales will be met at 200%150% of targeted performance and have recorded the related additional expense in 2016.2022. The performance shares based on market price however, are not expected to meetbe met at 166% of targeted performance. The effect of market conditions for performance and in that event, will be forfeited.  Any forfeiture related toshares based on market condition shares are included in the grant date fair value valuation and no forfeitures additional expenses were recognized in 2017.2022.

As of December 31, 2017,During 2022, the Company had approximately $1,642 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 1.8 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

A summary of non-vested shares as of December 31, 2017 and 2016, is presented below:

 

 

December 31, 2017

 

 

December 31, 2016

 

 

 

Number

of Shares

 

 

Weighted

Average

Grant

Date Fair

Value

 

 

Number

of Shares

 

 

Weighted

Average

Grant

Date Fair

Value

 

Nonvested shares at January 1st

 

 

119,022

 

 

$

14.18

 

 

 

104,403

 

 

$

17.05

 

Granted

 

 

128,594

 

 

 

15.43

 

 

 

52,170

 

 

 

14.39

 

Vested

 

 

(48,046

)

 

 

14.92

 

 

 

 

 

 

 

Forfeited

 

 

(13,513

)

 

 

13.08

 

 

 

(37,551

)

 

 

22.45

 

Nonvested shares at December 31st

 

 

186,057

 

 

$

14.93

 

 

 

119,022

 

 

$

14.18

 

Performance Incentive Stock Option Plan

For the three years ended December 31, 2017, the Company did not grant any employees performance incentive stock options to acquire shares of common stock.

Performance option activity is as follows:

 

 

Incentive

Stock Option

Plans

 

 

Weighted

Average

Price Per

Share

 

 

Exercisable

Weighted

Average

Price

Per Share

 

Balance outstanding, December 31, 2015

 

 

98,410

 

 

$

11.49

 

 

$

 

Options forfeited

 

 

(16,076

)

 

 

11.49

 

 

 

 

 

Balance outstanding, December 31, 2016

 

 

82,334

 

 

$

11.49

 

 

$

 

Options forfeited

 

 

(668

)

 

 

11.49

 

 

 

 

 

Balance outstanding, December 31, 2017

 

 

81,666

 

 

$

11.49

 

 

$

 


Information relating to performance stock options at December 31, 2017 is summarized by exercise price is as follows:

 

 

Outstanding Weighted Average

 

 

Exercisable Weighted Average

 

Exercise Price Per Share

 

Shares

 

 

Remaining

Life

(Months)

 

 

Exercise

Price

 

 

Shares

 

 

Exercise

Price

 

Performance Incentive Stock Option Plan:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$11.49

 

 

81,666

 

 

 

 

(1)

$

11.49

 

 

 

 

 

$

 

 

 

 

81,666

 

 

 

 

 

$

11.49

 

 

 

 

 

$

 

(1)

The Incentive Stock Option awards have been totally vested on 12/31/2017.  The remaining contractual term is 7 years for these awards.

The weighted average exercise price for performance options granted and exercisable and the weighted average remaining contractual life for performance options outstanding as of December 31, 2017 and 2016 was as follows:

 

 

Number

of

Shares

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Life

(Months)

 

 

Intrinsic

Value

(thousands)

 

As of December 31, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Performance Incentive Stock Option Plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding

 

 

81,666

 

 

$

11.49

 

 

 

 

 

$

666

 

Expected to Vest

 

 

81,666

 

 

$

11.49

 

 

 

 

 

$

666

 

Exercisable

 

 

 

 

$

 

 

 

 

 

$

 

As of December 31, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Performance Incentive Stock Option Plans:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding

 

 

82,334

 

 

$

11.49

 

 

 

12

 

 

$

631

 

Expected to Vest

 

 

75,312

 

 

$

11.49

 

 

 

12

 

 

$

577

 

Exercisable

 

 

 

 

$

 

 

 

 

 

$

 

During 2017, 2016 and 2015, the Company recognized stock-based compensation expense related to performance incentive stock options of $416, $188, and $149, respectively. In 2017, the Company assessed the likelihood of achieving the performance measures based on peer group information currently available for the performance incentive stock options awarded in 2014. The Company has concluded that the performance measure based on EBIT will beand net sales for the performance-based shares granted in 2019, when compared to the peer group, was met at 200%0% for EBIT and 123.8% for net sales of targeted performance and net sales will beall related additional expenses were recorded as of December 31, 2022. The 2019 performance shares based on market price was met at 200%28.5%; however, the market condition is reflected in the grant date fair value valuation and no additional expenses were recognized. As a result, 68,484 shares were forfeited since the Company did not achieve performance targets when compared to the peer group.

Stock Options

Under the terms of targetedthe Company’s ISOP, under which options to purchase common stock can be issued, all employees are eligible to receive non-assignable and non-transferable options to purchase shares. The exercise price of any option may not be less than the fair market value of the shares on the date of grant; provided, however, that the exercise price of any option granted to an eligible employee owning more than 10% of the outstanding common stock may not be less than 110% of the fair market value of the shares underlying such option on the date of grant. No options granted may be exercisable more than ten years after the date of grant.

In 2022, 2021 and 2020, no options were granted.

Incentive Stock Option Plans

Activity of the incentive stock option plans:

 

 

Number of
Shares

 

 

Weighted
Average
Price Per
Share

 

Balance outstanding, December 31, 2019

 

 

332,823

 

 

$

9.14

 

Options exercised

 

 

(196,736

)

 

 

7.79

 

Options forfeited

 

 

(13,000

)

 

 

7.50

 

Balance outstanding, December 31, 2020

 

 

123,087

 

 

 

11.48

 

Options exercised

 

 

(15,051

)

 

 

11.41

 

Balance outstanding, December 31, 2021

 

 

108,036

 

 

 

11.49

 

Options exercised

 

 

(39,140

)

 

 

11.49

 

Balance outstanding, December 31, 2022

 

 

68,896

 

 

$

11.49

 

71


Outstanding stock options at December 31, 2022, summarized by exercise price:

 

 

Outstanding Weighted Average

 

Exercise Price Per Share

 

Number of
Shares

 

 

Remaining
Life
(Months)

 

Exercise
Price

 

Outstanding stock options, December 31, 2022

 

 

68,896

 

 

24

 

$

11.49

 

Performance Incentive Stock Option Plan

Activity of the performance and have recorded the related additional expense in 2017.  Whileincentive stock option plan:

 

 

Number of
Shares

 

 

Weighted
Average
Price Per
Share

 

 

Balance outstanding, December 31, 2019

 

 

120,782

 

 

$

11.49

 

 

Options exercised

 

 

(6,124

)

 

 

11.49

 

 

Balance outstanding, December 31, 2021 and 2020

 

 

114,658

 

 

$

11.49

 

 

Options exercised

 

 

(32,850

)

 

 

11.49

 

 

Balance outstanding, December 31, 2022

 

 

81,808

 

 

$

11.49

 

 

All the performance incentive stock options based on marketoutstanding as of December 31, 2022, have an exercise price is likelyper share of $11.49 and a remaining life of 24 months.

The total intrinsic value of options exercised during 2022, 2021, and 2020 was $877, $119, and $1,393, respectively. Cash received from stock options exercised during 2022, 2021, and 2020 was $827, $172, and $1,533, respectively. All outstanding options are fully vested and the intrinsic value amounted to be met at 200% targeted performance, no additional expenses were recognized in 2017$1,540 as the grant date valuation of these awards reflects market conditions.December 31, 2022.

(13)(14) Accumulated Other Comprehensive Loss

The following table lists the beginning balance, annual activity and ending balance of eachforeign currency translation adjustment included as a component of accumulated other comprehensive loss:

Balance, December 31, 2019

$

(5,698

)

Foreign currency translation adjustment, net of tax effects of $2,521

(3,624

)

Balance, December 31, 2020

(9,322

)

Foreign currency translation adjustment, net of tax effects of $76

(4,462

)

Balance, December 31, 2021

(13,784

)

Foreign currency translation adjustment, net of tax effects of ($245)

1,602

Balance, December 31, 2022

$

(12,182

)

 

 

 

FX

Translation

 

Balance, December 31, 2014

 

$

(1,970

)

Other comprehensive loss before reclassifications

 

 

(1,571

)

Balance, December 31, 2015

 

 

(3,541

)

Other comprehensive loss before reclassifications

 

 

(1,310

)

Balance, December 31, 2016

 

 

(4,851

)

Other comprehensive loss before reclassifications

 

 

344

 

Balance, December 31, 2017

 

$

(4,507

)


(14)(15) Equity Method InvestmentsInvestment

The Company utilizes the equity method of accounting with respect to its investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients. For the years ended December 31, 2017, 2016 and 2015, the Company recognized losses of $177, $353, and $636, respectively on its equity method investment. In November 2015, TyraTech issued 105,333,333 shares and raised approximately £3,200 ($4,800, based on the exchange rate at the time). Due to the share issuance, the Company recognized a loss of $7 (for 2015) from the dilution of the Company’s ownership position, as required by ASC 323. As of December 31, 2017 and 2016, the Company’s ownership position in TyraTech was approximately 15.11%. As a result of the reduced equity share, the Company re-assessed its choice of equity method accounting for the investment and determined that it retains significant influence by retaining one out of five board seats and accordingly, this method of accounting continues to be appropriate. At December 31, 2017, the carrying value of the Company’s investment in TyraTech was $2,006 and the quoted market value based on TyraTech’s share price (Level 1 input) was $1,970.

At December 31, 2017, the Company performed an impairment review of its investment in TyraTech and concluded that the current condition was temporary and consequently determined that no impairment charge was appropriate. TyraTech’s shares trade on the AIM market of the London Stock Exchange under the trading symbol ‘TYR’. The Company’s equity investment is included in other assets on the consolidated balance sheets.

At a special meeting conducted on December 27, 2017, TyraTech shareholders approved the sale of its Vamouse product line to Alliance Pharmaceuticals, Ltd and the use of some of the proceeds from such sale for a tender offer for TyraTech shares.  That tender offer was concluded in January 2018.  AMVAC elected not to exercise its right to sell into such tender offer and, as a result, the Company’s ownership interest in TyraTech increased to approximately 35% at the conclusion of that transaction.  

On August 2, 2016, AMVAC BV entered into a joint venture with Huifeng.Huifeng (Hong Kong) Ltd, which is a wholly owned subsidiary of the Huifeng Group. The newresulting entity, Hong Kong JV, iswas intended to focus on activities such as market access and technology transfer between the two members. AMVAC BV is a 50%50% owner of the new entity. No material contributions were made to this joint venture in 2016.

On June 27, 2017, both AMVAC BV and Huifeng (Hong Kong) Ltd. made individual capital contributions of $950$950 to the Hong Kong JV. As of December 31, 2017,2021, 2020 and 2019, the Company’s ownership position in the Hong Kong JV was 50%50%. The Company utilizes the equity method of accounting with respect to this investment.

72


On July 7, 2017, the Hong Kong JV purchased the shares of Profeng Australia, Pty Ltd.(“Profeng”), for a total consideration of $1,900.$1,900. The purchase consists of Profeng Australia, Pty Ltd Trustee and Profeng Australia Unit Trust. Both Trust and Trustee were previously owned by Huifeng via(via its wholly owned subsidiary Huifeng (Hong Kong) Ltd.Ltd). For the yearyears ended December 31, 2017,2022, 2021, and 2020, the Company recognized incomelosses of $128$0, $388 (including a full impairment charge of $288 of the Company’s remaining book value of its Hong Kong JV investment) and $125, respectively, as a result of the Company’s ownership position in the Hong Kong JV. There were no losses recognized in the prior year.The Hong Kong JV is an inactive entity.

(16) Equity Investments

(15) Cost Method Investment

In February 2016, AMVAC BV made an equity investment of $3,283 in Biological Products for Agriculture (“Bi-PA”). Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of December 31, 2017,2022, 2021 and 2020, the Company’s ownership position in Bi-PA was 15%15%. Since this investment does not have readily determinable fair value, the Company has elected to measure the investment at cost less impairment, if any, and to record an increase or decrease for changes resulting from observable price changes in orderly transactions for the identical or a similar investment of Bi-PA. The Company utilizes the cost method of accounting with respect to this investment and will periodically reviewreviews the investment for possible impairment. The Company recorded an impairment charge in the amount of $399 during the year ended December 31, 2021. There was were no impairment or observable price changes on the investment as ofduring the years ended December 31, 2017.2022 and 2020. The investment is not material and is recorded within other assets on the consolidated balance sheets.sheets and amounted to $2,884 as of December 31, 2022 and 2021.


(16) Quarterly Data—Unaudited

 

 

March 31

 

 

June 30

 

 

September 30

 

 

December 31

 

Quarterly Data—2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

70,673

 

 

$

77,905

 

 

$

89,975

 

 

$

116,494

 

Gross profit

 

 

30,084

 

 

 

34,335

 

 

 

38,032

 

 

 

44,941

 

Net income attributable to American Vanguard

 

 

3,452

 

 

 

4,304

 

 

 

4,089

 

 

 

8,429

 

Basic net income per share

 

 

0.12

 

 

 

0.15

 

 

 

0.14

 

 

 

0.29

 

Diluted net income per share

 

 

0.12

 

 

 

0.15

 

 

 

0.14

 

 

 

0.28

 

Quarterly Data—2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

69,474

 

 

$

72,724

 

 

$

82,447

 

 

$

87,468

 

Gross profit

 

 

27,503

 

 

 

31,395

 

 

 

32,986

 

 

 

36,404

 

Net income attributable to American Vanguard

 

 

2,794

 

 

 

3,246

 

 

 

2,877

 

 

 

3,871

 

Basic net income per share

 

 

0.10

 

 

 

0.11

 

 

 

0.10

 

 

 

0.13

 

Diluted net income per share

 

 

0.10

 

 

 

0.11

 

 

 

0.10

 

 

 

0.13

 

Note: Totals may not agree with full year amounts dueOn April 1, 2020, AMVAC purchased 6.25 million shares, an ownership of approximately 8%, of common stock of Clean Seed Capital Group Ltd. (TSX Venture Exchange: “CSX”) for $1,190. The shares are publicly traded, have a readily determinable fair value, and are considered a Level 1 investment. The fair value of the stock amounted to rounding$784 and separate calculations each quarter.

(17) Subsequent Event

There is no reportable subsequent event$1,516 as of December 31, 2022 and 2021, respectively, and the Company recorded losses of $732 and $391 and a gain of $717 for the yearyears ended December 31, 2017,2022, 2021 and 2020, respectively.The investment is recorded within other assets on the consolidated balance sheets and amounted to $784 and $1,516 as of December 31, 2022 and 2021, respectively.

(17) Share Repurchase Programs

The Company periodically repurchases shares of its common stock under a board-authorized repurchase program through a combination of open market transactions and accelerated share repurchase ("ASR") arrangements.

On August 22, 2022, pursuant to a Board of Directors resolution, the filing dateCompany entered into an ASR to repurchase $20,000 of this Annual Report Formits common stock. Under the ASR agreement, the Company paid $20,000 and immediately received an initial delivery of 802,810 shares in the amount of $16,000, based on 10-Ka price of $19.93 per share, which represented 80% of the notional amount of the ASR based on the closing price of the Company’s common stock on the New York Stock Exchange ("NYSE") on August 22, 2022. On December 14, 2022, the ASR was completed, and pursuant to the settlement terms of the ASR, the Company received an additional 131,892 shares of its common stock. The average price paid for all of the shares delivered under the ASR was $21.40 per share.

On March 8, 2022, pursuant to a Board of Directors resolution, the Company announced its intention to repurchase an aggregate number of up to 1,000,000 shares of its common stock, par value $0.10 per share, in the open market over the succeeding one year, subject to limitations and restrictions under applicable securities laws. During 2022, the Company purchased 734,150 shares of its common stock for a total of $14,002 at an average price of $19.07 per share.

On August 30, 2021, pursuant to a Board of Directors resolution, the Company announced its intention to repurchase an aggregate number of 300,000 shares of its common stock, par value $0.10 per share, in the open market over the succeeding six months. During 2021, the Company purchased 300,000 shares of its common stock for a total of $4,579 at an average price of $15.26 per share.

73


The shares and respective amount are recorded as treasury shares on the Company’s consolidated balance sheets. The table below summarized the number of shares of the Company's common stock that requires recognition or disclosurewere repurchased during the years ended December 31, 2022 and 2021. The Company did not repurchase any of its common stock in our consolidated financial statements.2020.

Year ended

 

Total number of
shares purchased

 

 

Average price paid
per share

 

 

Total amount paid

 

December 31, 2022

 

 

1,668,852

 

 

$

20.37

 

 

$

34,002

 

December 31, 2021

 

 

300,000

 

 

$

15.26

 

 

$

4,579

 

(18) Supplemental Cash Flows Information

 

 

 

2022

 

 

2021

 

 

2020

 

Supplemental cash flow information:

 

 

 

 

 

 

 

 

 

Cash paid during the year for:

 

 

 

 

 

 

 

 

 

Interest

 

$

3,834

 

 

$

3,520

 

 

$

5,313

 

Income taxes, net

 

$

19,960

 

 

$

5,796

 

 

$

3,881

 

Non-cash transactions:

 

 

 

 

 

 

 

 

 

ROU assets in exchange for lease liabilities

 

$

4,468

 

 

$

18,521

 

 

$

6,309

 

Deferred consideration in connection with business and asset acquisitions

 

$

610

 

 

$

758

 

 

$

2,630

 

Cash dividends declared and included in accrued expenses

 

$

851

 

 

$

594

 

 

$

592

 

7074